(19) DANMARK

(10) **DK/EP 3107563 T3**

Patent- og
Varemærkestyrelsen

(12) Oversættelse af
europæisk patentskrift

(51) Int.Cl.: ***A 61 K 39/00 (2006.01)*** ***A 61 K 38/28 (2006.01)*** ***A 61 K 38/38 (2006.01)***
***A 61 K 39/35 (2006.01)*** ***A 61 K 47/54 (2017.01)*** ***A 61 P 37/02 (2006.01)***
***A 61 P 37/06 (2006.01)*** ***A 61 P 37/08 (2006.01)***

(45) Oversættelsen bekendtgjort den: **2021-05-25**

(80) Dato for Den Europæiske Patentmyndigheds
bekendtgørelse om meddelelse af patentet: **2021-04-07**

(86) Europæisk ansøgning nr.: **15744656.8**

(86) Europæisk indleveringsdag: **2015-02-20**

(87) Den europæiske ansøgnings publiceringsdag: **2016-12-28**

(86) International ansøgning nr.: **IB2015001145**

(87) Internationalt publikationsnr.: **WO2015140648**

(30) Prioritet: **2014-02-21 US 201461942942 P**

(84) Designerede stater: **AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR**

(73) Patenthaver: **Ecole Polytechnique Fédérale de Lausanne (EPFL) EPFL-TTO, EPFL Innovation Park J, 1015 Lausanne, Schweiz**
**Anokion SA, EPFL Innovation Park , En Ruchoz , Chemin De La Dent D'Oche 1A, 1024 Ecublens, Schweiz**

(72) Opfinder: **HUBBELL, Jeffrey A., 4837 S. Kimbark Avenue, Chicago, IL 60615-1915, USA**
**KONTOS, Stephane, Avenue D' Epenex 1b, CH-1022 Chavannes-pres-Renens, Schweiz**
**LORENTZ, Kristen Marie, Avenue D'Epenex 1b, CH-1022 Chavannes-pres-Renens, Schweiz**
**GAI, Shuning, Allee Waldo 8, CH-1196 Gland, Schweiz**
**WILSON, David Scott, 25 W Randolph St. 2809, Chicago, IL 60601, USA**

(74) Fuldmægtig i Danmark: **NORDIC PATENT SERVICE A/S, Bredgade 30, 1260 København K, Danmark**

(54) Benævnelse: **GLYCOMÅLRETTEDE TERAPEUTISKE MIDLER**

(56) Fremdragne publikationer:
**WO-A1-2011/154887**
**WO-A1-2013/121296**
**WO-A1-2014/023709**
**WO-A2-2011/086143**
**WO-A2-2012/083185**
**S. KONTOS ET AL: "PNAS Plus: Engineering antigens for in situ erythrocyte binding induces T-cell deletion", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, vol. 110, no. 1, 2 January 2013 (2013-01-02), pages E60-E68, XP55068885, ISSN: 0027-8424, DOI: 10.1073/pnas.1216353110**
**BARNEY YOO ET AL: "N -Acetylgalactosamino Dendrons as Clearing Agents to Enhance Liver Targeting of Model Antibody-Fusion Protein", BIOCONJUGATE CHEMISTRY., vol. 24, no. 12, 18 December 2013 (2013-12-18), pages 2088-2103, XP055224623, US ISSN: 1043-1802, DOI: 10.1021/bc400333m**

**Fortsættes ...**

ALLA TRAHTENHERTS ET AL: "An Internalizing Antibody Specific for the Human Asialoglycoprotein Receptor", HYBRIDOMA, vol. 28, no. 4, 1 August 2009 (2009-08-01) , pages 225-233, XP55084704, ISSN: 1554-0014, DOI: 10.1089/hyb.2009.0019
XIAORONG ZHAO ET AL: "Construction and characterization of an anti-asialoglycoprotein receptor single-chain variable-fragment-targeted melittin", BIOTECHNOLOGY AND APPLIED BIOCHEMISTRY, vol. 58, no. 6, 1 November 2011 (2011-11-01), pages 405-411, XP55084712, ISSN: 0885-4513, DOI: 10.1002/bab.57
COULSTOCK E ET AL: "Liver-targeting of interferon-alpha with tissue-specific domain antibodies", PLOS ONE, PUBLIC LIBRARY OF SCIENCE, US, vol. 8, no. 2, 1 January 2013 (2013-01-01) , pages e57263-1, XP002697904, ISSN: 1932-6203, DOI: 10.1371/JOURNAL.PONE.0057263 [retrieved on 2013-02-25]
SREEMAN K. MAMIDYALA: "Glycomimetic Ligands for the Human Asialoglycoprotein Receptor", JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, vol. 134, no. 4, 24 January 2012 (2012-01-24), pages 1978-1981, XP55048572, DOI: 10.1021/ja2104679|
MEAGER A ET AL: "Anti-cytokine autoantibodies in autoimmunity: preponderance of neutralizing autoantibodies against interferon-alpha, interferon-omega and interleukin-12 in patients with thymoma and/or myasthenia gravis", CLINICAL AND EXPERIMENTAL IMMUNOLOGY, WILEY-BLACKWELL PUBLISHING LTD, GB, vol. 132, no. 1, 1 April 2003 (2003-04-01) , pages 128-136, XP002470334, ISSN: 0009-9104, DOI: 10.1046/J.1365-2249.2003.02113.X
FOLGORI A ET AL: "A GENERAL STRATEGY TO IDENTIFY MIMOTOPES OF PATHOLOGICAL ANTIGENS USING ONLY RANDOM PEPTIDE LIBRARIES AND HUMAN SERA", EMBO (EUROPEAN MOLECULAR BIOLOGY ORGANIZATION) JOURNAL, WILEY, DE, vol. 13, no. 9, 1 May 1994 (1994-05-01), pages 2236-2243, ISSN: 0261-4189
DORNMAIR KLAUS ET AL: "T-cell-mediated autoimmunity: Novel techniques to characterize autoreactive T-cell receptors.", AMERICAN JOURNAL OF PATHOLOGY, vol. 163, no. 4, October 2003 (2003-10), pages 1215-1226, ISSN: 0002-9440
YESTE ADA ET AL: "Antigen Microarrays for the Study of Autoimmune Diseases", CLINICAL CHEMISTRY, vol. 59, no. 7, July 2013 (2013-07), pages 1036-1044, ISSN: 0009-9147(print)
ZHEYU SHEN ET AL: "A galactosamine-mediated drug delivery carrier for targeted liver cancer therapy", PHARMACOLOGICAL RESEARCH, ACADEMIC PRESS, LONDON, GB, vol. 64, no. 4, 15 June 2011 (2011-06-15), pages 410-419, ISSN: 1043-6618, DOI: 10.1016/J.PHRS.2011.06.015 [retrieved on 2011-06-22]

# DESCRIPTION

## FIELD OF THE INVENTION

**[0001]** The field of the invention relates to pharmaceutically acceptable compositions that are useful in the treatment of autoimmune disease and food allergy.

## BACKGROUND OF THE DISCLOSURE

**[0002]** Applications US 2012/0039989, US 2012/0178139 and WO 2013/121296 describe the targeting of antigens to erythrocytes to take advantage of the erythrocytes' role in antigen presentation fortolerization. Notwithstanding the positive results generated to date with this approach, the possibility of alternative approaches has remained of interest.

**[0003]** WO 2014/023709 A1 describes anti-ASGPR antibodies used for delivering compounds to the liver. Coulstock et al. PLOS ONE, 2013 and WO 2011/086143 A2 describe anti-ASGPR antibodies fused to IFNalpha. Meager et al. WO 2012/083185 A2 relates to a delivery system fro RNAi comprising an ASGP ligand.

## SUMMARY OF THE INVENTION

**[0004]** In a first aspect, the invention provides a composition comprising a compound of Formula 1:

$$X\left[-Y-Z\right]_m$$

Formula 1

where:

m is an integer from 1 to 100;

X comprises a food antigen selected from SEQ ID NO: 24, SEQ ID NO: 25, SEQ ID NO: 26, and SEQ ID NO: 27, to which patients develop an allergic or hypersensitivity response, or an antigen selected from SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, and SEQ ID NO: 17, against which a patient develops an autoimmune response;

Y comprises a linker moiety; and

Z comprises a liver-targeting moiety; wherein the liver-targeting moiety comprises galactose, galactosamine or N-acetylgalactosamine.

**[0005]** The galactose, galactosamine or N-acetylgalactosamine comprised in X can be conjugated at its C1, C2 or C6 to Y.

**[0006]** Y can be selected from N-hydroxysuccinamidyl linkers, malaemide linkers, vinylsulfone linkers, pyridyl di-thiol-poly(ethylene glycol) linkers, pyridyl di-thiol linkers, n-nitrophenyl carbonate linkers, NHS-ester linkers, and nitrophenoxy poly(ethylene glycol)ester linkers.

**[0007]** Y can also comprise: a structure represented by one of Formulae Ya to Yp:



Formula Ya



Formula Yb



Formula Yc



Formula Yd



FormulaYe



Formula Yf





Formula Yg



Formula Yh



Formula Yi



Formula Yj



Formula Yk



Formula YL



Formula Ym



Formula Yn



Formula Yo

and



Formula Yp

or has a portion represented by Formula Y'-CMP:



Formula Y'-CMP

where: the left bracket "(" indicates the bond between X and Y; the right or bottom bracket and ")" indicates the bond between Y and Z; n is an integer from about 1 to 100; p is an integer from about 2 to 150; q is an integer from about 1 to 44; $R^8$ is $-CH_2-$ or $-CH_2-CH_2-C(CH_3)(CN)-$; $R^9$ is a direct bond or $-CH_2-CH_2-$-NH-C(O)-; and Y' represents the remaining portion of Y.

**[0008]** In another aspect of the above, n is about 40 to 80, p is about 10 to 100, q is about 3 to 20, $R^8$ is $-CH_2-CH_2-C(CH_3)(CN)-$; and when $R^9$ is $-CH_2-CH_2-$-NH-C(O)-, Z is galactose or N-acetylgalactosamine conjugated at its C1.

**[0009]** In still another aspect of the above, Y comprises Formula Ya, Formula Yb, Formula Yh, Formula Yi, Formula Yk, Formula Ym or Formula Yn, particularly Formula Ya, Formula Yb, Formula Ym or Formula Yn.

**[0010]** In a second aspect, the invention provides a composition as recited in the first aspect of the invention or a composition comprising a compound of Formula 1:



Formula 1

where:

m is an integer from 1 to 100;

X comprises an antigen against which a patient develops an immune response;

Y comprises a linker moiety; and

Z comprises a liver-targeting moiety; wherein the liver-targeting moiety comprises galactose, galactosamine or N-acetylgalactosamine, for use in the tolerization of said patient with respect to antigen moiety X. X can further comprise: a foreign transplant antigen against which transplant recipients develop an unwanted immune response; a foreign food, animal, plant or environmental antigen against which patients develop an unwanted immune response; a foreign therapeutic agent against which patients develop an unwanted immune response; or a synthetic self-antigen against the endogenous version of which patients develop an unwanted immune response, or a tolerogenic portion thereof.

**[0011]** The disclosure also pertains to a method of treatment for an unwanted immune response against an antigen by administering to a mammal in need of such treatment an effective amount of a composition comprising a compound of Formula 1 as discussed above. In such method the composition can be administered for clearance of a circulating protein or peptide or antibody that specifically binds to antigen moiety X, which circulating protein or peptide or antibody is causatively involved in transplant rejection, immune response against a therapeutic agent, autoimmune disease, hypersensitivity and/or allergy. The composition can be administered in an amount effective to reduce a concentration of the antibodies that are causatively involved in transplant rejection, immune response against a therapeutic agent, autoimmune disease, hypersensitivity and/or allergy in blood of the patient by at least 50% w/w, as measured at a time between about 12 to about 48 hours after the administration. The composition can administered for tolerization of a patient with respect to antigen moiety X.

**[0012]** Further disclosed is a composition comprising a compound of Formula 2:

$$[X-Y]_{m'}-Z-[Y-X]_{m''}$$

Formula 2

where: m' is zero or an integer from about 1 to 10, m'' is zero or an integer from about 1 to 10, and the sum of m' + m'' is an integer from about 1 to 10 but is at least 1; each X is a foreign antigen or self-antigen against which a patient develops an unwanted immune response, or a tolerogenic portion thereof; each Y is a linker moiety or a direct bond, or an antibody, antibody fragment, peptide or other ligand that specifically binds X; and Z is a liver-targeting moiety, provided that X is not interferon, Ribavirin, Nexavar/ Sorafenib, Erbitus/Cetuximab, Avastatin/bevacizumab or Herceptin/trastuzumab when m'+m'' equals 1 and Z is DOM 26h-196-61

**[0013]** In the above aspect of the disclosure involving Formula 2, it is described that Z can comprise an ASGPR-targeted antibody, an ASGPR-targeted antibody fragment, an ASGPR-targeted peptide, an ASGPR-targeted scFv, or another ASGPR ligand. It is described that Y can be a linker having an immunoproteosome cleavage site. It is described that X can comprise a group of related antigens against which a patient develops an unwanted immune response or a group of tolerogenic fragments thereof. For example, X can be selected from

the groups comprising:

- two or more of insulin, proinsulin, preproinsulin, glutamic acid decarboxylase-65 GAD-67, glucose-6 phosphatase 2, insulinoma-associated protein 2, insulinoma-associated protein 2β, ICA69, ICA12, carboxypeptidase H, Imogen 38, GLIMA 38, chromogranin-A, HSP-60, caboxypeptidase E, peripherin, glucose transporter 2, hepatocarcinoma-intestine-pancreas/pancreatic associated protein, S100β, glial fibrillary acidic protein, regenerating gene II, pancreatic duodenal homeobox 1, dystrophia myotonica kinase, islet-specific glucose-6-phosphatase catalytic subunit-related protein, and SST G-protein coupled receptors 1-5;
- two or more of myelin basic protein, myelin oligodendrocyte glycoprotein, myelin proteolipid protein, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, and SEQ ID NO:17; and
- two or more of SEQ ID NO:24, SEQ ID NO:25, SEQ ID NO:26, and SEQ ID NO:27.

**[0014]** The disclosure also pertains to a method of treatment for an unwanted immune response against an antigen by administering to a mammal in need of such treatment an effective amount of a composition comprising a compound of Formula 2 as discussed above. In such method the composition can be administered for clearance of a circulating protein or peptide or antibody that specifically binds to antigen moiety X, which circulating protein or peptide or antibody is causatively involved in transplant rejection, immune response against a therapeutic agent, autoimmune disease, hypersensitivity and/or allergy. The composition can be administered in an amount effective to reduce a concentration of the antibodies that are causatively involved in transplant rejection, immune response against a therapeutic agent, autoimmune disease, hypersensitivity and/or allergy in blood of the patient by at least 50% w/w, as measured at a time between about 12 to about 48 hours after the administration. The composition can administered for tolerization of a patient with respect to antigen moiety X.

## BRIEF DESCRIPTION OF THE DRAWINGS

**[0015]**

Fig. 1 is series of graphs showing galactose conjugation [F1aA-PE-$m_4$-$n_{80}$ (Gal-PE)] preferentially targets OVA to cells of the liver, including the following: (A.) sinusoidal endothelial cells (LSECs), (B.) Kupffer cells (KC), (C.) hepatocytes, and (D.) other antigen-presenting cells (APCs).

Fig. 2 is a graph showing proliferation of OTI CD8+ T cells in mice treated with F1aA-OVA-$m_4$-$n_{80}$ (Gal-OVA), OVA or saline (i.e. naive).

Fig. 3 is a series of graphs showing the percentage of OT-I $CD8^+$ T cells presenting surface markers (A.) PD-1+ and (B.) Annexin-V+ in generations of proliferating T cells treated with

saline, OVA or F1aA-OVA-$m_4$-$n_{80}$ (GAL-OVA).

Fig. 4 is a graph showing galactose conjugation [F1aA-OVA-$m_4$-$n_{80}$ (Gal-OVA)] decreases the immunogenicity of OVA as determined by OVA-specific antibody titers (shown in Ab titers $log^{-1}$).

Fig. 5 shows that F1aA-OVA-$m_4$-$n_{80}$ (Gal-OVA) is able to deplete OVA-specific antibodies from the serum.

Fig. 6 shows that F1aA-OVA-$m_4$-$n_{80}$ (mGal-OVA), F1b-OVA-$m_1$-$n_{44}$-$p_{34}$ (pGal-OVA), and N'-DOM-$Gly_3$Ser-OVA-$Gly_3$Ser-6xHis-C' (Dom-OVA) are able to mitigate the OVA-specific immune response in draining lymphnodes after intradermal challenge with OVA and the andjuvant LPS.

Fig. 7 shows the characterization of F1aA-OVA-$m_4$-$n_{80}$ and F1b-OVA-$m_1$-$n_{44}$-$p_{34}$. (A). Size-exclusion HPCL traces of F1aA-OVA-$m_4$-$n_{80}$ (magenta), F1b-OVA-$m_1$-$n_{44}$-$p_{34}$ (blue) and unconjugated OVA (black). Shift to the left represents an increase in molecular weight. (B.) Polyacrylamide gel demonstrating increased molecular weight after OVA conjugation: (1.) Unconjugated OVA, (2.) F1aA-OVA-$m_4$-$n_{80}$ and (3.) F1 b-OVA-$m_1$-$n_{44}$-$p_{34}$.

Fig. 8 is a graph showing the normalized quantity of N-OVA-$Gly_3$Ser-6xHis-C (OVA), N-DOM-$Gly_3$Ser-OVA-$Gly_3$Ser-6xHis-C (DOM-OVA), or N-OVA-$Gly_3$Ser-DOM-$Gly_3$Ser-6xHis-C (OVA-DOM) in the circulation of mice after injection as an *i.v.* bolus.

Fig. 9 is a series of graphs showing the titer of anti-OVA IgG antibodies in the circulation of individual mice after treatment with saline, DOM and OVA, DOM-OVA, or OVA-DOM. Production of anti-OVA IgG was induced by *i.v.* injections of OVA alone (a) or OVA and CpG-B (b). Treatment times are indicated by vertical dashed lines. Titer is calculated as $log_{10}$ of the maximal fold dilution of plasma with detectable anti-OVA IgG.

## DETAILED DESCRIPTION

**[0016]** The two known asialoglycoprotein receptors ("ASGPRs") are expressed on hepatocytes and liver sinusoidal endothelial cells (or "LSECs"). Other galactose/galactosamine/N-acetylgalactosamine receptors can be found in various forms on multiple cell types [e.g., dendritic cells, hepatocytes, LSECs, and Kupffer cells]. Dendritic cells are considered "professional antigen presenting cells," because their primary function is to present antigens to the immune system for generating immune responses. Some cells within the liver are known to be able to present antigens, but the liver is more known to be involved in tolerogenesis. The liver is understood to be a tolerogenic organ. For example, lower incidences of rejection are reported in cases of multiple organ transplants when the liver is one of the organs transplanted. LSECs are much newer to the literature; consequently their role in tolerogenesis and/or moderation of inflammatory immune responses is not yet widely acknowledged or well

understood. However, it is becoming clear that they also can play a significant role in the induction of antigen-specific tolerance.

**[0017]** One of the distinctive features of the erythrocyte surface is its glycosylation, i.e., the presence of significant numbers of glycosylated proteins. Indeed, the glycophorins (e.g., glycophorin A) have been employed as targets for erythrocyte binding. Glycophorins are proteins with many covalently attached sugar chains, the end terminus of which is sialic acid. As an erythrocyte ages and becomes ripe for clearance, the terminal sialic acid of its glycophorins tends to be lost, leaving N-acetylgalactosamine at the free end. N-acetylgalactosamine is a ligand selectively received by the ASGPR associated with hepatic cells, leading to binding of N-acetylgalactosamine-containing substances by hepatic cells and their subsequent uptake and processing in the liver.

**[0018]** Heretofore, it has been understood by those skilled in the art that glycosylation of a therapeutic agent in a manner that results in hepatic targeting should be avoided due to first-pass clearance by the liver resulting in poor circulation half-life of the therapeutic agent. By the same token, some monoclonal antibodies need to be specifically glycosylated at ASN297 for optimal binding to their Fc receptors. It has now surprisingly been found that galactosylation can be used in a manner that induces tolerogenesis.

**[0019]** Disclosed are certain therapeutic compositions that are targeted for delivery to (and for uptake by) the liver, particularly hepatocytes, LSECs, Kupffer cells and/or stellate cells, more particularly hepatocytes and/or LSECs, and even more particularly to specifically bind ASGPR. Liver-targeting facilitates two mechanisms of treatment: tolerization and clearance. Tolerization takes advantage of the liver's role in clearing apoptotic cells and processing their proteins to be recognized by the immune system as "self," as well as the liver's role in sampling peripheral proteins for immune tolerance. Clearance takes advantage of the liver's role in blood purification by rapidly removing and breaking down toxins, polypeptides and the like. Targeting of these compositions to the liver is accomplished by a galactosylating moiety (e.g., galactose, galactosamine and N-acetylgalactosamine, particularly conjugated at C1, C2 or C6), by another liver-targeting moiety (e.g., a monoclonal antibody, or a fragment or an scFv thereof), or by de-sialylating a polypeptide for which such liver-targeting is desired. The galactosylating or other liver-targeting moiety can be chemically conjugated or recombinantly fused to an antigen, whereas desialylation exposes a galactose-like moiety on an antigen polypeptide. The antigen can be endogenous (a self-antigen) or exogenous (a foreign antigen), including but not limited to: a foreign transplant antigen against which transplant recipients develop an unwanted immune response (e.g., transplant rejection), a foreign food, animal, plant or environmental antigen to which patients develop an unwanted immune (e.g., allergic or hypersensitivity) response, a therapeutic agent to which patients develop an unwanted immune response (e.g., hypersensitivity and/or reduced therapeutic activity), a self-antigen to which patients develop an unwanted immune response (e.g., autoimmune disease), or a tolerogenic portion (e.g., a fragment or an epitope) thereof; these compositions are useful for inducing tolerization to the antigen. Alternatively, the galactosylating or other liver-targeting moiety can be conjugated to an antibody, antibody fragment or ligand that specifically binds a circulating protein or peptide

or antibody, which circulating protein or peptide or antibody is causatively involved in transplant rejection, immune response against a therapeutic agent, autoimmune disease, and/or allergy (as discussed above); these compositions are useful for clearing the circulating protein, peptide or antibody. Accordingly, the compositions of the present disclosure can be used for treating an unwanted immune response, e.g., transplant rejection, an immune response against a therapeutic agent, an autoimmune disease, and/or an allergy. Also disclosed are pharmaceutical compositions containing a therapeutically effective amount of a composition of the disclosure admixed with at least one pharmaceutically acceptable excipient. Further disclosed are methods for the treatment of an unwanted immune response, such as transplant rejection, response against a therapeutic agent, autoimmune disease or allergy.

**Definitions**

**[0020]** As used in the present specification, the following words and phrases are generally intended to have the meanings as set forth below, except to the extent that the context in which they are used indicates otherwise.

**[0021]** The singular forms "a," "an," and "the" include plural referents, unless the context clearly indicates otherwise.

**[0022]** The term "about" when used in connection with a numerical value is meant to encompass numerical values within a range typically having a lower limit that is, e.g., 5-10% smaller than the indicated numerical value and having an upper limit that is, e.g., 5-10% larger than the indicated numerical value.

**[0023]** An "antigen" is any substance that serves as a target for the receptors of an adaptive immune response, such as the T cell receptor, B cell receptor or an antibody. An antigen may originate from within the body ("self," "auto" or "endogenous"). An antigen may originate from outside the body ("non-self," "foreign" or "exogenous"), having entered, for example, by inhalation, ingestion, injection, or transplantation. Foreign antigens include, but are not limited to, food antigens, animal antigens, plant antigens, environmental antigens, therapeutic agents, as well as antigens present in an allograft transplant.

**[0024]** An "antigen-binding molecule" as used herein relates to molecules, in particular to proteins such as immunoglobulin molecules, which contain antibody variable regions providing a specific binding to an epitope. The antibody variable region can be present in, for example, a complete antibody, an antibody fragment, and a recombinant derivative of an antibody or antibody fragment. The term "antigen-binding fragment" of an antibody (or "binding portion"), as used herein, refers to one or more fragments of an antibody that retain the ability to specifically bind a target sequence. Antigen-binding fragments containing antibody variable regions include (without limitation) "Fv", "Fab", and "$F(ab')_2$" regions, "single domain antibodies (sdAb)", "nanobodies", "single chain Fv (scFv)" fragments, "tandem scFvs" ($V_HA$-$V_LA$-$V_HB$-

$V_LB$), "diabodies", "triabodies" or "tribodies", "single-chain diabodies (scDb)", and "bi-specific T-cell engagers (BiTEs)".

**[0025]** A "chemical modification" refers to a change in the naturally-occurring chemical structure of one or more amino acids of a polypeptide. Such modifications can be made to a side chain or a terminus, e.g., changing the amino-terminus or carboxyl terminus. In some embodiments, the modifications are useful for creating chemical groups that can conveniently be used to link the polypeptides to other materials, or to attach a therapeutic agent.

**[0026]** The term "comprising", which is synonymous with "including," "containing," or "characterized by," is inclusive or open-ended and does not exclude additional, unrecited elements or method steps. The phrase "consisting of" excludes any element, step, or ingredient not specified. The phrase "consisting essentially of" limits the scope of described subject matter to the specified materials or steps and those that do not materially affect its basic and novel characteristics.

**[0027]** "Conservative changes" can generally be made to an amino acid sequence without altering activity. These changes are termed "conservative substitutions" or mutations; that is, an amino acid belonging to a grouping of amino acids having a particular size or characteristic can be substituted for another amino acid. Substitutes for an amino acid sequence can be selected from other members of the class to which the amino acid belongs. For example, the nonpolar (hydrophobic) amino acids include alanine, leucine, isoleucine, valine, proline, phenylalanine, tryptophan, methionine, and tyrosine. The polar neutral amino acids include glycine, serine, threonine, cysteine, tyrosine, asparagine and glutamine. The positively charged (basic) amino acids include arginine, lysine and histidine. The negatively charged (acidic) amino acids include aspartic acid and glutamic acid. Such substitutions are not expected to substantially affect apparent molecular weight as determined by polyacrylamide gel electrophoresis or isoelectric point. Conservative substitutions also include substituting optical isomers of the sequences for other optical isomers, specifically D amino acids for L amino acids for one or more residues of a sequence. Moreover, all of the amino acids in a sequence can undergo a D to L isomer substitution. Exemplary conservative substitutions include, but are not limited to, Lys for Arg and vice versa to maintain a positive charge; Glu for Asp and vice versa to maintain a negative charge; Ser for Thr so that a free -OH is maintained; and Gln for Asn to maintain a free $-NH_2$. Yet another type of conservative substitution constutes the case where amino acids with desired chemical reactivities are introduced to impart reactive sites for chemical conjugation reactions, if the need for chemical derivativization arises. Such amino acids include but are not limited to Cys (to insert a sulfhydryl group), Lys (to insert a primary amine), Asp and Glu (to insert a carboxylic acid group), or specialized noncanonical amino acids containing ketone, azide, alkyne, alkene, and tetrazine side-chains. Conservative substitutions or additions of free $-NH_2$ or -SH bearing amino acids can be particularly advantageous for chemical conjugation with the linkers and galactosylating moieties of Formula 1. Moreover, point mutations, deletions, and insertions of the polypeptide sequences or corresponding nucleic acid sequences can in some cases be made without a loss of function of the polypeptide or nucleic acid fragment. Substitutions can include, e.g., 1, 2, 3, 4, 5, 6, 7, 8,

9, 10, 15, 20, 25, 30, 35, 40, 45, 50 or more residues. A variant usable in the present invention may exhibit a total number of up to 200 (up to 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, or 200) changes in the amino acid sequence (i.e. exchanges, insertions, deletions, N-terminal truncations, and/or C-terminal truncations). The amino acid residues described herein employ either the single letter amino acid designator or the three-letter abbreviation in keeping with the standard polypeptide nomenclature, J. Biol. Chem., (1969), 243, 3552-3559. All amino acid residue sequences are represented herein by formulae with left and right orientation in the conventional direction of amino-terminus to carboxy-terminus.

**[0028]** The terms "effective amount" or "therapeutically effective amount" refer to that amount of a composition of the disclosure that is sufficient to effect treatment, as defined below, when administered to a mammal in need of such treatment. This amount will vary depending upon the subject and disease condition being treated, the weight and age of the subject, the severity of the disease condition, the particular composition of the disclosure chosen, the dosing regimen to be followed, timing of administration, manner of administration and the like, all of which can readily be determined by one of ordinary skill in the art.

**[0029]** An "epitope", also known as antigenic determinant, is the segment of a macromolecule, e.g. a protein, which is recognized by the adaptive immune system, such as by antibodies, B cells, or T cells. An epitope is that part or segment of a macromolecule capable capable of binding to an antibody or antigen-binding fragment thereof. In this context, the term "binding" in particular relates to a specific binding. In the context of the present invention it is preferred that the term "epitope" refers to the segment of protein or polyprotein that is recognized by the immune system.

**[0030]** The term galactose is well known in the art and refers to a monosaccharide sugar that exists both in open-chain form and in cyclic form, having D- and L- isomers. In the cyclic form there are two anomers, namely alpha and beta. In the alpha form, the C1 alcohol group is in the axial position, whereas in the beta form, the C1 alcohol group is in the equatorial position. In particular, "galactose" refers to the cyclic six-membered pyranose, more in particular the D-isomer and even more particularly the alpha-D-form (α-D-galactopyranose). The structure and numbering of galactose is illustrated below.




**[0031]** The term "galactosylating moiety" refers to a particular type of liver-targeting moiety. Galactosylating moieties include, but are not limited to a galactose, galactosamine and/or N-acetylgalactosamine residue.

**[0032]** The term "liver-targeting moiety", refers to moieties having the abiity to direct, e.g., a polypeptide, to the liver. The liver comprises different cell types, including but not limited to hepatocytes, sinusoidal epithelial cells, Kupffer cells, stellate cells, and/or dendritic cells. Typically, a liver-targeting moiety directs a polypeptide to one or more of these cells. On the surface of the respective liver cells, receptors are present which recognize and specifically bind the liver-targeting moiety. Liver-targeting can be achieved by chemical conjugation of an antigen or ligand to a galactosylating moiety, desialylation of an antigen or ligand to expose underlying galactosyl moieties, recombinant fusion or chemical conjugation of an antigen or ligand to an ASGPR-binding moiety, or specific binding of an endogenous antibody to an antigen or ligand, where the antigen or ligand is: desialylated to expose underlying galactosyl moieties, conjugated to a galactosylating moiety, or recombinantly fused or chemically conjugated to an ASGPR-binding moiety. Naturally occurring desialylated proteins are not encompassed within the scope of the present disclosure.

**[0033]** The "numerical values" and "ranges" provided for the various substituents are intended to encompass all integers within the recited range. For example, when defining n as an integer representing a mixture including from about 1 to 100, particularly about 8 to 90 and more particularly about 40 to 80 ethylene glycol groups, where the mixture typically encompasses the integer specified as n ± about 10% (or for smaller integers from 1 to about 25, ±3), it should be understood that n can be an integer from about 1 to 100 (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 22, 25, 30, 34, 35, 37, 40, 41, 45, 50, 54, 55, 59, 60, 65, 70, 75, 80, 82, 83, 85, 88, 90, 95, 99, 100, 105 or 110) and that the disclosed mixture encompases ranges such as 1-4, 2-4, 2-6, 3-8, 7-13, 6-14, 18-23, 26-30, 42-50, 46-57, 60-78, 85-90, 90-110 and 107-113 ethylene glycol groups. The combined terms "about" and "±10%" or "±3" should be understood to disclose and provide specific support for equivalent ranges wherever used.

**[0034]** The term "optional" or "optionally" means that the subsequently described event or circumstance may or may not occur, and that the description includes instances where said event or circumstance occurs and instances in which it does not.

**[0035]** A peptide that specifically binds a particular target is referred to as a "ligand" for that target.

**[0036]** A "polypeptide" is a term that refers to a chain of amino acid residues, regardless of post-translational modification (e.g., phosphorylation or glycosylation) and/or complexation with additional polypeptides, and/or synthesis into multisubunit complexes with nucleic acids and/or carbohydrates, or other molecules. Proteoglycans therefore also are referred to herein as polypeptides. A long polypeptide (having over about 50 amino acids) is referred to as a "protein." A short polypeptide (having fewer than about 50 amino acids) is referred to as a "peptide." Depending upon size, amino acid composition and three dimensional structure, certain polypeptides can be referred to as an an "antigen-binding molecule," "antibody," an "antibody fragment" or a "ligand." Polypeptides can be produced by a number of methods,

many of which are well known in the art. For example, polypeptides can be obtained by extraction (e.g., from isolated cells), by expression of a recombinant nucleic acid encoding the polypeptide, or by chemical synthesis. Polypeptides can be produced by, for example, recombinant technology, and expression vectors encoding the polypeptide introduced into host cells (e.g., by transformation or transfection) for expression of the encoded polypeptide

**[0037]** As used herein, "pharmaceutically acceptable carrier" or "pharmaceutically acceptable excipient" includes any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents and the like. The use of such media and agents for pharmaceutically active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the active ingredient, its use in the therapeutic compositions is contemplated. Supplementary active ingredients can also be incorporated into the compositions.

**[0038]** The term "purified" as used herein with reference to a polypeptide refers to a polypeptide that has been chemically synthesized and is thus substantially uncontaminated by other polypeptides, or has been separated or isolated from most other cellular components by which it is naturally accompanied (e.g., other cellular proteins, polynucleotides, or cellular components). An example of a purified polypeptide is one that is at least 70%, by dry weight, free from the proteins and naturally occurring organic molecules with which it naturally associates. A preparation of a purified polypeptide therefore can be, for example, at least 80%, at least 90%, or at least 99%, by dry weight, the polypeptide. Polypeptides also can be engineered to contain a tag sequence (e.g., a polyhistidine tag, a myc tag, a FLAG® tag, or other affinity tag) that facilitates purification or marking (e.g., capture onto an affinity matrix, visualization under a microscope). Thus a purified composition that comprises a polypeptide refers to a purified polypeptide unless otherwise indicated. The term "isolated" indicates that the polypeptides or nucleic acids of the disclosure are not in their natural environment. Isolated products of the disclosure can thus be contained in a culture supernatant, partially enriched, produced from heterologous sources, cloned in a vector or formulated with a vehicle, etc.

**[0039]** The term "sequence identity" is used with regard to polypeptide sequence comparisons. This expression in particular refers to a percentage of sequence identity, for example at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% to the respective reference polypeptide or to the respective reference polynucleotide. Particularly, the polypeptide in question and the reference polypeptide exhibit the indicated sequence identity over a continuous stretch of 20, 30, 40, 45, 50, 60, 70, 80, 90, 100 or more amino acids or over the entire length of the reference polypeptide.

**[0040]** "Specific binding," as that term is commonly used in the biological arts, refers to a molecule that binds to a target with a relatively high affinity as compared to non-target tissues, and generally involves a plurality of non-covalent interactions, such as electrostatic interactions, van der Waals interactions, hydrogen bonding, and the like. Specific binding

interactions characterize antibody-antigen binding, enzyme-substrate binding, and certain protein-receptor interactions; while such molecules might bind tissues besides their specific targets from time to time, to the extent that such non-target binding is inconsequential, the high-affinity binding pair can still fall within the definition of specific binding.

**[0041]** The term "treatment" or "treating" means any treatment of a disease or disorder in a mammal, including:

preventing or protecting against the disease or disorder, that is, causing the clinical symptoms not to develop;

inhibiting the disease or disorder, that is, arresting or suppressing the development of clinical symptoms; and/or

relieving the disease or disorder, that is, causing the regression of clinical symptoms.

**[0042]** The term "unwanted immune response" refers to a reaction by the immune system of a subject, which in the given situation is not desirable. The reaction of the immune system is unwanted if such reaction does not lead to the prevention, reduction, or healing of a disease or disorder but instead causes, enhances or worsens a disorder or disease. Typically, a reaction of the immune system causes, enhances or worsens a disease if it is directed against an inappropriate target. Exemplified, an unwanted immune response includes but is not limited to transplant rejection, immune response against a therapeutic agent, autoimmune disease, and allergy or hypersensitivity.

**[0043]** The term "variant" is to be understood as a protein which differs in comparison to the protein from which it is derived by one or more changes in its length, sequence, or structure. The polypeptide from which a protein variant is derived is also known as the parent polypeptide or polynucleotide. The term "variant" comprises "fragments" or "derivatives" of the parent molecule. Typically, "fragments" are smaller in length or size than the parent molecule, whilst "derivatives" exhibit one or more differences in their sequence or structure in comparison to the parent molecule. Also encompassed modified molecules such as but not limited to post-translationally modified proteins (e.g. glycosylated, phosphorylated, ubiquitinated, palmitoylated, or proteolytically cleaved proteins) and modified nucleic acids such as methylated DNA. Also mixtures of different molecules such as but not limited to RNA-DNA hybrids, are encompassed by the term "variant". Naturally occurring and artificially constructed variants are to be understood to be encompassed by the term "variant" as used herein. Further, the variants usable in the present invention may also be derived from homologs, orthologs, or paralogs of the parent molecule or from artificially constructed variant, provided that the variant exhibits at least one biological activity of the parent molecule, i.e. is functionally active. A variant can be characterized by a certain degree of sequence identity to the parent polypeptide from which it is derived. More precisely, a protein variant in the context of the present disclosure may exhibit at least 80% sequence identity to its parent polypeptide.

Preferably, the sequence identity of protein variants is over a continuous stretch of 20, 30, 40, 45, 50, 60, 70, 80, 90, 100 or more amino acids.

**Compositions and pharmaceutical formulations for use**

**[0044]** One aspect of the second aspect of the invention are compositions and pharmaceutical formulations for use in the tolerization of patients, represented by Formula 1:



Formula 1

where:

m is an integer from about 1 to 100, particularly from about 1 to 20, and most particularly 1 to about 10;

X is an antigen moiety against which a patient develops an immune response;

Y is a linker moiety; and

Z is a liver-targeting moiety, wherein the liver-targeting moiety comprises galactose, galactosamine or N-acetylgalactosamine.

The value for m in Formula 1 will depend upon the nature of X, in that each antigen, antibody, antibody fragment or ligand will have an individual number and density of sites (predominantly the N-terminal amine, lysine residues and cysteine residues) to which a linker or galactosylating moiety can be bound. Antigens having a limited number of such sites can be derivatized, for example, at the N or C terminus, by adding lysine or cysteine residues (optionally via a cleavable linker, particularly a linker having an immunoproteosome cleavage site). Generally, it is preferred to provide an adequate degree of galactosylation in compositions of Formula 1 so as to facilitate uptake by liver cells. Pharmaceutical formulations and methods of the disclosure can employ a cocktail of compositions of Formula 1, respectively bearing different X moieties (e.g., several epitopes associated with a particular unwanted immune response).

**[0045]** The compositions for use of Formula 1 include the sub-genuses where X is a foreign transplant antigen against which transplant recipients develop an unwanted immune response (e.g., transplant rejection), a foreign food, animal, plant or environmental antigen against which patients develop an unwanted immune (e.g., allergic or hypersensitivity) response, a foreign therapeutic agent against which patients develop an unwanted immune response (e.g., hypersensitivity and/or reduced therapeutic activity), or a self-antigen against which patients develop an unwanted immune response (e.g., autoimmune disease); where Y is a linker of Formulae Ya through Yp; and/orwhere Z is galactose, galactosamine or N-acetylgalactosamine, as illustrated by Formulae 1a through 1p as described below with reference to the Reaction Schemes.

**[0046]** Further disclosed is a pharmaceutically acceptable composition represented by Formula 2:



Formula 2

where:

m' is zero or an integer from about 1 to 10, m" is zero or an integer from about 1 to 10, and the sum of m' + m" is an integer from about 1 to 10 but is at least 1;

X is an antigen moiety, particularly a foreign antigen or self-antigen against which a patient develops an unwanted immune response, or a tolerogenic portion (e.g., a fragment or an epitope) of such an antigen moiety;

Y is a linker moiety or a direct bond, or an antibody, antibody fragment, peptide or other ligand that specifically binds X; and

Z is a liver-targeting moiety, in particular an ASGPR-targeted antibody, an ASGPR-targeted antibody fragment, an ASGPR-targeted peptide, an ASGPR-targeted scFv, or another ASGPR ligand,

such composition optionally including amino acid sequences to facilitate isolation and purification [e.g., a "His tag" or "6xHis" having the sequence: HHHHHH (SEQ ID NO:1) and additional linkers [e.g., "$Gly_3Ser$" having the sequence: GGGS (SEQ ID NO:2)]. In the compositions of Formula 2 where m' + m" is greater than one, the X moieties can be the same or different, and the Y moieties can be the same or different. The value for m' + m" will be smaller (e.g., 3 or less) when X is a full protein, or larger (up to about 10) when X is a peptide. The linker(s) "Y" can advantageously comprise a cleavage site, particularly an immunoproteosome cleavage site.

**[0047]** Disclosed are compositions of Formula 2 that include the sub-genuses where X is a foreign transplant antigen against which transplant recipients develop an unwanted immune response (e.g., transplant rejection), a foreign food, animal, plant or environmental antigen against which patients develop an unwanted immune (e.g., allergic or hypersensitivity) response, a foreign therapeutic agent against which patients develop an unwanted immune response (e.g., hypersensitivity and/or reduced therapeutic activity), or a self-antigen against which patients develop an unwanted immune response (e.g., autoimmune disease).

**[0048]** Alternatively, in the compositions of Formula 1 and/or Formula 2, X can be an antibody, antibody fragment or ligand that specifically binds a circulating protein or peptide or antibody, which circulating protein or peptide or antibody is causatively involved in transplant rejection, immune response against a therapeutic agent, autoimmune disease, hypersensitivity and/or allergy.

**[0049]** The compositions of Formula 2 can be prepared as fusion proteins and can include

several components useful in their preparation and purification, such as a signal or leader sequence that directs the expressed polypeptide to a specific transport pathway and is subsequently cleaved from the polypeptide; therefore the signal sequence can be part of the expressed protein and DNA encoding it, but not part of the final composition. One example of a mammalian signal sequence used in expression systems is the Ig κ-chain sequence, which directs protein secretion: METDTLLLWVLLLWVPGSTG (SEQ ID NO:3). Similarly, one example of a common bacterial signal sequence used in expression systems is the pelB signal sequence, which directs expressed protein into the bacterial periplasm: MKYLLPTAAAGLLLLAAQPAMA (SEQ ID NO:4).

**Antigens**

**[0050]** The antigen employed as X in the composition for use of Formula 1 can be a protein or a peptide, e.g. the antigen may be a complete or partial therapeutic agent, a full-length transplant protein or peptide thereof, a full-length autoantigen or peptide thereof, a full-length allergen or peptide thereof, and/or a nucleic acid, or a mimetic of an aforementioned antigen.

**[0051]** Antigens employed in the practice of the second aspect of the present invention can be one or more of the following:

- Therapeutic agents that are proteins, peptides, antibodies and antibody-like molecules, including antibody fragments and fusion proteins with antibodies and antibody fragments. These include human, non-human (such as mouse) and non-natural (i.e., engineered) proteins, antibodies, chimeric antibodies, humanized antibodies, and non-antibody binding scaffolds, such as fibronectins, DARPins, knottins, and the like.
- Human allograft transplantation antigens against which transplant recipients develop an unwanted immune response.
- Self-antigens that cause an unwanted, autoimmune response. Those skilled in the art will appreciate that while self-antigens are of an endogenous origin in an autoimmune disease patient, the polypeptides employed in the disclosed compositions are typically synthesized exogenously (as opposed to being purified and concentrated from a source of origin).
- Foreign antigens, such as food, animal, plant and environmental antigens, against which a patient experiences an unwanted immune response. Those skilled in the art will appreciate that while a therapeutic protein can also be considered a foreign antigen due to its exogenous origin, for purposes of clarity in the description of the present disclosure such therapeutics are described as a separate group. Similarly, a plant or an animal antigen can be eaten and considered a food antigen, and an environmental antigen may originate from a plant. They are, however, all foreign antigens. In the interest of simplicity no attempt will be made to describe distingiush and define all of such potentially overlapping groups, as those skilled in the art can appreciate the antigens that can be employed in the compositions of the disclosure, particularly in light of the detailed description and examples.

The antigen can be a complete protein, a portion of a complete protein, a peptide, or the like, and can be derivatized (as discussed above) for attachment to a linker and/or galactosylating moiety, can be a variant and/or can contain conservative substitutions, particularly maintaining sequence identity, and/or can be desialylated.

**[0052]** In the embodiments of the second aspect of the invention where the antigen is a therapeutic protein, peptide, antibody or antibody-like molecule, specific antigens can be selected from: Abatacept, Abciximab, Adalimumab, Adenosine deaminase, Ado-trastuzumab emtansine, Agalsidase alfa, Agalsidase beta, Aldeslukin, Alglucerase, Alglucosidase alfa, α-1-proteinase inhibitor, Anakinra, Anistreplase (anisoylated plasminogen streptokinase activator complex), Antithrombin III, Antithymocyte globulin, Ateplase, Bevacizumab, Bivalirudin, Botulinum toxin type A, Botulinum toxin type B, C1-esterase inhibitor, Canakinumab, Carboxypeptidase G2 (Glucarpidase and Voraxaze), Certolizumab pegol, Cetuximab, Collagenase, Crotalidae immune Fab, Darbepoetin-α, Denosumab, Digoxin immune Fab, Dornase alfa, Eculizumab, Etanercept, Factor VIIa, Factor VIII, Factor IX, Factor XI, Factor XIII, Fibrinogen, Filgrastim, Galsulfase, Golimumab, Histrelin acetate, Hyaluronidase, Idursulphase, Imiglucerase, Infliximab, Insulin [including recombinant human insulin ("rHu insulin") and bovine insulin], Interferon-α2a, Interferon-α2b, Interferon-β1a, Interferon-β1b, Interferon-yl b, Ipilimumab, L-arginase, L-asparaginase, L-methionase, Lactase, Laronidase, Lepirudin / hirudin, Mecasermin, Mecasermin rinfabate, Methoxy Natalizumab, Octreotide, Ofatumumab, Oprelvekin, Pancreatic amylase, Pancreatic lipase, Papain, Peg-asparaginase, Peg-doxorubicin HCl, PEG-epoetin-β, Pegfilgrastim, Peg-Interferon-α2a, Peg-Interferon-α2b, Pegloticase, Pegvisomant, Phenylalanine ammonia-lyase (PAL), Protein C, Rasburicase (uricase), Sacrosidase, Salmon calcitonin, Sargramostim, Streptokinase, Tenecteplase, Teriparatide, Tocilizumab (atlizumab), Trastuzumab, Type 1 alpha-interferon, Ustekinumab, vW factor. The therapeutic protein can be obtained from natural sources (e.g., concentrated and purified) or synthesized, e.g., recombinantly, and includes antibody therapeutics that are typically IgG monoclonal or fragments or fusions.

**[0053]** Particular therapeutic protein, peptide, antibody or antibody-like molecules include Abciximab, Adalimumab, Agalsidase alfa, Agalsidase beta, Aldeslukin, Alglucosidase alfa, Factor VIII, Factor IX, Infliximab, Insulin (including rHu Insulin), L-asparaginase, Laronidase, Natalizumab, Octreotide, Phenylalanine ammonia-lyase (PAL), or Rasburicase (uricase) and generally IgG monoclonal antibodies in their varying formats.

**[0054]** Another particular group includes the hemostatic agents (Factor VIII and IX), Insulin (including rHu Insulin), and the non-human therapeutics uricase, PAL and asparaginase.

**[0055]** Unwanted immune response in hematology and transplant includes autoimmune aplastic anemia, transplant rejection (generally), and Graft vs. Host Disease (bone marrow transplant rejection). In the embodiments where the antigen is a human allograft transplantation antigen, specific sequences can be selected from: subunits of the various MHC class I and MHC class II haplotype proteins (for example, donor/recipient differences identified in tissue cross-matching), and single-amino-acid polymorphisms on minor blood group

antigens including RhCE, Kell, Kidd, Duffy and Ss. Such compositions can be prepared individually for a given donor/recipient pair.

**[0056]** In the embodiments of the second aspect of the invention where the antigen is a self-antigen, specific antigens (and the autoimmune disease with which they are associated) can be selected from:

- In type 1 diabetes mellitus, several main antigens have been identified: insulin, proinsulin, preproinsulin, glutamic acid decarboxylase-65 (GAD-65 or glutamate decarboxylase 2), GAD-67, glucose-6 phosphatase 2 (IGRP or islet-specific glucose 6 phosphatase catalytic subunit related protein), insulinoma-associated protein 2 (IA-2), and insulinoma-associated protein 2β (IA-2β); other antigens include ICA69, ICA12 (SOX-13), carboxypeptidase H, Imogen 38, GLIMA 38, chromogranin-A, HSP-60, caboxypeptidase E, peripherin, glucose transporter 2, hepatocarcinoma-intestine-pancreas/pancreatic associated protein, S100β, glial fibrillary acidic protein, regenerating gene II, pancreatic duodenal homeobox 1, dystrophia myotonica kinase, islet-specific glucose-6-phosphatase catalytic subunit-related protein, and SST G-protein coupled receptors 1-5. It should be noted that insulin is an example of an antigen that can be characterized both as a self-antigen and a therapeutic protein antigen. For example, rHu Insulin and bovine insulin are therapeutic protein antigens (that are the subject of unwanted immune attack), whereas endogenous human insulin is a self-antigen (that is the subject of an unwanted immune attack). Because endogenous human insulin is not available to be employed in a pharmaceutical composition a recombinant form is employed in the compositions of the disclosure.

  ◦ Human insulin, including an exogenously obtained form useful in the compositions of the disclosure, has the following sequence (UNIPROT P01308):
  MALWMRLLPL LALLALWGPD PAAAFVNQHL CGSHLVEALY LVCGERGFFY
  TPKTRREAED LQVGQVELGG GPGAGSLQPL ALEGSLQKRG IVEQCCTSIC
  SLYQLENYCN (SEQ ID NO:5).

  ◦ GAD-65, including an exogenously obtained form useful in the compositions of the disclosure, has the following sequence (UNIPROT Q05329):
  MASPGSGFWS FGSEDGSGDS ENPGTARAWC QVAQKFTGGI GNKLCALLYG
  DAEKPAESGG SQPPRAAARK AACACDQKPC SCSKVDVNYA FLHATDLLPA
  CDGERPTLAF LQDVMNILLQ YVVKSFDRST KVIDFHYPNE LLQEYNWELA
  DQPQNLEEIL MHCQTTLKYA IKTGHPRYFN QLSTGLDMVG LAADWLTSTA
  NTNMFTYEIA PVFVLLEYVT LKKMREIIGW PGGSGDGIFS PGGAISNMYA
  MMIARFKMFP EVKEKGMAAL PRLIAFTSEH SHFSLKKGAA ALGIGTDSVI
  LIKCDERGKM IPSDLERRIL EAKQKGFVPF LVSATAGTTV YGAFDPLLAV
  ADICKKYKIW MHVDAAWGGG LLMSRKHKWK LSGVERANSV TWNPHKMMGV
  PLQCSALLVR EEGLMQNCNQ MHASYLFQQD KHYDLSYDTG DKALQCGRHV
  DVFKLWLMWR AKGTTGFEAH VDKCLELAEY LYNIIKNREG YEMVFDGKPQ
  HTNVCFWYIP PSLRTLEDNE ERMSRLSKVA PVIKARMMEY GTTMVSYQPL
  GDKVNFFRMV ISNPAATHQD IDFLIEEIER LGQDL (SEQ ID NO:6).

  ◦ IGRP, including an exogenously obtained form useful in the compositions of the

disclosure, has the following sequence (UNIPROT QN9QR9):
MDFLHRNGVLIIQHLQKDYRAYYTFLNFMSNVGDPRNIFFIYFPLCFQFNQTVGTKMI
WVAVIGDWLNLIFKWILFGHRPYWWVQETQIYPNHSSPCLEQFPTTCETGPGSPSG
HAMGASCVWYVMVTAALSHTVCGMDKFSITLHRLTWSFLWSVFWLIQISVCISRVFI
ATHFPHQVILGVIGGMLVAEAFEHTPGIQTASLGTYLKTNLFLFLFAVGFYLLLRVLNI
DLLWSVPIAKKWCANPDWIHIDTTPFAGLVRNLGVLFGLGFAINSEMFLLSCRGGNN
YTLSFRLLCALTSLTILQLYHFLQIPTHEEHLFYVLSFCKSASIPLTVVAFIPYSVHMLM
KQSGKKSQ (SEQ ID NO:7).

- In autoimmune diseases of the thyroid, including Hashimoto's thyroiditis and Graves' disease, main antigens include thyroglobulin (TG), thyroid peroxidase (TPO) and thyrotropin receptor (TSHR); other antigens include sodium iodine symporter (NIS) and megalin. In thyroid-associated ophthalmopathy and dermopathy, in addition to thyroid autoantigens including TSHR, an antigen is insulin-like growth factor 1 receptor. In hypoparathyroidism, a main antigen is calcium sensitive receptor.
- In Addison's Disease, main antigens include 21-hydroxylase, 17D-hydroxylase, and P450 side chain cleavage enzyme (P450scc); other antigens include ACTH receptor, P450c21 and P450c17.
- In premature ovarian failure, main antigens include FSH receptor and □-enolase.
- In autoimmune hypophysitis, or pituitary autoimmune disease, main antigens include pituitary gland-specific protein factor (PGSF) 1a and 2; another antigen is type 2 iodothyronine deiodinase.
- In multiple sclerosis, main antigens include myelin basic protein ("MBP"), myelin oligodendrocyte glycoprotein ("MOG") and myelin proteolipid protein ("PLP").

◦ MBP, including an exogenously obtained form useful in the compositions of the disclosure, has the following sequence (UNIPROT P02686):
MGNHAGKRELNAEKASTNSETNRGESEKKRNLGELSRTTSEDNEVFGEADANQNN
GTSSQDTAVTDSKRTADPKNAWQDAHPADPGSRPHLIRLFSRDAPGREDNTFKDR
PSESDELQTIQEDSAATSESLDVMASQKRPSQRHGSKYLATASTMDHARHGFLPRH
RDTGILDSIGRFFGGDRGAPKRGSGKDSHHPARTAHYGSLPQKSHGRTQDENPVV
HFFKNIVTPRTPPPSQGKGRGLSLSRFSWGAEGQRPGFGYGGRASDYKSAHKGFK
GVDAQGTLSKIFKLGGRDSRSGSPMARR (SEQ ID NO:8).

◦ MOG, including an exogenously obtained form useful in the compositions of the disclosure, has the following sequence (UNIPROT Q16653):
MASLSRPSLPSCLCSFLLLLLLQVSSSYAGQFRVIGPRHPIRALVGDEVELPCRISPG
KNATGMEVGWYRPPFSRVVHLYRNGKDQDGDQAPEYRGRTELLKDAIGEGKVTLR
IRNVRFSDEGGFTCFFRDHSYQEEAAMELKVEDPFYWVSPGVLVLLAVLPVLLLQIT
VGLIFLCLQYRLRGKLRAEIENLHRTFDPHFLRVPCWKITLFVIVPVLGPLVALIICYNW
LHRRLAGQFLEELRNPF (SEQ ID NO:9).

◦ PLP, including an exogenously obtained form useful in the compositions of the disclosure, has the following sequence (UNIPROT P60201):
MGLLECCARCLVGAPFASLVATGLCFFGVALFCGCGHEALTGTEKLIETYFSKNYQD
YEYLINVIHAFQYVIYGTASFFFLYGALLLAEGFYTTGAVRQIFGDYKTTICGKGLSAT
VTGGQKGRGSRGQHQAHSLERVCHCLGKWLGHPDKFVGITYALTVVWLLVFACSA
VPVYIYFNTWTTCQSIAFPSKTSASIGSLCADARMYGVLPWNAFPGKVCGSNLLSIC

KTAEFQMTFHLFIAAFVGAAATLVSLLTFMIAATYNFAVLKLMGRGTKF (SEQ ID NO:10).

◦ Peptides/epitopes useful in the compositions of the disclosure for treating multiple sclerosis include some or all of the following sequences, individually in a composition of Formula 1, together in a cocktail of compositions of Formula 1, or fused in one or more compositions of Formula 2:

▪ MBP13-32: KYLATASTMDHARHGFLPRH (SEQ ID NO:11);

▪ MBP83-99: ENPWHFFKNIVTPRTP (SEQ ID NO:12);

▪ MBP111-129: LSRFSWGAEGQRPGFGYGG (SEQ ID NO:13);

▪ MBP146-170: AQGTLSKIFKLGGRDSRSGSPMARR (SEQ ID NO:14);

▪ MOG1-20: GQFRVIGPRHPIRALVGDEV (SEQ ID NO:15);

▪ MOG35-55: MEVGWYRPPFSRWHLYRNGK (SEQ ID NO:16); and

▪ PLP139-154: HCLGKWLGHPDKFVGI (SEQ ID NO:17).

- In rheumatoid arthritis, main antigens include collagen II, immunoglobulin binding protein, the fragment crystallizable region of immunoglobulin G, double-stranded DNA, and the natural and cirtullinated forms of proteins implicated in rheumatoid arthritis pathology, including fibrin/fibrinogen, vimentin, collagen I and II, and alpha-enolase.
- In autoimmune gastritis, a main antigen is H+,K+-ATPase.
- In pernicious angemis, a main antigen is intrinsic factor.
- In celiac disease, main antigens are tissue transglutaminase and the natural and deamidated forms of gluten or gluten-like proteins, such as alpha-, gamma-, and omega-gliadin, glutenin, hordein, secalin, and avenin. Those skilled in the art will appreciate, for example, that while the main antigen of celiac disease is alpha gliadin, alpha gliadin turns more immunogenic in the body through deamidation by tissue glutaminase converting alpha gliadin's glutamines to glutamic acid. Thus, while alpha gliadin is originally a foreign food antigen, once it has been modified in the body to become more immunogenic it can be characterized as a self-antigen.
- In vitiligo, a main antigen is tyrosinase, and tyrosinase related protein 1 and 2.

◦ MART1, Melanoma antigen recognized by T cells 1, Melan-A, including an exogenously obtained form useful in the compositions of the disclosure, has the following sequence (UNIPROT Q16655):

MPREDAHFIYGYPKKGHGHSYTTAEEAAGIGILTVILGVLLLIGCWYCRRRNGYRAL MDKSLHVGTQCALTRRCPQEGFDHRDSKVSLQEKNCEPVVPNAPPAYEKLSAEQS PPPYSP (SEQ ID NO:18).

◦ Tyrosinase, including an exogenously obtained form useful in the compositions of the disclosure, has the following sequence (UNIPROT P14679):

MLLAVLYCLLWSFQTSAGHFPRACVSSKNLMEKECCPPWSGDRSPCGQLSGRGS

CQNILLSNAPLGPQFPFTGVDDRESWPSVFYNRTCQCSGNFMGFNCGNCKFGFW
GPNCTERRLLVRRNIFDLSAPEKDKFFAYLTLAKHTISSDYVIPIGTYGQMKNGSTPM
FNDINIYDLFVWMHYYVSMDALLGGSEIWRDIDFAHEAPAFLPWHRLFLLRWEQEIQ
KLTGDENFTIPYWDWRDAEKCDICTDEYMGGQHPTNPNLLSPASFFSSWQIVCSRL
EEYNSHQSLCNGTPEGPLRRNPGNHDKSRTPRLPSSADVEFCLSLTQYESGSMDK
AANFSFRNTLEGFASPLTGIADASQSSMHNALHIYMNGTMSQVQGSANDPIFLLHHA
FVDSIFEQWLRRHRPLQEVYPEANAPIGHNRESYMVPFIPLYRNGDFFISSKDLGYD
YSYLQDSDPDSFQDYIKSYLEQASRIWSWLLGAAMVGAVLTALLAGLVSLLCRHKRK
QLPEEKQPLLMEKEDYHSLYQSHL (SEQ ID NO:19).

◦ Melanocyte protein PMEL, gp100, including an exogenously obtained form useful in the compositions of the disclosure, has the following sequence (UNIPROT P40967):

MDLVLKRCLLHLAVIGALLAVGATKVPRNQDWLGVSRQLRTKAWNRQLYPEWTEA
QRLDCWRGGQVSLKVSNDGPTLIGANASFSIALNFPGSQKVLPDGQVIWVNNTIING
SQVWGGQPVYPQETDDACIFPDGGPCPSGSWSQKRSFVYVWKTWGQYWQVLGG
PVSGLSIGTGRAMLGTHTMEVTVYHRRGSRSYVPLAHSSSAFTITDQVPFSVSVSQL
RALDGGNKHFLRNQPLTFALQLHDPSGYLAEADLSYTWDFGDSSGTLISRALVVTH
TYLEPGPVTAQVVLQAAIPLTSCGSSPVPGTTDGHRPTAEAPNTTAGQVPTTEVVG
TTPGQAPTAEPSGTTSVQVPTTEVISTAPVQMPTAESTGMTPEKVPVSEVMGTTLA

EMSTPEATGMTPAEVSIVVLSGTTAAQVTTTEWVETTARELPIPEPEGPDASSIMST
ESITGSLGPLLDGTATLRLVKRQVPLDCVLYRYGSFSVTLDIVQGIESAEILQAVPSGE
GDAFELTVSCQGGLPKEACMEISSPGCQPPAQRLCQPVLPSPACQLVLHQILKGGS
GTYCLNVSLADTNSLAVVSTQLIMPGQEAGLGQVPLIVGILLVLMAVVLASLIYRRRL
MKQDFSVPQLPHSSSHWLRLPRIFCSCPIGENSPLLSGQQV (SEQ ID NO:20).

- In myasthenia gravis, a main antigen is acetylcholine receptor.
- In pemphigus vulgaris and variants, main antigens are desmoglein 3, 1 and 4; other antigens include pemphaxin, desmocollins, plakoglobin, perplakin, desmoplakins, and acetylcholine receptor.
- In bullous pemphigoid, main antigens include BP180 and BP230; other antigens include plectin and laminin 5.
- In dermatitis herpetiformis Duhring, main antigens include endomysium and tissue transglutaminase.
- In epidermolysis bullosa acquisita, a main antigen is collagen VII.
- In systemic sclerosis, main antigens include matrix metalloproteinase 1 and 3, the collagen-specific molecular chaperone heat-shock protein 47, fibrillin-1, and PDGF receptor; other antigens include Scl-70, U1 RNP, Th/To, Ku, Jo1, NAG-2, centromere proteins, topoisomerase I, nucleolar proteins, RNA polymerase I, II and III, PM-Slc, fibrillarin, and B23.
- In mixed connective tissue disease, a main antigen is U1snRNP.
- In Sjogren's syndrome, the main antigens are nuclear antigens SS-A and SS-B; other antigens include fodrin, poly(ADP-ribose) polymerase and topoisomerase, muscarinic receptors, and the Fc-gamma receptor IIIb.
- In systemic lupus erythematosus, main antigens include nuclear proteins including the "Smith antigen," SS-A, high mobility group box 1 (HMGB1), nucleosomes, histone proteins and double-stranded DNA (against which auto-antibodies are made in the

disease process).

- In Goodpasture's syndrome, main antigens include glomerular basement membrane proteins including collagen IV.
- In rheumatic heart disease, a main antigen is cardiac myosin.
- In autoimmune polyendocrine syndrome type 1 antigens include aromatic L-amino acid decarboxylase, histidine decarboxylase, cysteine sulfinic acid decarboxylase, tryptophan hydroxylase, tyrosine hydroxylase, phenylalanine hydroxylase, hepatic P450 cytochromes P4501A2 and 2A6, SOX-9, SOX-10, calcium-sensing receptor protein, and the type 1 interferons interferon alpha, beta and omega.
- In neuromyelitis optica, a main antigen is AQP4.

  ◦ Aquaporin-4, including an exogenously obtained form useful in the compositions of the disclosure, has the following sequence (UNIPROT P55087):

  MSDRPTARRWGKCGPLCTRENIMVAFKGVWTQAFWKAVTAEFLAMLIFVLLSLGST
  INWGGTEKPLPVDMVLISLCFGLSIATMVQCFGHISGGHINPAVTVAMVCTRKISIAKS
  VFYIAAQCLGAIIGAGILYLVTPPSVVGGLGVTMVHGNLTAGHGLLVELIITFQLVFTIF
  ASCDSKRTDVTGSIALAIGFSVAIGHLFAINYTGASMNPARSFGPAVIMGNWENHWI

  YWVGPIIGAVLAGGLYEYVFCPDVEFKRRFKEAFSKAAQQTKGSYMEVEDNRSQVE
  TDDLILKPGVVHVIDVDRGEEKKGKDQSGEVLSSV (SEQ ID NO:21).
- In uveitis, main antigens include Retinal S-antigen or "S-arrestin" and interphotoreceptor retinoid binding protein (IRBP) or retinol-binding protein 3.

  ◦ S-arrestin, including an exogenously obtained form useful in the compositions of the disclosure, has the following sequence (UNIPROT P10523):

  MAASGKTSKS EPNHVIFKKI SRDKSVTIYL GNRDYIDHVS QVQPVDGVVL
  VDPDLVKGKK VYVTLTCAFR YGQEDIDVIG LTFRRDLYFS RVQVYPPVGA
  ASTPTKLQES LLKKLGSNTY PFLLTFPDYL PCSVMLQPAP QDSGKSCGVD
  FEVKAFATDS TDAEEDKIPK KSSVRLLIRK VQHAPLEMGP QPRAEAAWQF
  FMSDKPLHLA VSLNKEIYFH GEPIPVTVTV TNNTEKTVKK IKAFVEQVAN
  VVLYSSDYYV KPVAMEEAQE KVPPNSTLTK TLTLLPLLAN NRERRGIALD
  GKIKHEDTNL ASSTIIKEGI DRTVLGILVS YQIKVKLTVS GFLGELTSSE
  VATEVPFRLM HPQPEDPAKE SYQDANLVFE EFARHNLKDA GEAEEGKRDK
  NDVDE (SEQ ID NO:22).

  ◦ IRBP, including an exogenously obtained form useful in the compositions of the disclosure, has the following sequence (UNIPROT P10745):

  MMREWVLLMSVLLCGLAGPTHLFQPSLVLDMAKVLLDNYCFPENLLGMQEAIQQAI
  KSHEILSISDPQTLASVLTAGVQSSLNDPRLVISYEPSTPEPPPQVPALTSLSEEELLA
  WLQRGLRHEVLEGNVGYLRVDSVPGQEVLSMMGEFLVAHVWGNLMGTSALVLDL
  RHCTGGQVSGIPYIISYLHPGNTILHVDTIYNRPSNTTTEIWTLPQVLGERYGADKDV
  VVLTSSQTRGVAEDIAHILKQMRRAIVVGERTGGGALDLRKLRIGESDFFFTVPVSRS
  LGPLGGGSQTWEGSGVLPCVGTPAEQALEKALAILTLRSALPGVVHCLQEVLKDYY
  TLVDRVPTLLQHLASMDFSTVVSEEDLVTKLNAGLQAASEDPRLLVRAIGPTETPSW
  PAPDAAAEDSPGVAPELPEDEAIRQALVDSVFQVSVLPGNVGYLRFDSFADASVLG
  VLAPYVLRQVWEPLQDTEHLIMDLRHNPGGPSSAVPLLLSYFQGPEAGPVHLFTTY
  DRRTNITQEHFSHMELPGPRYSTQRGVYLLTSHRTATAAEEFAFLMQSLGWATLVG
  EITAGNLLHTRTVPLLDTPEGSLALTVPVLTFIDNHGEAWLGGGVVPDAIVLAEEALD

KAQEVLEFHQSLGALVEGTGHLLEAHYARPEVVGQTSALLRAKLAQGAYRTAVDLE
SLASQLTADLQEVSGDHRLLVFHSPGELVVEEAPPPPPAVPSPEELTYLIEALFKTEV
LPGQLGYLRFDAMAELETVKAVGPQLVRLVWQQLVDTAALVIDLRYNPGSYSTAIPL
LCSYFFEAEPRQHLYSVFDRATSKVTEVWTLPQVAGQRYGSHKDLYILMSHTSGSA
AEAFAHTMQDLQRATVIGEPTAGGALSVGIYQVGSSPLYASMPTQMAMSATTGKA
WDLAGVEPDITVPMSEALSIAQDIVALRAKVPTVLQTAGKLVADNYASAELGAKMAT
KLSGLQSRYSRVTSEVALAEILGADLQMLSGDPHLKAAHIPENAKDRIPGIVPMQIPS
PEVFEELIKFSFHTNVLEDNIGYLRFDMFGDGELLTQVSRLLVEHIWKKIMHTDAMIID
MRFNIGGPTSSIPILCSYFFDEGPPVLLDKIYSRPDDSVSELWTHAQVVGERYGSKK
SMVILTSSVTAGTAEEFTYIMKRLGRALVIGEVTSGGCQPPQTYHVDDTNLYLTIPTA
RSVGASDGSSWEGVGVTPHVVVPAEEALARAKEMLQHNQLRVKRSPGLQDHL
(SEQ ID NO:23).

**[0057]** In the embodiments of the second aspect of the invention where the antigen is a foreign antigen against which an immune response can be developed, such as food antigens, specific antigens can be:

- from peanut: conarachin (Ara h 1), allergen II (Ara h 2), arachis agglutinin, conglutin (Ara h 6);
  - conarachin, for example has the sequence identified as UNIPROT Q6PSU6
- from apple: 31 kda major allergen/disease resistance protein homolog (Mal d 2), lipid transfer protein precursor (Mal d 3), major allergen Mal d 1.03D (Mal d 1);
- from milk: α-lactalbumin (ALA), lactotransferrin; from kiwi: actinidin (Act c 1, Act d 1), phytocystatin, thaumatin-like protein (Act d 2), kiwellin (Act d 5);
- from egg whites: ovomucoid, ovalbumin, ovotransferrin, and lysozyme;
- from egg yolks: livetin, apovitillin, and vosvetin;
- from mustard: 2S albumin (Sin a 1), 11S globulin (Sin a 2), lipid transfer protein (Sin a 3), profilin (Sin a 4);
- from celery: profilin (Api g 4), high molecular weight glycoprotein (Api g 5);
- from shrimp: Pen a 1 allergen (Pen a 1), allergen Pen m 2 (Pen m 2), tropomyosin fast isoform;
- from wheat and/or other cerials: high molecular weight glutenin, low molecular weight glutenin, alpha-, gamma- and omega-gliadin, hordein, secalin and/or avenin;
  - peptides/epitopes useful in the compositions of the disclosure for treating Celiac Disease include some or all of the following sequences, individually in a composition of Formula 1, together in a cocktail of compositions of Formula 1, or fused in one or more compositions of Formula 2:

▪ DQ-2 relevant, Alpha-gliadin "33-mer" native:
LQLQPFPQPQLPYPQPQLPYPQPQLPYPQPQPF (SEQ ID NO:24)

▪ DQ-2 relevant, Alpha-gliadin "33-mer" deamidated:
LQLQPFPQPELPYPQPELPYPQPELPYPQPQPF (SEQ ID NO:25)

▪ DQ-8 relevant, Alpha-gliadin:
QQYPSGQGSFQPSQQNPQ (SEQ ID NO:26)

▪ DQ-8 relevant, Omega-gliadin (wheat, U5UA46):
QPFPQPEQPFPW (SEQ ID NO:27)

- from strawberry: major strawberry allergy Fra a 1-E (Fra a 1); and
- from banana: profilin (Mus xp 1).

**[0058]** In the embodiments of the second aspect of the invention where the antigen is a foreign antigen against which an immune response is developed, such as to animal, plant and environmental antigens, specific antigens can, for example, be: cat, mouse, dog, horse, bee, dust, tree and goldenrod, including the following proteins or peptides derived from:

- weeds, (including ragweed allergens amb a 1, 2, 3, 5, and 6, and Amb t 5; pigweed Che a 2 and 5; and other weed allergens Par j 1, 2, and 3, and Par o 1);
- grass (including major allergens Cyn d 1, 7, and 12; Dac g 1, 2, and 5; Hol l 1.01203; Lol p 1, 2, 3, 5, and 11; Mer a 1; Pha a 1; Poa p 1 and 5);
- pollen from ragweed and other weeds (including curly dock, lambs quarters, pigweed, plantain, sheep sorrel, and sagebrush), grass (including Bermuda, Johnson, Kentucky, Orchard, Sweet vernal, and Timothy grass), and trees (including catalpa, elm, hickory, olive, pecan, sycamore, and walnut);
- dust (including major allergens from species *Dermatophagoides pteronyssinus,* such as Der p 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 14, 15, 18, 20, 21, and 23; from species *Dermatophagoides farina,* such as Der f 1, 2, 3, 6, 7, 10, 11, 13, 14, 15, 16, 18, 22, and 24; from species *Blomia tropicalis* such as Blo t 1, 2, 3, 4, 5, 6, 10, 11, 12, 13, 19, and 21; also allergens Eur m 2 from *Euroglyphus maynei,* Tyr p 13 from *Tyrophagus putrescentiae,* and allergens Bla g 1, 2, and 4; Per a 1, 3, and 7 from cockroach);
- pets (including cats, dogs, rodents, and farm animals; major cat allergens include Fel d 1 through 8, cat IgA, BLa g 2, and cat albumin; major dog allergens include Can f 1 through 6, and dog albumin);
- bee stings, including major allergens Api m 1 through 12; and
- fungus, including allergens derived from, species of *Aspergillus* and *Penicillium,* as well as the species *Alternaria alternata, Davidiella tassiana,* and *Trichophyton rubrum.*

**[0059]** As will be appreciated by those skilled in the art, a patient can be tested to identify an antigen against which an unwanted immune response has developed, and a protein, peptide or the like can be developed based on that antigen and incorporated as X in a composition of the present disclosure.

**Sialated Antigens, Antibodies, Antibody Fragments**

**[0060]** Following are examples of antigens, antibodies, antibody fragments having sialylation that can be removed to leave glycosylation specifically targeting the ASGPR: follicle stimulating hormone (FSH), human chorionic gonadotropin (HCG), luteinizing hormone (LH), osteopontin, thyroid stimulating hormone (TSH), agalsidase alfa, agalsidase beta (FABRAZYME®; Genzyme), epoetin alfa and epoetin beta, follitropin alfa (GONAL-F®; Merck/Serono) and follitropin beta (FOLLISTIM®; Schering-Plough), insulin growth factor binding protein 6 (IGFBP-6), lutropin alfa (LUVERIS®; Merck/Serono), transforming growth factor β1, antithrombin (ATryn®/TROMBATE-III®; Genzyme/Talecris Biotherapeutics), thyrotropin alfa (THYROGEN®; Genzyme), lenograstim, sargramostim (LEUKINE®; Genzyme), interleukin-3, prourokinase, lymphotoxin, C1-esterase inhibitor (Berinert®; CSL), IgG-like antibodies, interferon beta, coagulation factor VIIa (NOVOSEVEN®; Novo Nordisk), coagulation factor VIII (moroctocog alfa), coagulation factor IX (nonacog alfa) (BENEFIX®; Wyeth), and the p55 tumor necrosis receptor fusion protein. (See: Byrne et al., Drug Discovery Today, Vol 12, No. 7/8, pages 319-326, Apr. 2007 and Sola et al., BioDrugs. 2010; 24(1): 9-21). Pharmaceutically relevant proteins that have previously been hyperglycosylated and can be desialylated for hepatocyte-ASGPR taregeting include: interferon alfa and gamma, luteinizing hormone, Fv antibody fragments, asparaginase, cholinesterase, darbepoetin alfa (AraNESP®; Amgen), trombopoietin, leptin, FSH, IFN-α2, serum albumin, and corifollitropin alfa.

**[0061]** Proteins with glycans that do not normally terminate in sialic acids, including proteins produced in bacteria or yeast (such as arginase, some insulins, and uricase) would not be amenable to desialylation.

**[0062]** Those skilled in the art will appreciate that publicly available references, such as UNIPROT, disclose the presence and location of sites for desialylation on most if not all antigens, antibodies, antibody fragments and ligands of interest.

**Antibodies and Peptide Ligands**

**[0063]** It is disclosed that if an antibody, antibody fragment or ligand is employed in the described compositions, such moieties are chosen to specifically bind a targeted circulating protein or peptide or antibody, and result in hepatic uptake of the circulating targeted moiety, possibly as an adduct with the targeting moiety, ultimately resulting in the clearance and inactivation of the circulating targeted moiety. For example, liver-targeted Factor VIII will bind and clear circulating Factor VIII antibodies. Procedures for the identification of such moieties will be familiar to those skilled in the art.

**Linkers**

**[0064]** The linkers employed in the compositions of the first and second aspect of the present invention ("Y" in Formula 1) can include N-hydroxysuccinamidyl linkers, malaemide linkers, vinylsulfone linkers, pyridyl di-thiol-poly(ethylene glycol) linkers, pyridyl di-thiol linkers, n-nitrophenyl carbonate linkers, NHS-ester linkers, nitrophenoxy poly(ethylene glycol)ester linkers and the like.

**[0065]** One particular group of linkers Formula Y'-CMP below (where Y' indicates the remaining portion of the linker and $R^9$ and Z are as defined). More particularly, in the group of linkers including Formula Y'-CMP, the $R^9$ substituent is an ethylacetamido group, and even more particularly the ethylacetamido is conjugated with C1 of N-acetylgalactosamine.




Formula Y'-CMP

**[0066]** Di-thiol-containing linkers, particularly particularly disulfanylethyl carbamate-containing linkers (named including a free amine of X, otherwise named a "disulfanyl ethyl ester" without including the free amine of X) are particularly advantageous in the present compositions as having the ability to cleave and release an antigen in its original form once inside a cell, for example as ilustrated below (where Y' indicates the remaining portion of the linker and X' and Z are as defined).




**[0067]** Particularly with regard to the linkers illustrated below in Formula Ya through Formula Yp:

the the left bracket "(" indicates the bond between X and Y;

the right or bottom bracket ")" indicates the bond between Y and Z;

n is an integer representing a mixture including from about 1 to 100, particularly about 8 to 90 (e.g., 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65 70,

75, 80, 85, 90 or 95), more particularly about 40 to 80 (e.g., 39, 40, 43, 45, 46, 48, 50, 52, 53, 55, 57, 60, 62, 65, 66, 68, 70, 73, 75, 78, 80 or 81) ethylene glycol groups, where the mixture typically encompasses the integer specified as n ±10%;

p is is an integer representing a mixture including from about 2 to 150, particularly about 20 to 100 (e.g., 18, 19, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65 70, 75, 80, 85, 90, 95, 100 or 105) and more particularly about 30 to 40 (e.g., 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43 or 44), where the mixture typically encompasses the integer specified as p ±10%;

q is is an integer representing a mixture including from about 1 to 44, particularly about 3 to 20 (e.g., 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21 or 22) and more particularly about 4 to 12 (e.g., 4, 5, 6, 7, 8, 9, 10, 11, 12 or 13), where the mixture typically encompasses the integer specified as q ±10%; and

$R^8$ is $-CH_2-$ ("methyl") or $-CH_2-CH_2-C(CH_3)(CN)-$ ("1-cyano-1-methyl-propyl" or "CMP").

$R^9$ is a direct bond or $-CH_2-CH_2--NH-C(O)-$ (an ethylacetamido group or "EtAcN"), as illustrated in the following structures of Formula 1 (where the EtAcN group is shown and the rest of the linker is referred to as Y'):




and Z is galactose, galactosamine or N-acetylgalactosamine conjugated at C1.




Formula Ya

-




Formula Yb





Formula Yc



Formula Yd



FormulaYe



Formula Yf



Formula Yg



Formula Yh



Formula Yi



Formula Yj



Formula Yk



Formula YL



Formula Ym



Formula Yn

(Linkers of Formula Yn can be synthisized via certain precursors that render Yn particularly suitable for conjugation to hydrophobic antigens.)



Formula Yo



Formula Yp

**[0068]** The linkers shown above as Formulae Yh through Yn are synthesized as isomers that are employed without separation. For example, the linkers of Formulae Yh, Yi, Yj and Yn will be a mixture of the 8,9-dihydro-**1*H***-dibenzo[*b*,*f*][1,2,3]triazolo[4,5-*d*]azocin-8yl and 8,9-dihydro-3H-dibenzo[*b*,*f*][1,2,3]triazolo[4,5-*d*]azocin-8yl structures illustrated below:



*3H*



*1H*

The linkers of Formulae Yk, YL and Ym will be a mixture of the 8,9-dihydro-1H-dibenzo[3,4:7,8]cycloocta[1,2-*d*][1,2,3]triazol-8-yl and 8,9-dihydro-1H-dibenzo[3,4:7,8]cycloocta[1,2-*d*][1,2,3]triazol-**9-yl** structures illustrated below:



-8-yl



-9-yl

The presence of such isomeric mixtures does not impair the functionality of the compositions employing such linkers.

**Galactosylating Moieties**

**[0069]** The galactosylating moieties employed in the compositions of the first and second aspect of the present invention serve to target the compositions to liver cells (for example, specifically binding hepatocytes) and can be selected from: galactose, galactosamine or N-acetylgalactosamine. It has been reported that ASGPR affinity can be retained while modifying either side of galactose's C3/C4 - diol anchor (Mamidyala, Sreeman K., et al., J. Am. Chem. Soc. 2012, 134, 1978-1981), therefore the points of conjugation are particularly at C1, C2 and C6.

**[0070]** Particular galactosylating moieties include galactose conjugated at C1 or C6, galactosamine conjugated at C2, and N-acetylgalactosamine conjugated at C6. Other particular galactosylating moieties include N-acetylgalactosamine conjugated at C2, more particularly conjugated to a linker bearing an $R^9$ substituent that is $CH_2$. Still other particular galactosylating moieties include galactose, galactosamine or N-acetylgalactosamine

conjugated at C1, more particularly conjugated to a linker bearing an $R^9$ substituent that is an ethylacetamido group.

**ASGPR Targeting Antibodies**

**[0071]** It is disclosed that if ASGPR-specific antibodies are employed in the compositions of the present disclosure, they also serve to target compositions of the disclosure to liver cells and can be selected from commercially available products, such as: Anti-Asialoglycoprotein Receptor 1 antibody (ab42488) from Abcam plc, Cambridge, UK and ASGPR1/2 (FL-291) (sc28977) from Santa Cruz Biotechnology, Inc., Dallas, TX. Alternatively, such antibodies can be expressed using any of a number of published sequences, such as the Dom26h-196-61, single-domain anti-ASGPR antibody:

EVQLLESGGGLVQPGGSLRLSCAASGFTFEKYAMAWVRQAPGKGLEWVSRISARGVTTYY
ADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCASHKRHEHTRFDSWGQGTLVTVSS
(SEQ.ID.No:6)

[Coulstock E, et al., (2013) "Liver-targeting of interferon-alpha with tissue-specific domain antibodies." PLoS One. 8(2):e57263 and US 2013/0078216], or such a sequence having conservative substitutions. The above-referenced US patent application discloses liver-targeting molecules such as DOM26h-196-61 for delivering certain therapeutics [including interferon (interferon alpha 2, interferon alpha 5, interferon alpha 6, or consensus interferon), Ribavirin, Nexavar/Sorafenib, Erbitus/Cetuximab, Avastatin/bevacizumab, and Herceptin/trastuzumab] for the treatment of liver diseases. The compositions of matter corresponding to Formula 2 employing DOM26h-196-61 or another liver-targeting molecule described in US 2013/0078216 do not include interferon (interferon alpha 2, interferon alpha 5, interferon alpha 6, or consensus interferon), Ribavirin, Nexavar/Sorafenib, Erbitus/Cetuximab, Avastatin/bevacizumab, and Herceptin/trastuzumab within their scope.

**[0072]** New sequences for an antibody, antibody fragment, or peptide that specifically targets ASGPR can be discovered using various methods known by those skilled in the art. These methods can include, but are not limited to, vaccination technology, hybridoma technology, library display technologies (including bacterial and phage platforms), endogenous repertoire screening technologies, directed evolution and rational design.

**Nomenclature**

**[0073]** The compositions of Formula 1 can be named using a combination of IUPAC and trivial names. For example, a compound corresponding to Formula 1 where X is a cyclobutyl moiety (shown instead of an antigen for illustrative purposes), Y is Formula Ya, m is 1, n is 4 and Z is N-acetylgalactosamin-2-yl:



can be named (*Z*)-(21-cyctobutyt-1-oxo-1-((2,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2*H*-pyran-3-yl)amino)-4,7,10,13-tetraoxa-16,17-dithiahenicosan-21-ylidene)triaz-1-yn-2-ium chloride, so the corresponding composition of the disclosure where X is tissue transglutaminase can be named (Z)-(21-(tissue transglutaminase)-1-oxo-1-((2,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2*H*-pyran-3-yl)amino)-4,7,10,13-tetraoxa-16,17-dithiahenicosan-21-ylidene)triaz-1-yn-2-ium chloride. The corresponding composition of the disclosure where X' is tissue transglutaminase, m is 2, n is 4 and Z' is N-acetylgalactosamin-2-yl can be named (3Z)-((tissue transgultaminase)-1,3-diylbis(1-oxo-1-((2,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2*H*-pyran-3-yl)amino)-4,7,10,13-tetraoxa-16,17-dithiahenicosan-21-yl-21-ylidene))bis(triaz-1-yn-2-ium chloride.

**[0074]** In the interest of simplification, the compositions of Formula 1 can be named using an alternative naming system by reference to X and correspondence to one of Formulae 1a to 1p (as illustrated in the reaction schemes) followed by recitation of the integers for variables m, n, p and/or q, $R^8$, $R^9$ and identification of the galactosylating moiety and the position at which it is conjugated. Under this system, the composition of Formula 1a where X is ovalbumin, m is 2, n is 4 and Z is N-acetylgalactosamin-2-yl can be named "F1a-OVA-$m_2$-$n_4$-2NAcGAL."

**[0075]** Similarly, the following composition of Formula 1




can be named "2-((2-(((3-(3-(22-((3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)tetrahydro-2*H*-pyran-2-yl)oxy)-16-cyano-16,18-dimethyl-13,19-dioxo-18-((phenylcarbonothioyl)thio)-3,6,9,12-tetraoxa-20-azadocosyl)-**3,9-dihydro**-8*H*-dibenzo[*b,f*][1,2,3]triazolo[4,5-*d*]azocin-8-yl)-3-oxopropyl)carbamoyl)oxy)ethyl)disulfanyl)ethyl insulin carboxylate." The isomer:




can be named "2-((2-(((3-(1-(22-((3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)tetrahydro-2*H*-pyran-2-yl)oxy)-16-cyano-16,18-dimethyl-13,19-dioxo-18-((phenylcarbonothioyl)thio)-3,6,9,12-tetraoxa-20-azadocosyl)-**1,9-dihydro**-8*H*-dibenzo[*b,f*[12,3]triazolo[4,5-*d*]azocin-8-yl)-3-oxopropyl)carbamoyl)-oxy)ethyl)disulfanyl)ethyl insulin carboxylate" (bold lettering highlights added for convenience in identifying the difference between the formal names). Employing the naming system asopted for the present disclosure, both isomers can be named "F1n-insulin-$m_1$-$n_1$-$p_1$-$q_4$-CMP-EtAcN-1NAcGAL" where CMP indicates that $R^8$ is 1-cyano-1-methyl-propyl,

EtAcN indicates that $R^9$ is ethylacetamido and 1NAcGAL indicates Z" is N-acetylgalactosamine conjugated at C1. Absence of the abbreviation EtAcN before the designation for Z would indicate that $R^9$ is a direct bond.

**[0076]** In the compositions of Formula 2, left-to-right orientation of should not be taken as specifying N to C ordering absent specific indication to the contrary. For example, the compound of Formula 2 where m' is 1, m" is 0, X is Ovalbumin, Y is $Gly_3Ser$ and Z is Anti-ASGPR Dom26h-196-61, can be named OVA-$Gly_3Ser$-DOM and read as covering both of the following:

N- OVA- $Gly_3Ser$- DOM-C
and

N- DOM- $Gly_3Ser$- OVA- C

**[0077]** The compositions of Formula 2, for example where m' is 1, m" is 0, X is Ovalbumin, Y is $Gly_3Ser$ and Z is Anti-ASGPR Dom26h-196-61 (having a purification tag attached via an additional linker) can be named as follows:

N- OVA- $Gly_3Ser$- DOM- $Gly_3Ser$-6xHis -C
or

N- DOM- $Gly_3Ser$- OVA- $Gly_3Ser$-6xHis -C

where the C' terminal $Gly_3Ser$-6xHis group represents an amino acid sequence that facilitates isolation and purification.

**[0078]** The composition of Formula 2 where m' is 1, m" is 1, each X is Factor VIII, each Y is $Gly_3Ser$ and Z is Anti-ASGPR Dom26h-196-61 (having a purification tag attached via an additional linker) can be named FVIII-$Gly_3Ser$-DOM-$Gly_3Ser$-FVIII-$Gly_3Ser$-6xHis and covers both of the following:

N-FVIII-$Gly_3Ser$-DOM-$Gly_3Ser$-FVIII-$Gly_3Ser$-6xHis-C
and

N-6xHis-$Gly_3Ser$-FVIII- $Gly_3Ser$-DOM-$Gly_3Ser$- FVIII-C.

**[0079]** The composition of Formula 2 where m' is 3, m" is 0, one, the three X antigens, respectively, are Alpha-gliadin "33-mer" deamidated (SEQ ID NO:25), Alpha-gliadin (SEQ ID NO:26) and Omega-gliadin (SEQ ID NO:27), each Y is a linker having an immunoproteosome cleavage site ("IPC"), and Z is Anti-ASGPR Dom26h-196-61 can be named:

Alpha-gliadin "33-mer" deamidated-IPC-Alpha-gliadin-IPC-Omega-gliadin-IPC-DOM.

**Preparation of the Compositions of The Disclosure**

**[0080]** The compositions of Formula 1 can be prepared, for example, by adjusting the procedures described in Zhu, L., et al., Bioconjugate Chem. 2010, 21, 2119-2127. Syntheses of certain compositions of Formula 1 are also described below with reference to Reaction Schemes 1 to 14. Other synthetic approaches will be apparent to those skilled in the art.

**[0081]** Formula 101 (below) is an alternative representation of X



where $R^1$ is a free surface amino ($-NH_2$) or thiol (-SH) moiety positioned on X's three-dimensional structure so as to be accessible for conjugation to a linker, and X' represents the remainder of X excluding the identified free amino group(s) [(X" is used in the reaction schemes to represent the remainder of X excluding free thiol group(s)]. Depending upon the identity of X, there will be at least one (the N-terminal amine) and can be multiple $R^1$ groups (predominantly from lysine residues or cysteine residues that are not involved in disulfide bonding), as represented by m, which is an integer from about 1 to 100, more typically 1 or from about 4 to 20, and most typically 1 to about 10.

**[0082]** Variables employed in the reaction schemes are as defined above, and additionally include the following, which should be understood to have these meanings absent any specific indication otherwise with respect to a particular reaction scheme or step.

- $R^2$ is OH or a protecting group;
- $R^3$ is OH, $NH_2$, NHAc, a protecting group or NH-protecting group;
- $R^4$ is OH or a protecting group;
- $R^5$ is OH or a protecting group;
- $R^6$ is OH or a protecting group;
- Z' is galactose conjugated at C1 or C6, galactosamine conjugated at C2, or N-acetylgalactosamine conjugated at C6;
- $R^8$ is $-CH_2-$ or $-CH_2-CH_2-C(CH_3)(CN)-$; and
- $R^9$ is a direct bond and Z" is N-acetylgalactosamine conjugated at C2;
- $R^9$ is an ethylacetamido group and Z" is galactose, galactosamine or N-acetylgalactosamine conjugated at C1.

**Synthetic Reaction Parameters**

**[0083]** The terms "solvent", "inert organic solvent" or "inert solvent" mean a solvent inert under the conditions of the reaction being described in conjunction therewith [including, for example, benzene, toluene, acetonitrile, tetrahydrofuran ("THF"), dimethylformamide ("DMF"), chloroform, methylene chloride (or dichloromethane), diethyl ether, methanol, pyridine and the like]. Unless specified to the contrary, the solvents used in the reactions of the present disclosure are inert organic solvents.

**[0084]** The term "q.s." means adding a quantity sufficient to achieve a stated function, e.g., to bring a solution to the desired volume (i.e., 100%).

**[0085]** Isolation and purification of the compounds and intermediates described herein can be effected, if desired, by any suitable separation or purification procedure such as, for example, filtration, extraction, crystallization, column chromatography, thin-layer chromatography or thick-layer chromatography, centrifugal size exclusion chromatography, high-performance liquid chromatography, recrystallization, sublimation, fast protein liquid chromatography, gel electrophoresis, dialysis, or a combination of these procedures. Specific illustrations of suitable separation and isolation procedures can be had by reference to the examples hereinbelow. However, other equivalent separation or isolation procedures can, of course, also be used.

**[0086]** Unless otherwise specified (including in the examples), all reactions are conducted at standard atmospheric pressure (about 1 atmosphere) and ambient (or room) temperature (about 20°C), at about pH 7.0-8.0.

**[0087]** Characterization of reaction products can be made by customary means, e.g., proton and carbon NMR, mass spectrometry, size exclusion chromatography, infrared spectroscopy, gel electrophoresis.

**[0088]** Reaction Scheme 1 illustrates the preparation of compositions of Formula 1 where Z can be galactose, galactosamine or N-acetylgalactosamine. In that regard and as defined above, Z' as employed in Reaction Scheme 1 encompases galactose conjugated at C1 and C6 and corresponding to the following structures according to Formula 1:







,

galactosamine conjugated at C2 and corresponding to the following structure according to Formula 1:





and N-acetylgalactosamine conjugated at C6 and corresponding to the following structure according to Formula 1:



Reaction Scheme 1














Formula 1a

**[0089]** As illustrated above in Reaction Scheme 1, Step 1, surface thiol group(s) can be generated on an antigen, antibody, antibody fragment or ligand having free surface amino group(s) (Formula 101') by contact with a Traut reagent (Formula 102) at a pH of about 8.0 for about 1 hour to give the Formula 103', from which unreacted Traut's reagent is removed, e.g., via centrifugal size exclusion chromatography. The two structures shown below, illustrate the product of Reaction Scheme 1, Step 1, respectively showing the free surface amino group(s) originally found on X (i.e., Formula 103' where X' represents the remainder of X excluding the identified free surface amino groups) and omitting the free surface amino group(s) (i.e., Formula 103). This parallels the distinction illustratted as between X and Formula 101. The convention has been followed in the subsequent reaction schemes.




**[0090]** In Reaction Scheme 1, Step 2, a pyridyl di-thiol-poly(ethylene glycol)-NHS ester (Formula 104) is contacted with galactosamine (Formula 105 where $R^3$ is $NH_2$ and $R^2$, $R^4$, $R^5$ and $R^6$ are OH) with stirring at about pH 8 for about 1 hour to give the corresponding pyridyl di-thiol-poly(ethylene glycol)-sugar of Formula 106A, which can be used without further purification.

**[0091]** In Reaction Scheme 1, Step 3, 4,4'-dithiodipyridine (Formula 107) is contacted with a thiol-poly(ethylene glycol)propanoic acid (Formula 108) to give the corresponding pyridyl di-thiol-poly(ethylene glycol)propanoic acid (Formula 109).

**[0092]** In Reaction Scheme 1, Step 4, the acid of Formula 109 is contacted with a protected galactose or N-acetylgalactosamine of Formula 105 where $R^2$ is OH and $R^3$, $R^4$, $R^5$ and $R^6$ are protecting groups ("PG"), where $R^6$ is OH and $R^2$, $R^3$, $R^4$ and $R^5$ are PG, or where $R^6$ is N-acetyl and $R^2$, $R^3$, $R^4$ and $R^5$ are PG to give the corresponding pyridyl di-thiol-poly(ethylene glycol)-sugars of Formulae 106B, 106C and 106D, which can be used following de-protection.

**[0093]** In Reaction Scheme 1, Step 5, to a stirred solution of the product of Step 1 (Formula 103') is added an excess (corresponding to the value of m) of the product of Step 2 or Step 4

(Formula 106, i.e., 106A, 106B, 106C or 106D) for about 1 hour, followed by centrifugal sized exclusion chromatography to remove any free remaining reactants to yield the corresponding product according to Formula 1a, respectively, Formula 1aA, Formula 1aB, Formula 1aC and Formula 1aD.

**[0094]** The compositions corresponding to Formula 1a can be named, respectively, e.g., as follows:

"F1aA-X'-$m_m$-$n_n$" or "F1a-X'-$m_m$-$n_n$-2NGAL"

"F1 aB-X'-$m_m$-$n_n$" or "F1a-X'-$m_m$-$n_n$-1GAL"

"F1aC-X'-$m_m$-$n_n$" or "F1a-X'-$m_m$-$n_n$-6GAL"

"F1aD-X'-$m_m$-$n_n$" or "F1 a-X'-$m_m$-$n_n$-6NAcGAL"

respectively, for products made employing an intermediate according to Formulae 106A-D.

**[0095]** Turning to Reaction Schemes 2-14 and for the purposes of the nomenclature employed therewith, except as expressly stated otherwise, Z" refers to N-acetylgalactosamine conjugated at C2:




or to galactose, galactosamine or N-acetylgalactosamine conjugated at C1. It should be noted that the C1 conjugated compositions need to be protected during synthesis, for example by cyclizing the amine with the C3 hydroxyl and de-protecting following incorporation of the protected galactosamine into the adjacent portion of the linker.

**[0096]** The poly(galactose methacrylate) reactants of Formulae 201, 401, 501, 601, 701, 803 and 1401 can be prepared by methacrylating galactose, e.g., contacting galactosamine and methacrylate anhydride, followed by reversible addition-fragmentation chain transfer (RAFT) polymerization with a corresponding RAFT agent in the presence of azobisisobutyronitrile (AIBN) in a suitable solvent, starting with freeze-thaw cycles followed by heating at about 60-80°C, preferably 70°C for about 5-8, preferably about 6 hours. The polymer can be precipitated in a lower alkanol, preferably methanol.

Reaction Scheme 2





Formula 1b

**[0097]** As illustrated in Reaction Scheme 2, an antigen, antibody, antibody fragment or ligand having free surface thiol group(s) prepared, e.g., as described with reference to Reaction Scheme 1, Step 1 (Formula 103') is contacted with an excess (corresponding to the value of m) of a pyridyl di-thiol-poly(ethylene glycol) of Formula 201 for about 1 hour to yield the corresponding product according to Formula 1b.

**[0098]** The compositions of Formula 1b can be named as follows:
"F1b-X'-$m_m$-$n_n$-$p_p$-2NAcGAL" or "F1b-X'-$m_m$-$n_n$-$p_p$-EtAcN-Z".
For example, the composition of Formula 1b where X' is uricase, m is 1, n is 4, p is 4 and Z" is N-acetylgalactosamine conjugated at C2 can be named "F1b-uricase-$m_1$-$n_4$-$p_4$-2NAcGAL" or "30-(uricase)-3,5,7,9-tetramethyl-12-oxo-1-phenyl-1-thioxo-3,5,7,9-tetrakis((2,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2*H*-pyran-3-yl)carbamoyl)-13,16,19,22-tetraoxa-2,25,26-trithiatriacontan-30-iminium".

Reaction Scheme 3



Formula 1c

**[0099]** As illustrated in Reaction Scheme 3, an antigen, antibody, antibody fragment or ligand having native free surface thiol group(s) (cysteines) [Formula 101" corresponding to Formula 101 and illustrating where X", as the term will be subsequently employed, represents X excluding the identified free surface thiol group(s)] is contacted with an excess (corresponding to the value of m) of a pyridyl di-thiol-poly(ethylene glycol) of Formula 201 to yield the corresponding product according to Formula 1c.

**[0100]** The compositions corresponding to Formula 1c can be named as follows:
"F1c-X'-$m_m$-$n_n$-$p_p$-2NAcGAL" or "F1c-X'-$m_m$-$n_n$-$p_p$-EtAcN-Z".

Reaction Scheme 4




Formula 1d

**[0101]** As illustrated in Reaction Scheme 4, an antigen, antibody, antibody fragment or ligand having native free surface thiol group(s) of Formula 101" is contacted with an excess (corresponding to the value of m) of a pyridyl di-thiol of Formula 401 to yield the corresponding product according to Formula 1d.

**[0102]** The compositions corresponding to Formula 1d can be named as follows: "F1d-X'-$m_m$-$p_p$-2NAcGAL" or "F1d-X'-$m_m$-$p_p$-EtAcN-Z".

Reaction Scheme 5




Formula 1e

**[0103]** As illustrated in Reaction Scheme 5, an antigen, antibody, antibody fragment or ligand having native free surface amino group(s) of Formula 101' is contacted with an excess (corresponding to the value of m) of a n-nitrophenyl carbonate of Formula 501 to yield the corresponding product according to Formula 1e.

**[0104]** The compositions corresponding to Formula 1e can be named as follows: "F1e-X'-$m_m$-$p_p$-2NAcGAL" or "F1e-X'-$m_m$-$p_p$-EtAcN-Z".

Reaction Scheme 6






Formula 1f

**[0105]** As illustrated in Reaction Scheme 6, an antigen, antibody, antibody fragment or ligand having native free surface amino group(s) of Formula 101' is contacted with an excess (corresponding to the value of m) of a n-nitrophenyl carbonate poly(ethylene glycol)ester of Formula 601 to yield the corresponding product according to Formula 1f.

**[0106]** The compositions corresponding to Formula 1f can be named as follows: "F1f-X'-$m_m$-$n_n$-$p_p$-2NAcGAL" or "F1f-X'-$m_m$-$n_n$-$p_p$-EtAcN-Z".

Reaction Scheme 7




Formula 1g

**[0107]** As illustrated in Reaction Scheme 7, an antigen, antibody, antibody fragment or ligand having native free surface amino group(s) of Formula 101' is contacted with an excess (corresponding to the value of m) of a NHS-ester poly(ethylene glycol)ester of Formula 701 to yield the corresponding product according to Formula 1g.

**[0108]** The compositions corresponding to Formula 1g can be named as follows: "F1g-X'-$m_m$-$p_p$-2NAcGAL" or "F1g-X'-$m_m$-$p_p$-EtAcN-Z"

Reaction Scheme 8





802



803

Step 2



and



Both, Formula 1h

**[0109]** As illustrated in Reaction Scheme 8, Step 1, an antigen, antibody, antibody fragment or ligand having native free surface amino group(s) of Formula 101' is contacted with an excess (corresponding to the value of m) of an amine-reactive linker for Click chemistry of Formula 801 to yield the corresponding product according to Formula 802.

**[0110]** In Reaction Scheme 8, Step 2, the product of Formula 802 is then contacted with an equivalent amount (again corresponding to the value of m) of a galactos(amine) polymer of Formula 803 to yield the corresponding isomeric product according to Formula 1h. The two isomers, illustrated above, result from non-specific cyclization of the azide of Formula 803 with the triple bond of Formula 802. Such non-specific cyclization occurs in the synthesis of other compositions where Y is selected from Formulae Yh through Yn, but will not be illustrated in each instance.

**[0111]** The compositions corresponding to Formula 1 h can be named as follows: "F1h-X'-$m_m$-$n_n$-$p_p$-$q_q$-2NAcGAL" or "F1h-X'-$m_m$-$n_n$-$p_p$-$q_q$-EtAcN-Z".

Reaction Scheme 9

101'



**[0112]** As illustrated in Reaction Scheme 9, Step 1, an antigen, antibody, antibody fragment or ligand having native free surface thiol group(s) of Formula 101" is contacted with an excess (corresponding to the value of m) of a thiol-reactive linker for Click chemistry of Formula 901 to yield the corresponding product according to Formula 902".

**[0113]** In Reaction Scheme 9, Step 2, the product of Formula 902" is then contacted with an equivalent amount (again corresponding to the value of m) of a galactos(amine) polymer of Formula 803 to yield the corresponding isomeric product according to Formula 1i.

**[0114]** The compositions corresponding to Formula 1i can be named as follows:
"F1i-X'-$m_m$-$n_n$-$p_p$-$q_q$-2NAcGAL" or "F1i-X'-$m_m$-$n_n$-$p_p$-$q_q$-EtAcN-Z".

**[0115]** By following the procedures described with regard to Reaction Scheme 9, but substituting starting material 101" with a compound of Formula 103' (derivatized with the Traut reagent) there is obtained the corresponding isomeric product of Formula 1j as shown below.



**[0116]** The compositions corresponding to Formula 1j can be named as follows: "F1j-X'-$m_m$-$n_n$-$p_p$-$q_q$-2NAcGAL" or "F1j-X'-$m_m$-$n_n$-$p_p$-$q_q$-EtAcN-Z".

Reaction Scheme 10




**[0117]** As illustrated in Reaction Scheme 10, Step 1, an antigen, antibody, antibody fragment or ligand having native free surface thiol group(s) of Formula 101" is contacted with an excess (corresponding to the value of m) of a thiol-reactive linker for Click chemistry of Formula 1001 to yield the corresponding product according to Formula 1002.

**[0118]** In Reaction Scheme 10, Step 2, the product of Formula 1002 is then contacted with an equivalent amount (again corresponding to the value of m) of a galactos(amine) polymer of Formula 803 to yield the corresponding isomeric product according to Formula 1k.

**[0119]** The compositions corresponding to Formula 1k can be named as follows: "F1k-X'-$m_m$-$n_n$-$p_p$-$q_q$-2NAcGAL" or "F1k-X'-$m_m$-$n_n$-$p_p$-$q_q$-EtAcN-Z".

**[0120]** By following the procedures described with regard to Reaction Scheme 10, but substituting starting material 101" with a compound of Formula 103' (derivatized with the Traut

reagent) there is obtained the corresponding isomeric product of Formula 1L as shown below.



Formula 1L

**[0121]** The compositions corresponding to Formula 1L can be named as follows: "F1L-X'-$m_m$-$n_n$-$p_p$-$q_q$-2NAcGAL" or "F1L-X'-$m_m$-$n_n$-$p_p$-$q_q$-EtAcN-Z".

**[0187]** Reaction Scheme 11






**[0122]** As illustrated in Reaction Scheme 11, Step 1, galactose, protected galactosamine or N-Acetyl-D-galactosamine (Formula1101 where $R^3$ and $R^4$ are OH, $R^3$ is NH-protecting group (e.g., cyclized with $R^4$) or $R^3$ is NHAc and $R^4$ is OH, respectively) is contacted with 2-chloroethan-1-ol followed by cooling and the dropwise addition of acetylchloride. The solution

is warmed to room temperature and then heated to 70°C for several hours. Ethanol is added to the crude product and the resulting solution is stirred in the presence of carbon and then filtered followed by solvent removal to yield the corresponding product of Formula 1102.

**[0123]** As illustrated in Reaction Scheme 11, Step 2, the product of Formula 1102 is added to an excess of sodium azide and heated to 90°C for several hours, then filtered followed by solvent removal to yield the corresponding product of Formula 1103.

**[0124]** As illustrated in Reaction Scheme 11, Step 3, the product of Formula 1103 is added to a solution of palladium on carbon and ethanol, and stirred under hydrogen gas (3 atm) for several hours, then filtered followed by solvent removal to yield the corresponding product of Formula 1104.

**[0125]** As illustrated in Reaction Scheme 11, Step 4, the product of Formula 1104 is added to a solution of methacrylate anhydride. Triethylamine is added and the reaction stirred for 2 hours followed by solvent removal and isolation to yield the corresponding product of Formula 1105.

**[0126]** As illustrated in Reaction Scheme 11, Step 5, an azide-modified uRAFT agent (Formula 1106) is added to a solution of the product of Formula 1105 with azobisisobutyronitrile, subjected to 4 free-pump-thaw cycles and then stirred at 70°C. After several hours the corresponding polymer product of Formula 1107 is precipitated by addition of a lower alkanol followed by solvent removal. Where $R^3$ is NH-protecting group (e.g., cyclized with $R^4$) the protecting group(s) is(are) removed at this point.

**[0127]** As illustrated in Reaction Scheme 11, Step 6, an antigen, antibody, antibody fragment or ligand having native free surface amino group(s) of Formula 101' is added to a pH 8.0 buffer and contacted with an excess (corresponding to the value of m) of a dioxopyrrolidine of Formula 1108 with stirring. After 1 hour unreacted Formula 1108 is removed and the resulting product of Formula 1109 is used without further purification.

**[0128]** As illustrated in Reaction Scheme 11, Step 7, the product of Formula 1107 is added to a pH 8.0 buffer, to which is added the product of Formula 1109. After stirring for 2 hours, the excess Formula 1107 is removed to yield the corresponding isomeric product of Formula 1m.

**[0129]** By substituting *N*-(2,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2*H*-pyran-3-yl)methacrylamide for the product of Formula 1105 in Step 5 and continuing with Steps 6 and 7, the corresponding isomeric product of Formula 1m where Z" is N-acetylgalactosamine conjugated at C2 are obtained.

**[0130]** The compositions corresponding to Formula 1m can be named as follows: "F1m-X'-$m_m$-$n_n$-$p_p$-$q_q$-EtAcN-Z" where Z" is 1GAL, 1NGAL or 1NAcGAL, or "F1m-X'-$m_m$-$n_n$-$p_p$-$q_q$-2NAcGAL".

Reaction Scheme 12









**[0131]** The synthetic approach of Reaction Scheme 12 is particularly suitable for hydrophobic antigens, antibodies, antibody fragments and ligands (e.g., Insulin) due to the use of organic solvents.

**[0132]** As illustrated in Reaction Scheme 12, Step 1, an antigen, antibody, antibody fragment or ligand having native free surface amino group(s) of Formula 101' is dissolved in an organic solvent (e.g., DMF) containing triethylamine. To this is added an amount (corresponding to the value of m) of a compound of Formula 1201 followed by stirring and the addition of t-butyl methyl ether. The corresponding product of Formula 1202 is recovered as a precipitate.

**[0133]** The product of Formula 1202 is resuspended in the organic solvent and an amount (corresponding to the value of m) of Formula 1107 (obtained, e.g., as described with reference to Reaction Scheme 11) is added followed by stirring. The reaction product is precipitated via the addition of dichloromethane, followed by filtration and solvent removal. Purification (e.g., resuspension in PBS followed by centrifugal size exclusion chromatography yields the corresponding isomeric product of Formula 1 n.

**[0134]** The compositions corresponding to Formula 1 n can be named as follows:

"F1n-X'-$m_m$-$n_n$-$p_p$-$q_q$-EtAcN-Z" where Z" is 1GAL, 1NGAL or 1 NAcGAL, or "F1m-X'-$n_m$-$n_n$-$p_p$-$q_q$-2NAcGAL".

Reaction Scheme 13




**[0135]** In Reaction Scheme 13, Step 1, a nitrophenoxycarbonyl-oxyalkyl di-thiol-poly(ethylene glycol)-NHS ester (Formula 1301) is contacted with galactose, galactosamine or N-acetylgalactosamine (Formula 105) to give the corresponding product of Formula 1302, along with the other two illustrated products, from which the desired nitrophenoxycarbonyl di-thiol-poly(ethylene glycol)-carboxyethyl galactose, galactosamine or N-acetylgalactosamine of Formula 1302 is isolated before proceeding to the next step.

**[0136]** As illustrated in Reaction Scheme 13, Step 2, an antigen, antibody, antibody fragment or ligand having native free surface amino group(s) of Formula 101' is contacted with an excess (corresponding to the value of m) of the proeuct of Formula 1302 to yield the corresponding product according to Formula 1o.

**[0137]** The compositions corresponding to Formula 1o can be named as follows: "F1o-X'-$m_m$-$n_n$-Z'."

Reaction Scheme 14





Formula 1p

**[0138]** As illustrated in Reaction Scheme 14, an antigen, antibody, antibody fragment or ligand having native free surface amino group(s) (Formula 101') is contacted with an excess (corresponding to the value of m) of a pyridyl di-thiol-poly(ethylene glycol)-NHS ester of Formula 1401 to yield the corresponding product according to Formula 1p.

**[0139]** The compositions corresponding to Formula 1p can be named as follows: "F1p-X'-$m_m$-$n_n$-$p_p$-2NAcGAL" or "F1p-X'-$m_m$-$n_n$-$p_p$-EtAcN-Z".

**Preparation of Fusion Proteins**

**[0140]** Fusion protein compositions of Formula 2 can be expressed via art-accepted methodology using commercially available mammalian, bacterial, yeast, or insect cell expression vectors, and published, discovered, or engineered gene sequences. Sequences encoding X, Y and Z together with tag sequences can be cloned into an expression vector, for example, into the mammalian expression vector pSecTag A, where the fusion protein is inserted C-terminal to the Ig κ-chain secretion leader sequence. Various other cloning techniques can be employed, including site-directed mutagenesis and variations of the QuikChange protocol (Geiser, *et al.*), and are known by those skilled in the art. Fusion proteins can be transiently expressed in mammalian cells [e.g., in human embryonic kidney (HEK293) cells or Chinese hamster ovary (CHO) cells] by transient transfection with the above-described vectors using polyethylenimine. Transfected cells are cultured in a suitable medium (e.g., FreeStyle 293 medium, Life Technologies) supplemented, for example, with valproic acid or DMSO for about 7 days, after which the cells are removed by centrifugation and the culture supernatants are collected and sterilized by filtration.

**[0141]** Alternatively, the fusion proteins can be stably expressed by creating stably transfected mammalian cell lines. Additionally, expression vectors can be used to produce fusion proteins in bacteria, such as *Escherichia coli, Corynebacterium,* or *Pseudomonas fluorescens* by using compatible media (e.g LB, 2XYT, SOB, SOC, TB and other broths), supplements (e.g. glycerol, glucose, and other supplements), and appropriate growth and expression conditions. Expression systems in yeast can commonly use *Saccharomyces cerevisiae* and *Pichia pastoris,* or other organisms for the genera *Saccharomyces, Pichia, Kluyveromyces,* and *Yarrowia,* and less commonly used organisms like the filamentous fungi *Aspergillus, Trichoderma,* or *Myceliophthora thermophila* C1. Insect expression systems can utilze

baculovirus infected insect cells or non-lytic insect cell expression to achieve protein expression levels in high quantitiy; most common insect cells include but are not limited to Sf9 and Sf21 (from *Spodoptera frugiperda*), Hi-5 (from *Trichoplusia ni*), and Schneider 2 and 3 (from *Drosophila melanogaster*).

**[0142]** The expressed fusion protein products can be purified from the culture supernatants by affinity chromatography (e.g., using a HisTrap $Ni^{2+}$ sepharose column, GE Healthcare, for a His-tagged fusion protein), followed by other chromatographic polishing steps such as size exclusion chromatography (e.g., using a Superdex 75 column, GE Healthcare) or ion exchange chromatography. Protein purity can be verified, e.g., by Coomassie Brilliant Blue staining of SDS-PAGE gels and western blotting (e.g. anti-6xHis tag western blotting for a His-tagged fusion protein). Protein concentration can be determined using the Beer-Lambert Law, for which the absorbance at 280 nm can be measured, e.g., using a NanoDrop 2000 (Thermo Scientific). The molecular weight and extinction coefficient can be estimated from the protein's amino acid sequence, e.g., using the ExPASy ProtParam tool. Endotoxin levels can be measured, e.g., using the HEK-Blue TLR4 reporter cell line (Invivogen) according to manufacturer's instructions.

**Preparation of Desialylated Antigens, Antibodies, Antibody Fragments and Ligands**

**[0143]** Desialylated proteins can be produced via art-accepted methodology using commercially available neuraminidase (also known as acetyl-neuraminyl hydrolase or sialidase) enzyme or sulfuric acid. For enzymatic desialylation of a protein of interest, the protein can be incubated together with neuraminidase at 37°C for 1 hour, or longer as necessary. For chemical desialylation through acid hydrolysis, a protein of interest can be treated with 0.025 N sulfuric acid at 80°C for 1 hour, or longer as necessary. The desialylated protein can then be purified from the reaction mixture by immobilized metal ion affinity chromatography (e.g., using a HisTrap Ni2+ sepharose column, GE Healthcare), followed by size exclusion chromatography (e.g., using a Superdex 75 column, GE Healthcare). Protein purity can be verified, e.g., by Coomassie Brilliant Blue staining of SDS-PAGE gels and anti-6xHis tag western blotting. Desialylation can be verified, e.g. by lectin-based detection of protein sialic acid content in western blots or colorimetric quantification of sialic acid content using commercially available kits (e.g. Abcam, ProZyme, or Sigma). Desialylated protein concentration can be determined using the Beer-Lambert Law, for which the absorbance at 280 nm can be measured, e.g., using a NanoDrop 2000 (Thermo Scientific). The molecular weight and extinction coefficient can be estimated from the protein's amino acid sequence, e.g., using the ExPASy ProtParam tool. Endotoxin levels can be measured, e.g., using the HEK-Blue TLR4 reporter cell line (Invivogen) according to manufacturer's instructions.

**Particular Processes and Last Steps**

**[0144]** A compound of Formula 103' is contacted with an excess (corresponding to the value of m) of a compound of Formula 106 to give the corresponding product of Formula 1a.

**[0145]** A compound of Formula 103' is contacted with an excess (corresponding to the value of m) of a compound of Formula 201 to give the corresponding product of Formula 1b.

**[0146]** A compound of Formula 802, 902 or 1002 is contacted with an excess (corresponding to the value of m) of a compound of Formula 803 to give the corresponding product of Formula 1h, Formula 1i or Formula 1k, respectively.

**[0147]** A compound of Formula 1109 is contacted with an excess (corresponding to the value of m) of a compound of Formula 1107 to give the corresponding product of Formula 1m, particularly where n is about 80, p is about 30, q is about 4, and m being a function of the antigen is about 2 to 10.

**[0148]** A compound of Formula 1202 is contacted with an excess (corresponding to the value of m) of a compound of Formula 1107 to give the corresponding product of Formula 1n, particularly where n is about 1, p is about 30, q is about **4**, and m being a function of the antigen is about 2 to 10.

**Particular Compositions for use**

**[0149]** By way of non-limiting example, a particular group preferred for the compositions and pharmaceutical formulations for use in the tolerization of a patient of the present invention are the following combinations and permutations of substituent groups of Formula 1 (sub-grouped, respectively, in increasing order of preference):

- X is a foreign transplant antigen against which transplant recipients develop an immune response, a foreign antigen to which patients develop an immune response, a therapeutic protein to which patients develop an immune response, a self-antigen to which patients develop an immune response.
- X is a therapeutic protein to which patients develop an immune response selected from: Abatacept, Abciximab, Adalimumab, Adenosine deaminase, Ado-trastuzumab emtansine, Agalsidase alfa, Agalsidase beta, Aldeslukin, Alglucerase, Alglucosidase alfa, α-1-proteinase inhibitor, Anakinra, Anistreplase (anisoylated plasminogen streptokinase activator complex), Antithrombin III, Antithymocyte globulin, Ateplase, Bevacizumab, Bivalirudin, Botulinum toxin type A, Botulinum toxin type B, C1-esterase inhibitor, Canakinumab, Carboxypeptidase G2 (Glucarpidase and Voraxaze), Certolizumab pegol, Cetuximab, Collagenase, Crotalidae immune Fab, Darbepoetin-α, Denosumab, Digoxin immune Fab, Dornase alfa, Eculizumab, Etanercept, Factor VIIa, Factor VIII, Factor IX, Factor XI, Factor XIII, Fibrinogen, Filgrastim, Galsulfase, Golimumab, Histrelin acetate, Hyaluronidase, Idursulphase, Imiglucerase, Infliximab, Insulin (including rHu insulin and bovine insulin), Interferon-α2a, Interferon-α2b, Interferon-β1a, Interferon-β1b,

Interferon-ylb, Ipilimumab, L-arginase, L-asparaginase, L-methionase, Lactase, Laronidase, Lepirudin / hirudin, Mecasermin, Mecasermin rinfabate, Methoxy Ofatumumab, Natalizumab, Octreotide, Oprelvekin, Pancreatic amylase, Pancreatic lipase, Papain, Peg-asparaginase, Peg-doxorubicin HCl, PEG-epoetin-β, Pegfilgrastim, Peg-Interferon-α2a, Peg-Interferon-α2b, Pegloticase, Pegvisomant, Phenylalanine ammonia-lyase (PAL), Protein C, Rasburicase (uricase), Sacrosidase, Salmon calcitonin, Sargramostim, Streptokinase, Tenecteplase, Teriparatide, Tocilizumab (atlizumab), Trastuzumab, Type 1 alpha-interferon, Ustekinumab, and vW factor.

◦ Especially where X is Abciximab, Adalimumab, Agalsidase alfa, Agalsidase beta, Aldeslukin, Alglucosidase alfa, Factor VIII, Factor IX, Infliximab, L-asparaginase, Laronidase, Natalizumab, Octreotide, Phenylalanine ammonia-lyase (PAL), or Rasburicase (uricase).

▪ Particularly where X is Factor VIII, Factor IX, uricase, PAL or asparaginase.

- X is a self-antigen polypeptide selected for treating type 1 diabetes mellitus, pediatric multiple sclerosis, juvenile rheumatoid arthritis, celiac disease, or alopecia universalis.

  ◦ Especially where X is a self-antigen polypeptide selected for treating new onset type 1 diabetes mellitus, pediatric multiple sclerosis or celiac disease.
- X is a foreign antigen to which patients develop an immune response

  ◦ From peanut, including conarachin (Ara h 1)

  ◦ From wheat, including Alpha-gliadin "33-mer" native (SEQ ID NO:24), Alpha-gliadin "33-mer" deamidated (SEQ ID NO:25), Alpha-gliadin (SEQ ID NO:26) and Omega-gliadin (SEQ ID NO:27).

  ◦ From cat, including Fel d 1A (UNIPROT P30438) and Cat albumin (UNIPROT P49064).

  ◦ From dog, including Can f 1 (UNIPROT 018873) and Dog albumin (UNIPROT P49822).

- X is a foreign transplant antigen against which transplant recipients develop an immune response, e.g. a human leukocyte antigen protein.
- Y is a linker selected from: Formula Ya, Formula Yb, Formula Yh, Formula Yi, Formula Yk, Formula Ym, Formula Yn, Formula Yo and Formula Yp.

  ◦ Especially where n is 8 to 90 ±10%, p is 20 to 100 ±10%, and q is 3 to 20 ±3.

  ▪ Particularly where n is 40 to 80 ±10%, p is 30 to 40 ±10%, and q is 4 to 12 ±3.

  ◦ Especially where Y is Formula Ya, Formula Yb, Formula Ym or Formula Yn.

  ▪ Particularly where n is 8 to 90 ±10%, p is 20 to 100 ±10% and q is 3 to 20 ±3.

    ◦ More particularly where n is 40 to 80 ±10%, p is 30 to 40 ±10%, and q is 4 to 12 ±3.

  ▪ Particularly where Z is conjugated to Y via an ethylacetamido group.

    ◦ More particularly where Z is conjugated to Y at its C1.

- More particularly where $R^8$ is CMP.

- More particularly where $R^8$ is CMP.

- Particularly where $R^8$ is CMP.

- Z is galactose, galactosamine or N-acetylgalactosamine.
  - Especially where Z is galactose or N-acetylgalactosamine conjugated at C1, C2 or C6.
    - Particularly where Z is galactose or N-acetylgalactosamine conjugated at C1 or C2.
      - More particularly where Z is N-acetylgalactosamine conjugated at C1.

**[0150]** Each of the above-described groups and sub-groups are individually preferred and can be combined to describe further preferred aspects of the disclosure, for example but not by way of limitation, as follows:

- X is a self-antigen polypeptide selected for treating type 1 diabetes mellitus, pediatric multiple sclerosis, juvenile rheumatoid arthritis, celiac disease, or alopecia universalis.

  - Especially where X is a self-antigen polypeptide selected for treating new onset type 1 diabetes mellitus, pediatric multiple sclerosis or celiac disease.

    - Particularly where Y is a linker selected from: Formula Ya, Formula Yb, Formula Yh, Formula Yi, Formula Yk, Formula Ym, Formula Yn, Formula Yo and Formula Yp.

      - Especially where n is 8 to 90 ±10%, p is 20 to 100 ±10%, and q is 3 to 20 ±3.
        - Particularly where n is 40 to 80 ±10%, p is 30 to 40 ±10%, and q is 4 to 12 ±3.
      - Especially where Y is Formula Ya, Formula Yb, Formula Ym or Formula Yn.

        - Particularly where n is 8 to 90 ±10%, p is 20 to 100 ±10% and q is 3 to 20 ±3..

        - More particularly where n is 40 to 80 ±10%, p is 30 to 40 ±10%, and q is 4 to 12 ±3.

          - Even more particularly where Z is conjugated to Y via an ethylacetamido group.

        - More particularly where Z is conjugated to Y via an ethylacetamido group.

      - Especially where Z is galactose, galactosamine or N-acetylgalactosamine.
        - Particularly where Z is galactose or N-acetylgalactosamine conjugated at C1, C2 or C6.
          - More particularly where Z is galactose or N-acetylgalactosamine conjugated at C1 or C2.
            - Even more particularly where Z is N-acetylgalactosamine conjugated at C1.

▪ Particularly where Z is galactose, galactosamine or N-acetylgalactosamine.

◦ Especially where Z is galactose or N-acetylgalactosamine conjugated at C1, C2 or C6.

◦ Particularly where Z is galactose or N-acetylgalactosamine conjugated at C1 or C2.

▪ More particularly where Z is N-acetylgalactosamine conjugated at C1.

◦ Especially where Y is a linker selected from: Formula Ya, Formula Yb, Formula Yh, Formula Yi, Formula Yk, Formula Ym, Formula Yn, Formula Yo and Formula Yp.

▪ Paritcularly where n is 8 to 90 ±10%, p is 20 to 100 ±10%, and q is 3 to 20 ±3.

◦ More particularly where n is 40 to 80 ±10%, p is 30 to 40 ±10%, and q is 4 to 12 ±3.

▪ Particularly where Y is Formula Ya, Formula Yb, Formula Ym or Formula Yn.

◦ More particularly where n is 8 to 90 ±10%, p is 20 to 100 ±10% and q is 3 to 20 ±3..

◦ More preferably where n is 40 to 80 ±10%, p is 30 to 40 ±10%, and q is 4 to 12 ±3.

◦ More particularly where Z is conjugated to Y via an ethylacetamido group.

◦ Especially where Z is galactose, galactosamine or N-acetylgalactosamine.

▪ Particularly where Z is galactose or N-acetylgalactosamine conjugated at C1, C2 or C6.

◦ More particularly where Z is galactose or N-acetylgalactosamine conjugated at C1 or C2.

◦ More preferably where Z is N-acetylgalactosamine conjugated at C1.

- m is an integer from about 1 to 100.

◦ m is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65 70, 75, 80, 85, 90, 95, 100 or 110.

◦ Particularly m is from about 1 to 20.

▪ m is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21 or 22.

▪ More particularly m is about 10.

◦ m is 9, 10 or 11.

- n is an integer representing a mixture including from about 1 to 100

◦ n is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 22, 25, 30, 34, 35, 37, 40, 41, 45, 50, 54, 55, 59, 60, 65, 70, 75, 80, 82, 83, 85, 88, 90, 95, 99, 100, 105 or 110.

▪ Particularly n is about 8 to 90.

▪ Particularly n is 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 22, 25, 30, 34, 35, 37, 40, 41, 45, 50, 54, 55, 59, 60, 65, 70, 75, 80, 82, 83, 85, 88, 90, 95 or 99.

- More particularly n is about 40 to 80.
- More particularly n is 37, 40, 41, 45, 50, 54, 55, 59, 60, 65, 70, 75, 80, 82, 83 or 88.

◦ n represents a mixture encompassing the ranges 1-4, 2-4, 2-6, 3-8, 7-13, 6-14, 15-25, 26-30, 42-50, 46-57, 60-82, 85-90, 90-110 and 107-113.
▪ Particularly n represents a mixture encompasing the ranges 7-13, 6-14, 15-25, 26-30, 42-50, 46-57, 60-82, 85-90 and 82-99.

- More particularly n represents a mixture encompasing the ranges 36-44, 42-50, 46-57, 60-82 and 75-85.

◦ p is is an integer representing a mixture including from about 2 to 150.

▪ p is 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65 70, 75, 80, 85, 90, 95, 100, 110, 120, 130, 140, 150, 160 or 165.

▪ Particularly where n is an integer representing a mixture including from about 1 to 100.

- Particularly n is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 22, 25, 30, 34, 35, 37, 40, 41, 45, 50, 54, 55, 59, 60, 65, 70, 75, 80, 82, 83, 85, 88, 90, 95, 99, 100, 105 or 110.

◦ More particularly where n is about 8 to 90.

◦ More particularly n is 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 22, 25, 30, 34, 35, 37, 40, 41, 45, 50, 54, 55, 59, 60, 65, 70, 75, 80, 82, 83, 85, 88, 90, 95 or 99.

▪ Even more particularly where n is about 40 to 80.

▪ Even more particularly n is 37, 40, 41, 45, 50, 54, 55, 59, 60, 65, 70, 75, 80, 82, 83 or 88.

- More particularly p is 18, 19, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65 70, 75, 80, 85, 90, 95, 100 or 110.

◦ Particularly where n is an integer representing a mixture including from about 1 to 100.
▪ Particularly n is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 22, 25, 30, 34, 35, 37, 40, 41, 45, 50, 54, 55, 59, 60, 65, 70, 75, 80, 82, 83, 85, 88, 90, 95, 99, 100, 105 or 110.

- More particularly where n is about 8 to 90.

- More particularly n is 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 22, 25, 30, 34, 35, 37, 40, 41, 45, 50, 54, 55, 59, 60, 65, 70, 75, 80, 82, 83, 85, 88, 90, 95 or 99.

  - Even more particularly where n is about 40 to 80.

  - Even more particularly n is 37, 40, 41, 45, 50, 54, 55, 59, 60, 65, 70, 75, 80, 82, 83 or 88.

- More particularly p is 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, or 44.
- Particularly where n is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 22, 25, 30, 34, 35, 37, 40, 41, 45, 50, 54, 55, 59, 60, 65, 70, 75, 80, 82, 83, 85, 88, 90, 95, 99, 100, 105 or 110.

  - More particularly where n is about 8 to 90.
  - More particularly n is 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 22, 25, 30, 34, 35, 37, 40, 41, 45, 50, 54, 55, 59, 60, 65, 70, 75, 80, 82, 83, 85, 88, 90, 95 or 99.

    - Even more particularly where n is about 40 to 80.

    - Even more particularly n is 37, 40, 41, 45, 50, 54, 55, 59, 60, 65, 70, 75, 80, 82, 83 or 88.

    - q is is an integer representing a mixture including from about 1 to 44.
    - q is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 44 or 48.

**[0151]** By way of non-limiting example, a particular group preferred for the disclosed compositions, pharmaceutical formulations, methods of manufacture and use are the following combinations and permutations of substituent groups of Formula 2 (sub-grouped, respectively, in increasing order of preference):

- X is a therapeutic protein to which patients develop an unwanted immune response selected from: Abatacept, Abciximab, Adalimumab, Adenosine deaminase, Ado-trastuzumab emtansine, Agalsidase alfa, Agalsidase beta, Aldeslukin, Alglucerase, Alglucosidase alfa, α-1-proteinase inhibitor, Anakinra, Anistreplase (anisoylated plasminogen streptokinase activator complex), Antithrombin III, Antithymocyte globulin, Ateplase, Bevacizumab, Bivalirudin, Botulinum toxin type A, Botulinum toxin type B, C1-esterase inhibitor, Canakinumab, Carboxypeptidase G2 (Glucarpidase and Voraxaze), Certolizumab pegol, Cetuximab, Collagenase, Crotalidae immune Fab, Darbepoetin-α, Denosumab, Digoxin immune Fab, Dornase alfa, Eculizumab, Etanercept, Factor Vila, Factor VIII, Factor IX, Factor XI, Factor XIII, Fibrinogen, Filgrastim, Galsulfase, Golimumab, Histrelin acetate, Hyaluronidase, Idursulphase, Imiglucerase, Infliximab,

Insulin, Interferon-α2a, Interferon-α2b, Interferon-β1a, Interferon-β1b, Interferon-ylb, Ipilimumab, L-arginase, L-asparaginase, L-methionase, Lactase, Laronidase, Lepirudin / hirudin, Mecasermin, Mecasermin rinfabate, Methoxy Ofatumumab, Natalizumab, Octreotide, Oprelvekin, Pancreatic amylase, Pancreatic lipase, Papain, Peg-asparaginase, Peg-doxorubicin HCl, PEG-epoetin-β, Pegfilgrastim, Peg-Interferon-α2a, Peg-Interferon-α2b, Pegloticase, Pegvisomant, Phenylalanine ammonia-lyase (PAL), Protein C, Rasburicase (uricase), Sacrosidase, Salmon calcitonin, Sargramostim, Streptokinase, Tenecteplase, Teriparatide, Tocilizumab (atlizumab), Trastuzumab, Type 1 alpha-interferon, Ustekinumab, and vW factor; provided that interferon (interferon alpha 2, interferon alpha 5, interferon alpha 6, or consensus interferon), Ribavirin, Nexavar/ Sorafenib, Erbitus/Cetuximab, Avastatin/bevacizumab, and Herceptin/trastuzumab are excluded from the scope of Formula 2 when m'+m" equals 1 and Z is DOM 26h-196-61 or another of the liver-targeting molecules described in US 2013/0078216.

◦ Especially where X is Abciximab, Adalimumab, Agalsidase alfa, Agalsidase beta, Aldeslukin, Alglucosidase alfa, Factor VIII, Factor IX, Infliximab, L-asparaginase, Laronidase, Natalizumab, Octreotide, Phenylalanine ammonia-lyase (PAL), or Rasburicase (uricase).

▪ Particularly where X is Factor VIII, Factor IX, uricase, PAL or asparaginase.

- X is a self-antigen polypeptide selected for treating type 1 diabetes mellitus, pediatric multiple sclerosis, juvenile rheumatoid arthritis, celiac disease, or alopecia universalis.
  ◦ Especially where X is a self-antigen polypeptide selected for treating new onset type 1 diabetes mellitus, pediatric multiple sclerosis or celiac disease.
- X is a foreign antigen to which patients develop an unwanted immune response

  ◦ From peanut, including conarachin (Ara h 1).

  ◦ From wheat, including Alpha-gliadin "33-mer" native (SEQ ID NO:24), Alpha-gliadin "33-mer" deamidated (SEQ ID NO:25), Alpha-gliadin (SEQ ID NO:26) and Omega-gliadin (SEQ ID NO:27).

  ◦ From cat, including Fel d 1A (UNIPROT P30438) and Cat albumin (UNIPROT P49064).

  ◦ From dog, including Can f 1 (UNIPROT 018873) and Dog albumin (UNIPROT P49822).

- X s is a foreign transplant antigen against which transplant recipients develop an unwanted immune response, e.g. a human leukocyte antigen protein.
- X is an antibody, antibody fragment or ligand that specifically binds a circulating protein or peptide or antibody, which circulating protein or peptide or antibody gives rise to transplant rejection, immune response against a therapeutic agent, autoimmune disease, and/or allergy.
  ◦ Especially where X binds an endogenous circulating protein or peptide or antibody.
- Y is $Gly_3Ser$.
- Z is Anti-ASGPR Dom26h-196-61 or a conservative substitution.
- m' + m" equals 1 or 2 and X is a full length protein, including protein therapeutics.
- m' + m" equals 1 or 2 where m' is 1 and m" is 0 or 1.

- m' + m'' equals 2 to about 10 where X is a group of self-antigen peptides (epitopes) known to be associated with a particular autoimmune disease or for treatment of genetically diverse target populations.
  ◦ m' + m'' equals about 4 to 7 where the autoimmune disease is multiple sclerosis and X is indpendently selected from: MBP13-32 (SEQ ID NO:11), MBP83-99 (SEQ ID NO:12), MBP111-129 (SEQ ID NO:13), MBP146-170 (SEQ ID NO:14), MOG1-20 (SEQ ID NO:15), MOG35-55 (SEQ ID NO:16) and PLP139-154 (SEQ ID NO:17).
  ▪ m' + m'' equals 7 and X is, respectively, MBP13-32 (SEQ ID NO:11), MBP83-99 (SEQ ID NO:12), MBP111-129 (SEQ ID NO:13), MBP146-170 (SEQ ID NO:14), MOG1-20 (SEQ ID NO:15), MOG35-55 (SEQ ID NO:16) and PLP139-154 (SEQ ID NO:17).

**[0152]** As with the above discussion regarding Formula 1, each of the above-described groups and sub-groups for Formula 2 are individually preferred and can be combined to describe further preferred aspects of the disclosure.

## Utility, Testing and Administration

### General Utility

**[0153]** The compositions for use of the invention find use in a variety of applications including, as will be appreciated by those in the art, treatment of transplant rejection, immune response against a therapeutic agent, autoimmune disease, and food allergy.

**[0154]** In a preferred embodiment, the compositions for use of the invention are used to modulate, particularly down-regulate, antigen-specific undesirable immune response.

**[0155]** The compositions of the disclosure are useful to bind and clear from the circulation specific undesired proteins, including antibodies endogenously generated in a patient (i.e., not exogenous antibodies administered to a patient), peptides and the like, which cause autoimmunity and associated pathologies, allergy, inflammatory immune responses, and anaphylaxis.

**[0156]** In the present disclosure, antigens are targeted to the liver for presentation via antigen-presenting cells to specifically down-regulate the immune system or for clearance of unwanted circulating proteins. This is distinct from previous uses of liver targeting, for example as described in US 2013/0078216, where the purpose of liver-targeting molecules such as DOM26h-196-61 was the delivery of therapeutic agents to treat liver diseases such as fibrosis, hepatitis, Cirrhosis and liver cancer.

**[0157]** The present disclosure provides compositions and compositions for use to treat

unwanted immune response to self-antigens and foreign antigens, including but not limited to: a foreign transplant antigen against which transplant recipients develop an unwanted immune response (e.g., transplant rejection), a foreign antigen to which patients develop an unwanted immune (e.g., allergic or hypersensitivity) response, a therapeutic agent to which patients develop an unwanted immune response (e.g., hypersensitivity and/or reduced therapeutic activity), a self antigen to which patients develop an unwanted immune response (e.g., autoimmune disease)

**[0158]** Autoimmune disease states that can be treated using the methods and compositions disclosed herein include, but are not limited to: Acute Disseminated Encephalomyelitis (ADEM); Acute interstital allergic nephritis (drug allergies); Acute necrotizing hemorrhagic leukoencephalitis; Addison's Disease; Alopecia areata; Alopecia universalis; Ankylosing Spondylitis; Arthritis, juvenile; Arthritis, psoriatic; Arthritis, rheumatoid; Atopic Dermatitis; Autoimmune aplastic anemia; Autoimmune gastritis; Autoimmune hepatitis; Autoimmune hypophysitis; Autoimmune oophoritis; Autoimmune orchitis; Autoimmune polyendocrine syndrome type 1; Autoimmune polyendocrine syndrome type 2; Autoimmune thyroiditis; Behcet's disease; Bronchiolitis obliterans; Bullous pemphigoid; Celiac disease; Churg-Strauss syndrome; Chronic inflammatory demyelinating polyneuropathy; Cicatricial pemphigoid; Crohn's disease; Coxsackie myocarditis; Dermatitis herpetiformis Duhring; Diabetes mellitus (Type 1); Erythema nodosum; Epidermolysis bullosa acquisita, Giant cell arteritis (temporal arteritis); Giant cell myocarditis; Goodpasture's syndrome; Graves' disease; Guillain-Barre syndrome; Hashimoto's encephalitis; Hashimoto's thyroiditis; IgG4-related sclerosing disease; Lambert-Eaton syndrome; Mixed connective tissue disease; Mucha-Habermann disease; Multiple sclerosis; Myasthenia gravis; Optic neuritis; Neuromyelitis optica; Pemphigus vulgaris and variants; Pernicious angemis; Pituitary autoimmune disease; Polymyositis; Postpericardiotomy syndrome; Premature ovarian failure; Primary Biliary Cirrhosis; Primary sclerosing cholangitis; Psoriasis; Rheumatic heart disease; Sjogren's syndrome; Systemic lupus erythematosus; Systemic sclerosis; Ulcerative colitis; Undifferentiated connective tissue disease (UCTD); Uveitis; Vitiligo; and Wegener's granulomatosis.

**[0159]** A particular group of autoimmune disease states that can be treated using the compositions for use provided herein include, but are not limited to: Acute necrotizing hemorrhagic leukoencephalitis; Addison's Disease; Arthritis, psoriatic; Arthritis, rheumatoid; Autoimmune aplastic anemia; Autoimmune hypophysitis; Autoimmune gastritis; Autoimmune polyendocrine syndrome type 1; Bullous pemphigoid; Celiac disease; Coxsackie myocarditis; Dermatitis herpetiformis Duhring; Diabetes mellitus (Type 1); Epidermolysis bullosa acquisita; Giant cell myocarditis; Goodpasture's syndrome; Graves' disease; Hashimoto's thyroiditis; Mixed connective tissue disease; Multiple sclerosis; Myasthenia gravis; Neuromyelitis optica; Pernicious angemis; Pemphigus vulgaris and variants; Pituitary autoimmune disease; Premature ovarian failure; Rheumatic heart disease; Systemic sclerosis; Sjogren's syndrome; Systemic lupus erythematosus; and Vitiligo.

**[0160]** In the embodiments of the second aspect of the invention employing an antigen against which an immune response is developed, such as food antigens, treatment can be provided for

reactions against, for example: peanut, apple, milk, egg whites, egg yolks, mustard, celery, shrimp, wheat (and other cereals), strawberry and banana.

**[0161]** As will be appreciated by those skilled in the art, a patient can be tested to identify a foreign antigen against which an unwanted immune response has developed, and a composition of the disclosure can be developed based on that antigen.

**Testing**

**[0162]** In establishing the utility of the compositions and compositions for use of the invention, specificity in binding to antigen-presenting cells in the liver (particularly binding to hepatocytes and specifically ASGPR) should initially be determined. This can be accomplished, for example, by employing a marker (such as the fluorescent marker phycoerythrin ("PE")) in a composition of the disclosure. The composition is administered to suitable experimental subjects. Controls, e.g., unconjugated PE or vehicle (saline) are administered to other group(s) of subjects. The composition and controls are allowed to circulate for a period of 1 to 5 hours, after which the spleens and livers of the subjects are harvested and measured for fluorescence. The specific cells in which fluorescence is found can be subsequently identified. Compositions of the disclosure, when tested in this manner, show higher levels of concentration in the antigen-presenting cells of the liver as compared with unconjugated PE or vehicle.

**[0163]** Effectiveness in immune modulation can be tested by measuring the proliferation of OT-I $CD8^+$ cells (transplanted into host mice) in response to the administration of a composition of the disclosure incorporating a known antigen, such as ovalbumin ("OVA"), as compared with administration of the antigen alone or just vehicle. Compositions of the disclosure, when tested in this manner, show an increase of OT1 cell proliferation as compared with antigen alone or vehicle, demonstrating increased CD8+ T-cell cross-priming. To distinguish T cells being expanded into a functional effector phenotype from those being expanded and deleted, the proliferating OT-I $CD8^+$ T cells can be phenotypically analyzed for molecular signitures of exhaustion [such as programmed death-1 (PD-1), FasL, and others], as well as annexin-V as a hallmark of apoptosis and thus deletion. The OT-I $CD8^+$ T cells can also be assessed for their responsiveness to an antigen challenge with adjuvant in order to demonstrate functional non-responsiveness, and thus immune tolerance, towards the antigen. To do so, the cells are analyzed for inflammatory signatures after administration of compositions of the disclosure into host mice followed by an antigen challenge. Compositions of the disclosure when tested in this manner demonstrate very low (e.g., background) levels of inflammatory OT-I $CD8^+$ T cell responses towards OVA, thus demonstrating immune tolerance.

**[0164]** Humoral immune response can be tested by administering a composition of the disclosure incorporating a known antigen, such as OVA, as compared with the administration of the antigen alone or just vehicle, and measuring the levels of resulting antibodies. Compositions of the disclosure when tested in this manner show very low (e.g., background)

levels of antibody formation responsive to their administration and the administration of vehicle, with significantly higher levels of antibody formation responsive to administration of the antigen.

**[0165]** Effectiveness in tolerization against an antigen can be tested as above with reference to humoral immune response, where several weeks following treatment(s) with a composition of the disclosure a group of subjects is challenged by administration of the antigen alone, followed by measuring the levels of antibodies to the antigen. Compositions of the disclosure when tested in this manner show low levels of antibody formation responsive to challenge with the antigen in groups pretreated with such compositions as compared to groups that are not pretreated.

**[0166]** Disease-focused experimental models are well known to those skilled in the art and include the NOD (or non-obese diabetic) mouse model of autoimmunity and tolerance and the EAE (experimental autoimmune encephalomyelitis) model for the human inflammatory demyelinating disease, multiple sclerosis. In particular, the NOD mouse develops spontaneous autoimmune diabetes (similar to type 1a diabetes in humans). Groups of NOD mice are treated with test compound or a negative control, followed by measurement of BLOOD GLUCOSE. Successful treatment corresponds to likelihood of treating diabetes in humans or proof of mechanism for approaches to the treatment of other autoimmune diseases. (See, e.g., Anderson and Bluestone, Annu. Rev. Immunol. 2005;23:447-85.)

**Administration**

**[0167]** The compositions and compositions for use of the disclosure are administered at a therapeutically effective dosage, e.g., a dosage sufficient to provide treatment for the disease states previously described. Administration of the compounds of the disclosure or the pharmaceutically acceptable salts thereof can be via any of the accepted modes of administration for agents that serve similar utilities.

**[0168]** While human dosage levels have yet to be optimized for the compounds of the disclosure, these can initially be extrapolated from the about 10 μg to 100 μg doses administered for mice. Generally, an individual human dose is from about 0.01 to 2.0 mg/kg of body weight, preferably about 0.1 to 1.5 mg/kg of body weight, and most preferably about 0.3 to 1.0 mg/kg of body weight. Treatment can be administered for a single day or a period of days, and can be repeated at intervals of several days, one or several weeks, or one or several months. Administration can be as a single dose (e.g., as a bolus) or as an initial bolus followed by continuous infusion of the remaining portion of a complete dose over time, e.g., 1 to 7 days. The amount of active compound administered will, of course, be dependent on any or all of the following: the subject and disease state being treated, the severity of the affliction, the manner and schedule of administration and the judgment of the prescribing physician. It will also be appreciated that amounts administered will depend upon the molecular weight of the antigen, antibody, antibody fragment or ligand as well as the size of the linker.

**[0169]** The compositions and compositions for use of the disclosure can be administered either alone or in combination with other pharmaceutically acceptable excipients. While all typical routes of administration are contemplated, it is presently preferred to provide liquid dosage forms suitable for injection. The formulations will typically include a conventional pharmaceutical carrier or excipient and a composition of the disclosure or a pharmaceutically acceptable salt thereof. In addition, these compositions can include other medicinal agents, pharmaceutical agents, carriers, and the like, including, but not limited to the therapeutic protein, peptide, antibody or antibody-like molecule corresponding to the antigen (X) employed in the composition of the disclosure, and other active agents that can act as immune-modulating agents and more specifically can have inhibitory effects on B-cells, including anti-folates, immune suppressants, cyostatics, mitotic inhibitors, and anti-metabolites, or combinations thereof.

**[0170]** Generally, depending on the intended mode of administration, the pharmaceutically acceptable composition will contain about 0.1% to 95%, preferably about 0.5% to 50%, by weight of a composition of the disclosure, the remainder being suitable pharmaceutical excipients, carriers, etc. Dosage forms or compositions containing active ingredient in the range of 0.005% to 95% with the balance made up from non-toxic carrier can be prepared.

**[0171]** Liquid pharmaceutically administrable compositions can, for example, be prepared by dissolving, dispersing, etc. an active composition of the disclosure (e.g., a lyophilized powder) and optional pharmaceutical adjuvants in a carrier, such as, for example, water (water for injection), saline, aqueous dextrose, glycerol, glycols, ethanol or the like (excluding galactoses), to thereby form a solution or suspension. If desired, the pharmaceutical composition to be administered can also contain minor amounts of nontoxic auxiliary substances such as wetting agents, emulsifying agents, stabilizing agents, solubilizing agents, pH buffering agents and the like, for example, sodium acetate, sodium citrate, cyclodextrine derivatives, sorbitan monolaurate, triethanolamine acetate and triethanolamine oleate, etc., osmolytes, amino acids, sugars and carbohydrates, proteins and polymers, salts, surfactants, chelators and antioxidants, preservatives, and specific ligands. Actual methods of preparing such dosage forms are known, or will be apparent, to those skilled in this art; for example, see Remington: The Science and Practice of Pharmacy, Pharmaceutical Press, 22nd Edition, 2012. The composition or formulation to be administered will, in any event, contain a quantity of the active compound in an amount effective to treat the symptoms of the subject being treated.

## EXAMPLES

**[0172]** The following examples serve to more fully describe the manner of using the above-described disclosure, as well as to set forth the best modes contemplated for carrying out the first or second aspect of the invention. It is understood that these examples in no way serve to limit the true scope of this disclosure, but rather are presented for illustrative purposes.

### Example 1

**F1aA-OVA-$m_4$-$n_{80}$ (or F1a-OVA-$m_4$-$n_{80}$-2NGAL)**

**1A. Formula 103' where X' is OVA and m is 4**

**[0173]** In an endotoxin-free tube, OVA (5.0 mg, 0.00012 mmol) was added to 100 µl of pH 8.0 PBS containing 5 mM EDTA and stirred. Separately, 1 mg of Traut's Reagent was dissolved in 100 µl of pH 7.0 PBS, and 16 µl (0.00119 mmol) of the Traut's Reagent solution so obtained was added to the stirred solution of OVA with continued stirring. After 1 hour, excess Traut's Reagent was removed using a centrifugal size exclusion column to afford the corresponding product of Formula 103'.

**1B. Formula 106A where n is 80**

**[0174]** In an endotoxin-free tube, galactosamine (10.0 mg, 0.04638 mmol) was dissolved with stirring in 100 µl of pH 8.0 PBS containing 5 mM EDTA. Pyridyl dithiol-poly(ethylene glycol)-NHS ester (Formula 104 where n is 80) (16.23 mg, 0.00464 mmol) dissolved in 100 µl of pH 7.0 PBS was added to the stirring solution of galactosamine. After 1 hour, the resulting pyridyl dithiol-poly(ethylene glycol)-N-acetylgalactosamine (Formula 106A) was ready to be used without further purification.

**1C. Formula 1aA where X' is OVA, m is 4, n is 80 (and Z' is C2 galactosamine)**

**[0175]** The purified OVA-Traut conjugate of Formula 103' prepared in Example 1A was added directly to the stirring product of Formula 106A prepared in Example 1B. After 1hour, the resulting product of Formula 1a was purified by passing the reaction mixture through a centrifugal size exclusion column. Characterization (UHPLC SEC, gel electrophoresis) confirmed product identity. (See Fig. 5.)

**1D. Other Compounds of Formula 103'**

**[0176]** By following the procedure described in Example 1A and substituting OVA with the following:

- Abciximab,
- Adalimumab,

- Agalsidase alfa,
- Agalsidase beta,
- Aldeslukin,
- Alglucosidase alfa,
- Factor VIII,
- Factor IX,
- L-asparaginase,
- Laronidase,
- Octreotide,
- Phenylalanine ammonia-lyase,
- Rasburicase,
- Insulin (SEQ ID NO:5),
- GAD-65 (SEQ ID NO:6),
- IGRP (SEQ ID NO:7)
- MBP (SEQ ID NO:8),
- MOG (SEQ ID NO:9),
- PLP (SEQ ID NO:10),
- MBP13-32 (SEQ ID NO:11),
- MBP83-99 (SEQ ID NO:12),
- MBP111-129 (SEQ ID NO:13),
- MBP146-170 (SEQ ID NO:14),
- MOG1-20 (SEQ ID NO:15),
- MOG35-55 (SEQ ID NO:16),
- PLP139-154 (SEQ ID NO:17),
- MART1 (SEQ ID NO:18),
- Tyrosinase (SEQ ID NO:19),
- PMEL (SEQ ID NO:20),
- Aquaporin-4 (SEQ ID NO:21),
- S-arrestin (SEQ ID NO:22),
- IRBP (SEQ ID NO:23),
- Conarachin (UNIPROT Q6PSU6),
- Alpha-gliadin "33-mer" native (SEQ ID NO:24),
- Alpha-gliadin "33-mer" deamidated (SEQ ID NO:25),
- Alpha-gliadin (SEQ ID NO:26),
- Omega-gliadin (SEQ ID NO:27),
- Fel d 1A (UNIPROT P30438),
- Cat albumin (UNIPROT P49064),
- Can f 1 (UNIPROT 018873),
- Dog albumin (UNIPROT P49822), and
- RhCE example (UNIPROT P18577),

there are obtained the following corresponding compounds of Formula 103' where:

- X is Abciximab and m is 10,
- X is Adalimumab and m is 11,

- X is Agalsidase alfa and m is 14,
- X is Agalsidase beta and m is 14,
- X is Aldeslukin and m is 6,
- X is Alglucosidase alfa and m is 13,
- X is Factor VIII and m is 100,
- X is Factor IX and m is 18,
- X is L-asparaginase and m is 5,
- X is Laronidase and m is 7,
- X is Octreotide and m is 1,
- X is Phenylalanine ammonia-lyase and m is 12,
- X is Rasburicase and m is 12,
- X is Insulin (SEQ ID NO:5) and m is 2,
- X is GAD-65 (SEQ ID NO:6) and m is 8,
- X is IGRP (SEQ ID NO:7) and m is 7,
- X is MBP (SEQ ID NO:8) and m is 6,
- X is MOG (SEQ ID NO:9) and m is 5,
- X is PLP (SEQ ID NO:10) and m is 8,
- X is MBP13-32 (SEQ ID NO:11) and m is 1,
- X is MBP83-99 (SEQ ID NO:12) and m is 1,
- X is MBP111-129 (SEQ ID NO:13) and m is 1,
- X is MBP146-170 (SEQ ID NO:14) and m is 2,
- X is MOG1-20 (SEQ ID NO:15) and m is 1,
- X is MOG35-55 (SEQ ID NO:16) and m is 2,
- X is PLP139-154 (SEQ ID NO:17) and m is 3,
- X is MART1 (SEQ ID NO:18) and m is 4,
- X is Tyrosinase (SEQ ID NO:19) and m is 8,
- X is PMEL (SEQ ID NO:20) and m is 5,
- X is Aquaporin-4 (SEQ ID NO:21) and m is 4,
- X is S-arrestin (SEQ ID NO:22) and m is 12,
- X is IRBP (SEQ ID NO:23) and m is 21,
- X is Conarachin and m is 21,
- X is Alpha-gliadin "33-mer" native (SEQ ID NO:24) and m is 1,
- X is Alpha-gliadin "33-mer" deamidated (SEQ ID NO:25) and m is 1,
- X is Alpha-gliadin (SEQ ID NO:26) and m is 1,
- X is Omega-gliadin (SEQ ID NO:27) and m is 1,
- X is Fel d 1 and m is 4,
- X is Cat albumin and m is 16,
- X is Can f1 and m is 6,
- X is Dog albumin and m is 23, and
- X is RhCE example and m is 10.

**1E. Other Compounds of Formula 1aA**

**[0177]** By following the procedure described in Example 1C and substituting the compounds of Formula 103', for example as obtained in Example 1D, there are obtained the following corresponding compounds of Formula 1aA:

- F1aA-Abciximab-$m_{10}$-$n_{80}$,
- F1aA-Adalimumab-$m_{11}$-$n_{80}$,
- F1aA-Agalsidase alfa-$m_{14}$-$n_{80}$,
- F1aA-Agalsidase beta-$m_{14}$-$n_{80}$,
- F1aA-Aldeslukin-$m_{6}$-$n_{80}$,
- F1aA-Alglucosidase alfa-$m_{13}$-$n_{80}$,
- F1aA-Factor VIII-$m_{100}$-$n_{80}$,
- F1aA-Factor IX-$m_{18}$-$n_{80}$,
- F1aA-L-asparaginase-$m_{5}$-$n_{80}$,
- F1aA-Laronidase-$m_{7}$-$n_{80}$,
- F1aA-Octreotide-$m_{1}$-$n_{80}$,
- F1aA-Phenylalanine ammonia-lyase-$m_{12}$-$n_{80}$,
- F1aA-Rasburicase-$m_{12}$-$n_{80}$,
- F1aA-Insulin-$m_{2}$-$n_{80}$,
- F1aA-GAD-65-$m_{8}$-$n_{80}$,
- F1aA-IGRP-$m_{7}$-$n_{80}$,
- F1aA-MBP-$m_{6}$-$n_{80}$,
- F1aA-MOG-$m_{5}$-$n_{80}$,
- F1aA-PLP-$m_{8}$-$n_{66}$,
- F1aA-MBP13-32-$m_{1}$-$n_{80}$,
- F1aA-MBP83-99-$m_{1}$-$n_{80}$,
- F1aA-MBP111-129-$m_{1}$-$n_{80}$,
- F1aA-MBP146-170-$m_{2}$-$n_{80}$,
- F1aA-MOG1-20-$m_{1}$-$n_{80}$,
- F1aA-MOG35-55-$m_{2}$-$n_{80}$,
- F1aA-PLP1 39-154-$m_{3}$-$n_{80}$,
- F1aA-MART1-$m_{4}$-$n_{80}$,
- F1aA-Tyrosinase-$m_{8}$-$n_{80}$,
- F1aA-PMEL-$m_{5}$-$n_{80}$,
- F1aA-Aquaporin-4-$m_{4}$-$n_{80}$,
- F1aA-S-arrestin-$m_{12}$-$n_{80}$,
- F1aA-IRBP-$M_{21}$-$n_{80}$,
- F1aA-Conarachin-$m_{21}$-$n_{80}$,
- F1aA-Alpha-gliadin "33-mer" native-$m_{1}$-$n_{80}$,

- F1aA-Alpha-gliadin "33-mer" deamidated-$m_1$-$n_{80}$,
- F1aA-Alpha-gliadin-$m_1$-$n_{80}$,
- F1aA-Omega-gliadin-$m_1$-$n_{80}$,
- F1aA-Fel d 1-$m_4$-$n_{80}$,
- F1aA-Cat albumin-$m_{16}$-$n_{80}$,
- F1aA-Can f 1-$m_6$-$n_{80}$,
- F1aA-Dog albumin-$m_{23}$-$n_{80}$, and
- F1aA-RhCE-$m_{10}$-$n_{80}$.

**1F. Other Compounds of Formula 106A**

**[0178]** By following the procedure described in Example 1B and substituting the pyridyl dithiol-poly(ethylene glycol)-NHS ester (Formula 104 where n is 80) with the following:

- Formula 104 where n is 12,
- Formula 104 where n is 33,
- Formula 104 where n is 40,
- Formula 104 where n is 43,
- Formula 104 where n is 50,
- Formula 104 where n is 60,
- Formula 104 where n is 75, and
- Formula 104 where n is 80,

there are obtained the following corresponding compounds of Formula 106A where:

- n is 12,
- n is 33,
- n is 40,
- n is 43,
- n is 50,
- n is 60,
- n is 75, and
- n is 84,

**1G. Other Compounds of Formula 1aA**

**[0179]** By following the procedure described in Example 1E and substituting the compound of Formula 106A with the compounds obtained in Example 1F, there are obtained the

corresponding compounds of Formula 1aA where n is 12, 33, 40, 43, 50, 60, 75 and 84, such as:

- F1aA-Insulin-$m_2$-$n_{12}$,
- F1aA-Insulin-$m_2$-$n_{33}$,
- F1aA-Insulin-$m_2$-$n_{40}$,
- F1aA-Insulin-$m_2$-$n_{43}$,
- F1aA-Insulin-$m_2$-$n_{50}$,
- F1aA-Insulin-$m_2$-$n_{60}$,
- F1aA-Insulin-$m_2$-$n_{75}$, and
- F1aA-Insulin-$m_2$-$n_{84}$.

**Example 2**

**F1b-OVA-$m_1$-$n_4$-$p_{34}$-2NAcGAL**

**2A. Formula 103' where X' is Ovalbumin and m is 1**

**[0180]** In an endotoxin-free tube, OVA (6.5 mg, 0.000155 mmol) was added to 200 µl of pH 8.0 PBS containing 5 mM EDTA and stirred. Separately, 1 mg of Taut's Reagent was dissolved in 100 µl of pH 7.0 PBS, and 43 µl (0.00310 mmol) of the Traut's Reagent solution so obtained was added to the stirred solution of OVA with continued stirring. After 1 hour, non-reacted Traut's Reagent was removed using a centrifugal size exclusion column to afford the product of Formula 103'.

**2B. Formula 1b where X' is Ovalbumin, m is 1, n is 4, p is 34, $R^9$ is a direct bond and Z'' is 2NAcGAL**

**[0181]** In a micro centrifuge tube, poly(Galactosamine Methacrylate)-(pyridyl disulfide) (Formula 201) (20.0 mg, 0.0020 mmol) was solubilized in 50 µl of pH 8.0 PBS containing 5 mM EDTA. To this was added the purified OVA-Traut product from Example 2A followed by stirring for 1 hour. The resulting product of Formula 1b was purified by passing the reaction mixture through a centrifugal size exclusion column. Characterization (UHPLC SEC, gel electrophoresis) confirmed the identity of the product. (See Fig. 5.)

**2C. Other Compounds of Formula 1b**

**[0182]** By following the procedure described in Example 2B and substituting the compounds of Formula 103', for example as obtained in Example 1D, there are obtained the following corresponding compounds of Formula 1b:

- F1b-Abciximab-$m_{10}$-$n_4$-$p_{34}$-2NAcGAL,
- F1b-Adalimumab-$m_{11}$-$n_4$-$p_{34}$-2NAcGAL,
- F1b-Agalsidase alfa-$m_{14}$-$n_4$-$p_{34}$-2NAcGAL,
- F1b-Agalsidase beta-$m_{14}$-$n_4$-$p_{34}$-2NAcGAL,
- F1b-Aldeslukin-$m_6$-$n_4$-$p_{34}$-2NAcGAL,
- F1b-Alglucosidase alfa-$m_{13}$-$n_4$-$p_{34}$-2NAcGAL,
- F1 b-Factor VIII-$m_{100}$-$n_4$-$p_{34}$-2NAcGAL,
- F1b-Factor IX-$m_{18}$-$n_4$-$p_{34}$-2NAcGAL,
- F1b-L-asparaginase-$m_5$-$n_4$-$p_{34}$-2NAcGAL,
- F1b-Laronidase-$m_7$-$n_4$-$p_{34}$-2NAcGAL,
- F1b-Octreotide-$m_1$-$n_4$-$p_{34}$-2NAcGAL,
- F1b-Phenylalanine ammonia-lyase-$m_{12}$-$n_4$-$p_{34}$-2NAcGAL,
- F1b-Rasburicase-$m_{12}$-$n_4$-$p_{34}$-2NAcGAL,
- F1b-Insulin-$m_2$-$n_4$-$p_{34}$-2NAcGAL,
- F1b-GAD-65-$m_8$-$n_4$-$p_{34}$-2NAcGAL,
- F1b-IGRP-$m_7$-$n_4$-$p_{34}$-2NAcGAL,
- F1b-MBP-$m_6$-$n_4$-$p_{34}$-2NAcGAL,
- F1b-MOG-$m_5$-$n_4$-$p_{34}$-2NAcGAL,
- F1b-PLP-$m_3$-$n_4$-$p_{34}$-2NAcGAL,
- F1b-MBP13-32-$m_1$-$n_4$-$p_{34}$-2NAcGAL,
- F1b-MBP83-99-$m_1$-$n_4$-$p_{34}$-2NAcGAL,
- F1b-MBP111-129-$m_1$-$n_4$-$p_{34}$-2NAcGAL,
- F1b-MBP146-170-$m_2$-$n_4$-$p_{34}$-2NAcGAL,
- F1 b-MOG1 -20-$m_1$-$n_4$-$p_{34}$-2NAcGAL,
- F1b-MOG35-55-$m_2$-$n_4$-$p_{34}$-2NAcGAL,
- F1b-PLP139-154-$m_3$-$n_4$-$p_{34}$-2NAcGAL,
- F1 b-MART1 -$m_4$-$n_4$-$p_{34}$-2NAcGAL,
- F1b-Tyrosinase-$m_3$-$n_4$-$p_{34}$-2NAcGAL,
- F1b-PMEL-$m_5$-$n_4$-$p_{34}$-2NAcGAL,
- F1b-Aquaporin-4-$m_4$-$n_4$-$p_{34}$-2NAcGAL,
- F1b-S-arrestin-$m_{12}$-$n_4$-$p_{34}$-2NAcGAL,
- F1b-IRBP-$m_{21}$-$n_4$-$p_{34}$-2NAcGAL,
- F1b-Conarachin-$m_{21}$-$n_4$-$p_{34}$-2NAcGAL,

- F1b-Alpha-gliadin "33-mer" native-$m_1$-$n_4$-$p_{34}$-2NAcGAL,
- F1b-Alpha-gliadin "33-mer" deamidated-$m_1$-$n_4$-$p_{34}$-2NAcGAL,
- F1b-Alpha-gliadin-$m_1$-$n_4$-$p_{34}$-2NAcGAL,
- F1b-Omega-gliadin-$m_1$-$n_4$-$p_{34}$-2NAcGAL,
- F1b-Fel d 1-$m_4$-$n_4$-$p_{34}$-2NAcGAL,
- F1b-Cat albumin-$m_{16}$-$n_4$-$p_{34}$-2NAcGAL,
- F1 b-Can f 1-$m_6$-$n_4$-$p_{34}$-2NAcGAL,
- F1b-Dog albumin-$m_{23}$-$n_4$-$p_{34}$-2NAcGAL, and
- F1b-RhCE-$m_{10}$-$n_4$-$p_{34}$-2NAcGAL.

**Example 3**

**F1f-OVA-$m_1$-$n_4$-$p_{33}$-2NAcGAL**

**3A. Formula 1f where X' is Ovalbumin and m is 1, n is 4, p is 33, $R^9$ is a direct bond and Z'' is 2NAcGAL**

**[0183]** In an endotoxin-free tube, OVA (4.0 mg, 0.0000952381 mmol) was added to 0.1 ml of pH 7.4 PBS and stirred. Separately, poly-(n-Acetylgalactosamine)-p-nitrophenyol carbonate of Formula 601 where n is 4 and p is 33 (33.0 mg, 0.002380952 mmol) was added to 100 µl of pH 7.5 PBS and vortexed until dissolved. The two solutions were combined and the mixture was stirred vigorously for 1 hour. The mixture was then collected and dialyzed for 3 days against pH 7.4 PBS (30 kDa molecular weight cut off) to afford the product of Formula 1f.

**Example 4**

**F1g-PVA-$m_1$-$p_{90}$-2NAcGAL**

**4A. Formula 1q where X' is Ovalbumin and m is 1, p is 90, $R^9$ is a direct bond and Z'' is 2NAcGAL**

**[0184]** In an endotoxin-free tube, OVA (5.0 mg, 0.000119048 mmol) was added to 0.2 ml of pH

7.4 PBS and stirred. To the stirring solution was added 75 mg (0.00297619 mmol) of Poly(Galactosamine Methacrylate)-NHS (Formula 701) dissolved in 0.4 ml of pH 7.4 PBS. The mixture was allowed to stir for 2 hours. The mixture was then collected and dialyzed for 3 days against pH 7.4 PBS (30 kDa molecular weight cut off) to afford the product of Formula 1g.

**Example 5**

**F1h-OVA-$m_2$-$n_{45}$-$p_{55}$-$q_4$-2NAcGAL**

**5A. Formula 802' where X' is Ovalbumin, m is 2 and n is 45**

**[0185]** In an endotoxin-free tube, OVA (3.0 mg, 0.0000714286 mmol) was added to 150 µl of pH 8.0 PBS containing 5 mM EDTA and stirred. Dibenzocyclooctyne-PEG-(p-nitrophenyl carbonate) (Formula 801) (5.265 mg, 0.002142857 mmol) dissolved in DMF was added to the OVA solution and stirred for 1 hour. The excess dibenzocyclooctyne-PEG-(p-nitrophenyl carbonate) was removed using a centrifugal size exclusion column to afford the product of Formula 802'.

**5B. Formula 1h where X' is Ovalbumin, m is 2, n is 45, p is 55, q is 4, $R^8$ is $CH_2$, $R^9$ is a direct bond and Z'' is 2NAcGAL**

**[0186]** Poly(Galactosamine Methacrylate)-N3 (Formula 803 where p is 55, q is 4 and Z'' is N-acetylgalactosamine) (33 mg, 0.002142857 mmol) was dissolved in 100 µl of pH 7.4 PBS and added to the product of Example 5A with stirring. After 1 hour, the resulting product of Formula 1h was purified by centrifugal size exclusion chromatography.

**Example 6**

**F1j-OVA-$m_{10}$-$n_{45}$-$p_{55}$-$q_4$-2NAcGAL**

**6A. Formula 103' where X' is Ovalbumin and m is 10**

**[0187]** In an endotoxin-free tube, OVA (5.0 mg, 0.00019 mmol) was added to 150 µl of pH 8.0 PBS containing 5 mM EDTA and stirred. Separately, 1 mg of Taut's Reagent was dissolved in

100 µl of pH 7.0 PBS, and 16 µl (0.0019 mmol) of the Traut's Reagent solution so obtained was added to the stirred solution of OVA with continued stirring. After 1 hour, non-reacted Traut's Reagent was removed using a centrifugal size exclusion column to afford the product of Formula 103'.

**6B. Formula 902'' where X' is Ovalbumin, m is 10 and n is 45**

**[0188]** Dibenzocyclooctyne-PEG-(pyridyl disulfide) (Formula 901 where n is 45) (6.0 mg, 0.00238 mmol) was dissolved in DMF and the resulting solution was added to the OVA solution obtained in Example 6A and stirred for 1 hour. The excess dibenzocyclooctyne-PEG-(pyridyl disulfide) was removed using centrifugal size exclusion chromatography to afford the product of Formula 902''.

**6C. Formula 1j where X' is Ovalbumin, m is 10, n is 45, p is 55, q is 4, $R^8$ is $CH_2$, $R^9$ is a direct bond and Z'' is 2NAcGAL**

**[0189]** Poly(Galactosamine Methacrylate)-N3 (Formula 803 where p is 55, q is 4 and Z'' is N-acetylgalactosamine) (36 mg, 0.00238 mmol) was dissolved in 150 µl of pH 7.4 PBS and added to the product of Example 6B with stirring. After 1 hour, the resulting product of Formula 1j was purified (excess p(GMA)-N3 removed) by centrifugal size exclusion chromatography. Characterization (UHPLC SEC, gel electrophoresis) confirmed the identity of the product.

**Example 7**

**F1L-OVA-$m_2$-$n_{80}$-$p_{55}$-$q_4$-2NAcGAL**

**7A. Formula 1002 where X' is Ovalbumin, m is 2 and n is 80**

**[0190]** Dibenzocyclooctyne-PEG-(pyridyl disulfide) (Formula 1001 where n is 80) (9.0 mg, 0.00238 mmol) was dissolved in DMF and the resulting solution was added to a purified OVA solution of Formula 103' (where X' is Ovalbumin and m is 2), for example prepared as described in Example 6A and stirred for 1 hour. The excess dibenzocyclooctyne-PEG-(pyridyl disulfide) was removed using centrifugal size exclusion chromatography to afford the product of Formula 1002.

**7B. Formula 1L where X' is Ovalbumin, m is 2, n is 80, p is 55, q is 4, $R^8$ is $CH_2$, $R^9$ is a direct bond and Z'' is 2NAcGAL**

**[0191]** Poly(Galactosamine Methacrylate)-N3 (Formula 803 where p is 55, q is 4 and Z'' is N-Acetylgalactosamine) (36 mg, 0.00238 mmol) was dissolved in 150 µl of pH 7.4 PBS and added to the product of Example 7A with stirring. After 1 hour, the resulting product of Formula 1L was purified (excess poly(Galactosamine Methacrylate)-N3 removed) by centrifugal size exclusion chromatography. Characterization (UHPLC SEC, gel electrophoresis) confirmed the identity of the product.

**Example 8**

**Preparation of poly(Galactosamine methacrylate) Polymers**

**8A. Galactosamine Methacrylate**

**[0192]** To stirred galactosamine hydrochloride (2.15 g, 10.0 mmol) was added 0.5 M sodium methoxide (22 ml, 11.0 mmol). After 30 minutes, methacrylate anhydride (14.694 g, 11.0 mmol) was added and stirring continued for 4 hours. The resulting galactosamine methacrylate was loaded onto silica gel via rotovap and purified via column chromatography using DCM:MeOH (85:15).

**8B. Formula 201 where n is 4 and p is 30**

**[0193]** Galactose methacrylate (600 mg, 2.43 mmol), 2-(2-(2-(2-(pyridin-2-yldisulfanyl)ethoxy)ethoxy)ethoxy)ethyl 2-((phenylcarbonothioyl)thio)acetate (44.8 mg, 0.081 mmol) and AIBN (3.174089069 mg, 0.016 mmol) were added to 1.5 ml of DMF in a Schlenk Flask. The reaction mixture was subjected to 4 freeze-thaw chycles and then stirred at 70°C for 6 hours. The desired polymer product of Formula 201 was precipitated in 12 ml of methanol, and excess solvent was removed under reduced pressure.

**Example 9**

**Preparation of F1aA-PE-$m_3$-$n_{80}$**

**9A. Formula 103' where X' is Phycoerythrin**

**[0194]** In an endotoxin-free tube, phycoerythrin ("PE") (purchased from Pierce) (200 µl 0.000004 mmol) was added to 50 µl of pH 8.0 PBS containing 5 mM EDTA and stirred. Separately, 1 mg of Taut's Reagent was dissolved in 100 µl of pH 7.0 PBS, and 21 µl (0.00013 mmol) of the Traut's Reagent solution so obtained was added to the stirred solution of PE with continued stirring. After 1 hour, excess Traut's Reagent was removed using a centrifugal size exclusion column to afford the product of Formula 103'.

**9B. Formula 106A where n is 80**

**[0195]** In an endotoxin-free tube, galactosamine (7.0 mg, 0.03246 mmol) was dissolved with stirring in 100 µl of pH 8.0 PBS containing 5 mM EDTA. Pyridyl dithiol-poly(ethylene glycol)-NHS ester (Formula 104 where n is 80) (16.23 mg, 0.00464 mmol) dissolved in 50 µl of pH 7.0 PBS was added to the stirring solution of galactosamine. After 1 hour, the resulting product of Formula 106A was ready to be used without further purification.

**9C. Formula 1a where X' is Phycoerythrin, m is 3, n is 80 and Z' is galactosamine**

**[0196]** The purified PE-Traut conjugates prepared in Example 9A were added directly to the stirring product of Formula 106A prepared in Example 9B. After 1hour, the resulting product of Formula 1a was purified by passing the reaction mixture through a centrifugal size exclusion column. Characterization (UHPLC SEC, gel electrophoresis) confirmed the identity of the product.

**Example 10**

**OVA-DOM**

**10A. Preparation of Expression Vector**

**[0197]** The mammalian cell expression vector pSecTag A was purchased from Life Technologies. The gene encoding the anti-ASGPR domain antibody, Dom26h-196-61, herein referred to as "DOM", was purchased as a codon-optimized sequence for protein expression in human cells, from the provider Genscript. Sequences encoding OVA, DOM, the flexible linker $Gly_3Ser$, and the 6xHis tag were cloned into mammalian expression vector pSecTag A, C-terminal to the Ig κ-chain secretion leader sequence, by site-directed mutagenesis, following a

variation of the QuikChange protocol (Geiser, *et al.*)

**10B. Expression and Purification of Formula 2 where m' is 1, m'' is 0, X is Ovalbumin, Y is $Gly_3Ser$, Z is Anti-ASGPR Dom26h-196-61**

**[0198]** HEK293 cells were transiently transfected with modified pSecTag A vectors, prepared for example as described in Example 10A, using polyethylenimine. Transfected cells were cultured in FreeStyle 293 medium (Life Technologies) supplemented with valproic acid for 7 days, after which the cells were removed by centrifugation and the culture supernatants were collected and sterilized by filtration. The OVA/DOM fusion proteins of Formula 2 were purified from the culture supernatants by immobilized metal ion affinity chromatography using a HisTrap $Ni^{2+}$ sepharose column (GE Healthcare), followed by size exclusion chromatography using a Superdex 75 column (GE Healthcare), having the following generalized structure:
N- OVA- $Gly_3Ser$- DOM- $Gly_3Ser$-6xHis -C
and the following amino acid sequence:
GSIGAASMEFCFDVFKELKVHHANENIFYCPIAIMSALAMVYLGAKDSTRTQINKVVRFDKLPGFGDSI
EAQCGTSVNVHSSLRDILNQITKPNDVYSFSLASRLYAEERYPILPEYLQCVKELYRGGLEPINFQTAA
DQARELINSWVESQTNGIIRNVLQPSSVDSQTAMVLVNAIVFKGLWEKAFKDEDTQAMPFRVTEQES
KPVQMMYQIGLFRVASMASEKMKILELPFASGTMSMLVLLPDEVSGLEQLESIINFEKLTEWTSSNVM
EERKIKVYLPRMKMEEKYNLTSVLMAMGITDVFSSSANLSGISSAESLKISQAVHAAHAEINEAGREVV
GSAEAGVDAASVSEEFRADHPFLFCIKHIATNAVLFFGRCVSPGGGSEVQLLESGGGLVQPGGSLRL
SCAASGFTFEKYAMAWVRQAPGKGLEWVSRISARGVTTYYADSVKGRFTISRDNSKNTLYLQMNSL
RAEDTAVYYCASHKRHEHTRFDSWGQGTLVTVSSGGGSHHHHHH (SEQ ID NO:28)

**[0199]** Protein purity was verified by Coomassie Brilliant Blue staining of SDS-PAGE gels and anti-6xHis tag western blotting. Protein concentration was determined using the Beer-Lambert Law, for which the absorbance at 280 nm was measured using a NanoDrop 2000 (Thermo Scientific), and the molecular weight (57.3 kDa) and extinction coefficient (57,090 $M^{-1}$ $cm^{-1}$) were estimated from the protein's amino acid sequence, using the ExPASy ProtParam tool. Endotoxin levels were measured using the HEK-BLUE TLR reporter cell line (Invivogen) according to manufacturer's instructions.

**10C. Other Compositions of Formula 2**

**[0200]** By following the procedures described in Examples 10A and 10B and substituting the pSecTag A vectors accordingly, there were obtained the following fusion proteins of Formula 2:
N-DOM-$Gly_3Ser$-OVA-$Gly_3Ser$-6xHis-C
having the following amino acid sequence:
EVQLLESGGGLVQPGGSLRLSCAASGFTFEKYAMAWVRQAPGKGLEWVSRISARGVTTYYADSVK
GRFTISRDNSKNTLYLQMNSLRAEDTAVYYCASHKRHEHTRFDSWGQGTLVTVSSGGGSGSIGAAS
MEFCFDVFKELKVHHANENIFYCPIAIMSALAMVYLGAKDSTRTQINKVVRFDKLPGFGDSIEAQCGTS

VNVHSSLRDILNQITKPNDVYSFSLASRLYAEERYPILPEYLQCVKELYRGGLEPINFQTAADQARELIN
SWVESQTNGIIRNVLQPSSVDSQTAMVLVNAIVFKGLWEKAFKDEDTQAMPFRVTEQESKPVQMMY
QIGLFRVASMASEKMKILELPFASGTMSMLVLLPDEVSGLEQLESIINFEKLTEWTSSNVMEERKIKVY
LPRMKMEEKYNLTSVLMAMGITDVFSSSANLSGISSAESLKISQAVHAAHAEINEAGREVVGSAEAGV
DAASVSEEFRADHPFLFCIKHIATNAVLFFGRCVSPGGGSHHHHHH (SEQ ID NO:29);

and

N- OVA-$Gly_3Ser$-DOM-$Gly_3Ser$-OVA-$Gly_3Ser$-6xHis -C having the following amino acid sequence:

GSIGAASMEFCFDVFKELKVHHANENIFYCPIAIMSALAMVYLGAKDSTRTQINKVVRFDKLPGFGDSI
EAQCGTSVNVHSSLRDILNQITKPNDVYSFSLASRLYAEERYPILPEYLQCVKELYRGGLEPINFQTAA
DQARELINSWVESQTNGIIRNVLQPSSVDSQTAMVLVNAIVFKGLWEKAFKDEDTQAMPFRVTEQES
KPVQMMYQIGLFRVASMASEKMKILELPFASGTMSMLVLLPDEVSGLEQLESIINFEKLTEWTSSNVM
EERKIKVYLPRMKMEEKYNLTSVLMAMGITDVFSSSANLSGISSAESLKISQAVHAAHAEINEAGREVV
GSAEAGVDAASVSEEFRADHPFLFCIKHIATNAVLFFGRCVSPGGGSEVQLLESGGGLVQPGGSLRL
SCAASGFTFEKYAMAWVRQAPGKGLEWVSRISARGVTTYYADSVKGRFTISRDNSKNTLYLQMNSL
RAEDTAVYYCASHKRHEHTRFDSWGQGTLVTVSSGGGSGSIGAASMEFCFDVFKELKVHHANENIF
YCPIAIMSALAMVYLGAKDSTRTQINKVVRFDKLPGFGDSIEAQCGTSVNVHSSLRDILNQITKPNDVY
SFSLASRLYAEERYPILPEYLQCVKELYRGGLEPINFQTAADQARELINSWVESQTNGIIRNVLQPSSV
DSQTAMVLVNAIVFKGLWEKAFKDEDTQAMPFRVTEQESKPVQMMYQIGLFRVASMASEKMKILELP
FASGTMSMLVLLPDEVSGLEQLESIINFEKLTEWTSSNVMEERKIKVYLPRMKMEEKYNLTSVLMAMG
ITDVFSSSANLSGISSAESLKISQAVHAAHAEINEAGREVVGSAEAGVDAASVSEEFRADHPFLFCIKHI
ATNAVLFFGRCVSPGGGSHHHHHH (SEQ ID NO:30).

**10D. Other Compositions of Formula 2**

**[0201]** By following the procedures described in Examples 10A and 10B and substituting for $Gly_3Ser$ the vectors for a linker having an immunoproteosome cleavage site ("IPC"), and for OVA the vectors for:

MBP13-32 (SEQ ID NO:11),

MBP83-99 (SEQ ID NO:12),

MBP111-129 (SEQ ID NO:13),

MBP146-170 (SEQ ID NO:14),

MOG1-20 (SEQ ID NO:15),

MOG35-55 (SEQ ID NO:16), and

PLP139-154 (SEQ ID NO:17),

or the vectors for:

Alpha-gliadin "33-mer" deamidated (SEQ ID NO:25)

Alpha-gliadin (SEQ ID NO:26), and

Omega-gliadin (SEQ ID NO:27),

there are obtained the following fusion proteins of Formula 2:

- MBP13-32-IPC-MBP83-99-IPC-MBP111-129-IPC-MBP146-170-IPC-MOG1-20-IPC-MOG35-55-IPC-PLP139-154-IPC-DOM, and
- Alpha-gliadin "33-mer" deamidated-IPC-Alpha-gliadin-IPC-Omega-gliadin-IPC-DOM.

**Example 11**

**Desialylated OVA**

**11A. Preparation of Expression Vector**

**[0202]** The mammalian cell expression vector pSecTag A was purchased from Life Technologies. Sequences encoding OVA, the flexible linker Gly3Ser, and the 6xHis tag were cloned into pSecTag A, C-terminal to the Ig κ-chain secretion leader sequence, by site-directed mutagenesis, following a variation of the QuikChange protocol (Geiser, et al.)

**11B. Expression and Purification of OVA**

**[0203]** HEK293 cells were transiently transfected with modified pSecTag A vector, prepared for example as described in Example 10A, using polyethylenimine. Transfected cells were cultured in FreeStyle 293 medium (Life Technologies) supplemented with valproic acid for 7 days, after which the cells were removed by centrifugation and the culture supernatants are collected and sterilized by filtration. OVA protein was purified from the culture supernatant by immobilized metal ion affinity chromatography using a HisTrap Ni2+ sepharose column (GE Healthcare), followed by size exclusion chromatography using a Superdex 75 column (GE Healthcare), having the following structure:

N'- OVA Gly3Ser 6xHis -C'

and the following amino acid sequence:

GSIGAASMEFCFDVFKELKVHHANENIFYCPIAIMSALAMVYLGAKDSTRTQINKVVRFDKLPGFGDSI

EAQCGTSVNVHSSLRDILNQITKPNDVYSFSLASRLYAEERYPILPEYLQCVKELYRGGLEPINFQTAA

DQARELINSWVESQTNGIIRNVLQPSSVDSQTAMVLVNAIVFKGLWEKAFKDEDTQAMPFRVTEQES

KPVQMMYQIGLFRVASMASEKMKILELPFASGTMSMLVLLPDEVSGLEQLESIINFEKLTEWTSSNVM

EERKIKVYLPRMKMEEKYNLTSVLMAMGITDVFSSSANLSGISSAESLKISQAVHAAHAEINEAGREVV

GSAEAGVDAASVSEEFRADHPFLFCIKHIATNAVLFFGRCVSPGGGSHHHHHH (SEQ ID NO:31)

**[0204]** Protein purity was verified by Coomassie Brilliant Blue staining of SDS-PAGE gels and anti-6xHis tag western blotting. Protein concentration was determined using the Beer-Lambert Law, for which the absorbance at 280 nm was measured using a NanoDrop 2000 (Thermo Scientific), and the molecular weight (43.8 kDa) and extinction coefficient (31,525 M-1 cm-1) were estimated from the protein's amino acid sequence, using the ExPASy ProtParam tool.

**11C. Desialylation**

**[0205]** OVA is desialylated by incubation with neuraminidase for 1 hour at 37°C (New England Biolabs). Desialylated OVA is purified from the reaction mixture by immobilized metal ion affinity chromatography (e.g., using a HisTrap Ni2+ sepharose column, GE Healthcare), followed by size exclusion chromatography (e.g., using a Superdex 75 column, GE Healthcare).

**[0206]** Protein purity is verified by Coomassie Brilliant Blue staining of SDS-PAGE gels and anti-6xHis tag western blotting. Desialylation is verified by Sambucus nigra lectin-based detection of protein sialic acid content in western blots (Vector Biolabs) and by a sialic acid-mediated fluorescence assay (ProZyme). Desialylated protein concentration is determined using the Beer-Lambert Law, as described above for the protein before desialylation. Endotoxin levels are measured using the HEK-Blue TLR4 reporter cell line (Invivogen) according to manufacturer's instructions.

**Example 12**

**Hepatic Distribution**

**[0207]** 12A. F1aA-PE-$m_3$-$n_{80}$ was prepared, for example, as described in Example 9. A 30µg/100µl solution in sterile saline was prepared for injection.

**[0208]** The F1aA-PE-$m_3$-$n_{80}$ solution (30µg) was administered to one of three groups of C57 black 6 mice 3 per group) via tail vein injection. The two other groups of mice received an equivalent volume of phycoerythrin in 100 µl of saline or saline vehicle. Three hours after administration, the livers and spleens of these animals were harvested and the level of cellular fluorescents in these organs was determined by flow cytometry as an indication of cellular PE content.

**[0209]** As shown in Fig. 1, sinusoidal endothelial cells (LSECs), hepatocytes, kupffer cells (KC), and other antigen-presenting cells (APCs) from the livers of mice treated with F1 aA-PE-$m_3$-$n_{80}$

exhibited at least a three-fold increase in fluorescence as compared with animals that received PE solution. No detectible difference in fluorescence was found in spleen cells harvested from the three groups. These results confirm that F1aA-PE-$m_3$-$n_{80}$ has sufficient specificity for binding to antigen-presenting cells in the liver.

**[0210]** 12B. By following the procedure described in Example 12A and substituting F1aA-PE-$m_3$-$n_{80}$ with the compounds F1b-PE-$m_3$-$n_4$-$p_{34}$-2NAcGAL, F1f-PE-$m_3$-$n_4$-$p_{33}$-2NAcGAL, F1g-PE-$m_3$-$p_{90}$-2NAcGAL, F1h-PE-$m_3$-$n_{45}$-$p_{55}$-$q_4$-2NAcGAL, F1j-PE-$m_3$-$n_{45}$-$p_{55}$-$q_4$-2NAcGAL, F1L-PE-$m_3$-$n_{80}$-$p_{55}$-$q_4$-2NAcGAL, F1m-PE-$m_3$-$n_{80}$-$p_{30}$-$q_4$-CMP-2NHAc, F1m-PE-$m_3$-$n_{62}$-$p_{30}$-$q_8$-CMP-2OH, F1n-PE-$m_3$-$n_1$-$p_{30}$-$q_4$-CMP-2NHAc and F1n-PE-$m_3$-$n_{33}$-$p_{30}$-$q_8$-CMP-20H, prepared, for example, as described with reference to Example 9 by substitution for X in Examples 2B, 3, 4, 5B, 6B, 7B, 19G, 19L, 20B and 20F, respectively it is confirmed that the compounds F1aA-PE-$m_3$-$n_{90}$ with the compounds **F1**b-PE-$m_3$-$n_4$-$p_{34}$-2NAcGAL, F1f-PE-$m_3$-$n_4$-$p_{33}$-2NAcGAL, F1g-PE-$m_3$-$p_{90}$-2NAcGAL, **F1**h-PE-$m_3$-$n_{45}$-$p_{55}$-$q_4$-2NAcGAL, F1j-PE-$m_3$-$n_{45}$-$p_{55}$-$q_4$-2NAcGAL, F1L-PE-$M_3$-$n_{80}$-$p_{55}$-$q_4$-2NAcGAL, F1m-PE-$m_3$-$n_{80}$-$p_{30}$-$q_4$-CMP-2NHAc, F1m-PE-$m_3$-$n_{62}$-$p_{30}$-$q_8$-CMP-2OH, F1n-PE-$m_3$-$n_1$-$p_{30}$-$q_4$-CMP-2NHAc and F1n-PE-$m_3$-$n_{33}$-$p_{30}$-$q_8$-CMP-2OH have sufficient specificity for binding to antigen-presenting cells in the liver.

**Example 13**

**Proliferation of Antigen-specific OT1 CD8+ Tcells**

**[0211]** 13A. F1aA-OVA-$m_4$-$n_{80}$ synthesized, for example, as described in Example 1, was prepared as a 10µg/100µl saline solution for injection. On day 0, $10^6$OT-1 T cells were fluorecently labeled and adoptively transferred into 3 groups of CD 45.2 mice (5 per group) via tail vein injection. The next day (i.e. Day 1), to each of the 3 groups of mice were administed, respectively, 10 µg of F1aA-OVA-$m_4$-$n_{80}$, OVA or saline via tail vein injection. On day 6, the animals were sacrificed and the % of splenic proliferating OT-1 cells was determined via florescence activated cell sorting.

**[0212]** The results from this study (see Fig. 2) show that the percentage of proliferating OTI T cells in mice treated with F1aA-OVA-$m_4$-$n_{80}$ ("Gal-OVA" in Fig. 2) was significantly greater than the percentage of proliferating OTI cells in the spleens of mice treated with OVA or saline ("naïve" in Fig. 2). The increase in OTI cell-proliferation demonstrates the increased CD8+ T-cell cross-priming in animals treated with F1aA-OVA-$m_4$-$n_{80}$ versus the other therapies. In concert with the results from Example 12, these results indicate that the ability of F1aA-OVA-$m_4$-$n_{80}$ to target antigens to the liver increases OVA presentation by antigen presenting cells in the liver to OVA-specific OTI T cells.

**[0213]** 13B. To distinguish T cells being expanded into a functional effector phenotype from those being expanded and deleted, the proliferating OTI $CD8^+$ T cells were analyzed for annexin-V, as a hallmark of apoptosis and thus deletion, as well as the exhaustion marker programmed death-1 (PD-1). As shown in Fig. 3, F1aA-OVA-$m_4$-$n_{80}$ ("Gal-OVA" in Fig. 3) induced much higher numbers of annexin-$V^+$ and PD-$1^+$ proliferating OTI $CD8^+$ T cells than soluble OVA.

**[0214]** 13C. By following the procedure described in Examples 13A and 13B, and substituting F1aA-OVA-$m_4$-$n_8$ with the compounds of Formula 1 obtained, for example, as described in Examples 3A, 4A, 5B, 6C, 7B and 19G, it is shown the compounds from Examples 3A, 4A, 5B, 6C, 7B and 19G induce much higher numbers of annexin-$V^+$ and PD-$1^+$ proliferating OTI $CD8^+$ T cells than soluble OVA.

**[0215]** 13D. By following the procedure described in Examples 13A and 13B and substituting F1aA-OVA-$m_4$-$n_8$ with the compounds of Formulae 1 and 2 obtained, for example, as described in Examples 1E, 1G, 2C, 10D, 191, 19L, 20B, 20D and 20F, and substituting OVA with the antigens corresponding to X (or X' or X''), respectively, it is shown that the compounds from Examples 1E, 1G, 2C, 10D, 191, 19L, 20B, 20D and 20F induce much higher numbers of annexin-$V^+$ and PD-$1^+$ proliferating OTI $CD8^+$ T cells than soluble antigen X.

**Example 14**

**F1aA-OVA-$m_4$-$n_8$ does not induce an OVA-specific antibody response**

**[0216]** 14A. In order to assess the humoral immune response to F1aA-OVA-$m_4$-$n_8$ we treated mice with a weekly i.v. injection of either F1aA-OVA-$m_4$-$n_8$ or OVA, then measured the levels of OVA-specific antibodies in the blood. On day 0, 7, and 14 of the experiment, mice were administered an i.v. injection of 100 µl of saline contining one of the following: 1.) 6 µg of OVA; 2.) 6 µg of F1aA-OVA-$m_4$-$n_8$; 3.) 30 µg of OVA; 4.) 30 µg of F1aA-OVA-$m_4$-$n_8$, or 5.) saline alone. Each group contained 5 mice. On day 19, the mice were bled via cheek puncture, and the titer of OVA-specific antibodies in each mouse's blood was determined via ELISA. The results for this study show that although mice treated with 6 and 30 µg of OVA had increased OVA-specific antibody titers, mice treated with both 6 and 30 µg of F1aA-OVA-$m_4$-$n_8$ ("Gal-OVA" in Fig. 4) had blood titers similar to mice treated with saline (i.e. vehicle treated animals) (Fig. 4). For example mice treated with 6 and 30 µg of OVA had an average antibody titer of 3.5 and 2.5, respectively; whereas, mice treated with 6 and 30 µg of OVA had an average antibody titer of 0.75 and 0.25, respectively.

**[0217]** 14B. By following the procedure described in Example 14A and substituting F1aA-OVA-

$m_4$-$n_8$ with the compounds of Formula 1 obtained, for example, as described in Examples 3A, 4A, 5B, 6C, 7B and 19G, it is shown that mice treated with the compounds from Examples 3A, 4A, 5B, 6C, 7B and 19G have OVA-specific antibody titers similar to mice treated with saline.

**[0218]** 14C. By following the procedure described in Example 14A and substituting **F1aA-OVA-$m_4$-$n_8$** with the compounds of Formulae 1 and 2 obtained, for example, as described in Examples 1E, 1G, 2C, 10D, 191, 19L, 20B, 20D and 20F, and substituting OVA with the antigens corresponding to X (or X' or X''), respectively, it is shown that mice treated with the compounds from Examples 1E, 1G, 2C, 10D, 191, 19L, 20B, 20D and 20F have antigen X-specific antibody titers similar to mice treated with saline.

**Example 15**

**F1aA-OVA-$m_4$-$n_8$ depletes OVA-specific antibodies**

**[0219]** 15A. We treated mice that had different OVA-antibody blood titers (each mouse had a titer from 0 to 4.5) with an i.v. injection of 20 µg of F1aA-OVA-$m_4$-$n_8$solubilized in 100 µl saline. Mice were given i.v. injections of F1aA-OVA-$m_4$-$n_8$ on days 0, 5, 7, 12, and 14 (Injections of F1aA-OVA-$m_4$-$n_8$ are labeled as "Gal-OVA" and shown as green arrows on the x-axis of Fig. 5). In order to determine the ability of F1aA-OVA-$m_4$-$n_8$ to deplete serum OVA-specific antibodies, the mice were bled on day -1 to establish an intital antibody titer and then subsequent bleeds were carried out after each injection of F1aA-OVA-$m_4$-$n_8$ on days 2, 6, 9. 13, and 16. The antibody titer for each mouse was determined via ELISA. The results from this study show that F1aA-OVA-$m_4$-$n_8$ is able to deplete serum antibody levels in mice. For example, one day after the first F1aA-OVA-$m_4$-$n_8$ injection (i.e. day 2), mice with postivie OVA-antibody titers experience a 5 to 100-fold decrease in serum antibody levels (Fig. 5). Our results show that although over the course of the 19 day experiment, antibody titers did increase for certain mice, the titer levels never reached the initial antibody titer measured on Day -1 and subsequent doeses of F1aA-OVA-$m_4$-$n_8$ were effective in reducing these transient increases in antibody titers. These results demonstrate that F1aA-OVA-$m_4$-$n_8$ has the specificity to bind serum OVA-specific antibodies and the kinetics required to deplete OVA-specific serum antibodies.

**[0220]** 15B. By following the procedure described in Example 15A and substituting F1aA-OVA-$m_4$-$n_8$ with the compounds of Formula 1 obtained, for example, as described in Examples 3A, 4A, 5B, 6C, 7B and 19G, it is shown that the compounds from Examples 3A, 4A, 5B, 6C, 7B and 19G have the specificity to bind serum OVA-specific antibodies and the kinetics required to deplete OVA-specific serum antibodies.

**[0221]** 15C. By following the procedure described in Example 15A and substituting F1aA-OVA-

$m_4$-$n_8$ with the compounds of Formulae 1 and 2 obtained, for example, as described in Examples 1E, 1G, 2C, 10D, 191, 19L, 20B, 20D and 20F, and substituting OVA with the antigens corresponding to X (or X' or X''), respectively, it is shown that the compounds from Examples 1E, 1G, 2C, 10D, 191, 19L, 20B, 20D and 20F have the specificity to bind serum antigen X-specific antibodies and the kinetics required to deplete antigen X-specific serum antibodies.

**Example 16**

**OT-1 challenge-to-tolerance model**

**[0222]** 16A. Using an established OTI challenge-to-tolerance model (Liu, Iyoda, et al., 2002), the ability of F1aA-OVA-$m_4$-$n_8$ (mGal-OVA), F1b-OVA-$m_1$-$n_4$-$p_{34}$ (pGal-OVA), and N-DOM-$Gly_3$Ser-OVA-$Gly_3$Ser-6xHis-C (Dom-OVA) to prevent subsequent immune responses to vaccine-mediated antigen challenge were demonstrated - even with a challenge involving a very strong bacterially-derived adjuvant (i.e. lipopolysaccharide). To tolerize, 233 nmol of either F1aA-OVA-$m_4$-$n_8$, F1b-OVA-$m_1$-$n_4$-$p_{34}$, N-DOM-$Gly_3$Ser-OVA-$Gly_3$Ser-6xHis-C, or soluble OVA were intravenously administered in 100 µl saline at 1 and 6 days following adoptive transfer of OTI $CD8^+$ ($CD45.2^+$) T cells to $CD45.1^+$ mice (n = 5 mice per group). After 9 additional days to allow potential deletion of the transferred T cells, the recipient mice were then challenged with OVA (10 µg) adjuvanted with lipopolysaccharide (LPS) (50 ng) by intradermal injection. Characterization of the draining lymph nodes 4 d after challenge allowed a determination as to whether or not deletion actually took place.

**[0223]** 16B. Intravenous administration of FlaA-OVA-$m_4$-$n_8$, F1b-OVA-$m_1$-$n_4$-$p_{34}$, and N-DOM-$Gly_3$Ser-OVA-$Gly_3$Ser-6xHis-C resulted in profound reductions in OTI $CD8^+$ T cell populations in the draining lymph nodes as compared to mice treated with unmodified OVA prior to antigen challenge with LPS, demonstrating deletional tolerance. For example, Fig. 6 shows that the draining lymph nodes from mice treated with either F1aA-OVA-$m_4$-$n_8$ (mGal-OVA), F1b-OVA-$m_1$-$n_4$-$p_{34}$ (pGal-OVA), and N-DOM-$Gly_3$Ser-OVA-$Gly_3$Ser-6xHis-C (Dom-OVA) contained over 9-fold fewer OTI $CD8^+$ T cells as compared to OVA-treated mice, and more than 43-fold fewer than the challenge control mice that did not receive intravenous injections of antigen; responses in spleen cells were similar. These results demonstrate that F1aA-OVA-$m_4$-$n_8$, F1b-OVA-$m_1$-$n_4$-$p_{34}$, and N-DOM-$Gly_3$Ser-OVA-$Gly_3$Ser-6xHis-C mitigated an OVA-specific immune response after adjuvented OVA challenge.

**[0224]** 16C. By following the procedure described in Examples 16A and B, and substituting F1aA-OVA-$m_4$-$n_8$, F1b-OVA-$m_1$-$n_4$-$p_{34}$, and N-DOM-$Gly_3$Ser-OVA-$Gly_3$Ser-exHis-C with the compounds of Formula 1 obtained, for example, as described in Examples 3A, 4A, 5B, 6C, 7B

and 19G, it is shown that the compounds from Examples 3A, 4A, 5B, 6C, 7B and 19G mitigate an OVA-specific immune response after adjuvented OVA challenge.

**[0225]** 16D. By following the procedure described in Examples 16A and B, and substituting F1aA-OVA-$m_4$-$n_8$, F1b-OVA-$m_1$-$n_4$-$p_{34}$, and N-DOM-$Gly_3$Ser-OVA-$Gly_3$Ser-6xHis-C with the compounds of Formulae 1 and 2 obtained, for example, as described in Examples 1E, 1G, 2C, 10D, 191, 19L, 20B, 20D and 20F, and substituting OVA with the antigens corresponding to X (or X' or X''), respectively, it is shown that the compounds from Examples 1 E, 1G, 2C, 10D, 191, 19L, 20B, 20D and 20F mitigate an antigen X-specific immune response after adjuvented antigen X challenge.

**Example 17**

**Pharmacokinetics**

**[0226]** 17A. OVA and fusion proteins N-DOM-$Gly_3$Ser-OVA-$Gly_3$Ser-6xHis-C and N-OVA-$Gly_3$Ser-DOM-$Gly_3$Ser-6xHis-C (prepared, e.g., as described in Example 10) are labeled with IRDye 800CW (LI-COR Biosciences) according to manufacturer's instructions. Unreacted dye is removed using Zeba desalting columns (Thermo Scientific). The labeled proteins, 50 µg in 100 µl PBS per dose, are administered *i.v.* or s.c into C57BL/6 mice (5 mice per group). At time = 0, 0.25, 0.5, 1, 2, 4, 8, 24, 48, and 96 hours after injection, blood samples are collected from the tip of the tail into heparin-coated capillary tubes. Samples are store at 4°C, protected from light, until analysis.

**[0227]** On the day of analysis, blood samples are centrifuged to remove cellular components. Plasma is transferred to fresh capillary tubes and scanned using an Odyssey Infrared Imaging System (LI-COR Biosciences). Signal is acquired in the 800 nm channel. Using the image-processing program ImageJ (US National Institutes of Health), each sample is approximated as a line of width 2 and the mean intensity along the line is determined as a relative measure of the amount of circulating protein at that time point.

**[0228]** Fluorescence signals (normalized to fluorescence at time = 0) vs. time for OVA and fusion proteins DOM-OVA and OVA-DOM, along with curve fits in the form of bi-exponential decays, in Figure 8, show that the ASGPR-targeted OVA fusion proteins are cleared from circulation more quickly than unmodified OVA.

**[0229]** 17B. By following the procedure described in Example 17A and substituting N-DOM-$Gly_3$Ser-OVA-$Gly_3$Ser-6xHis-C fusion protein and OVA with asialo-Factor VIII and Factor VIII, respectively, it is shown that asialo-Factor VIII is cleared from circulation much more quickly than unmodified Factor VIII.

**Example 18**

**Biodistribution**

**[0230]** 18A. OVA and N-DOM-$Gly_3$Ser-OVA-$Gly_3$Ser-6xHis-C fusion protein (prepared, e.g., as described in Example 10) are labeled with Alexa Fluor 647 (Life Technologies) according to manufacturer's instructions. Unreacted dye is removed using Zeba desalting columns (Thermo Scientific). Labeled proteins, 50 µg in 100 µl PBS per dose, are administered *i.v.* or s.c into C57BL/6 mice (5 mice per group). Two hours after injection, mice are euthanized by $CO_2$ asphyxiation. The blood, heart, intestines, kidneys, liver, lungs, stomach, spleen, and remaining carcass are imaged using an IVIS Spectrum imaging system (Caliper Life Sciences). Data is acquired and analyzed using Living Image software (Caliper Life Sciences). Single cell suspensions of liver and spleen are prepared and stained with fluorescently conjugated antibodies against MHC class II, CD1d, CD3, CD4, CD8α, CD11b, CD11c, CD14, CD19, CD45, CD123, and/or Lin in PBS with 0.1% (w/v) BSA. Samples are analyzed using a LSR II flow cytometer and FACS Diva software (BD Biosciences).

**[0231]** A histogram showing fluorescence signal densities (photons/weight) for each organ and each protein shows that in animals injected with N-DOM-$Gly_3$Ser-OVA-$Gly_3$Ser-6xHis-C fusion protein the highest fluorescence signal is in the liver as compared to those treated with unmodified OVA.

**[0232]** A histogram showing percentages of N-DOM-$Gly_3$Ser-OVA-$Gly_3$Ser-6xHis-C and OVA-positive cells shows that animals injected with N-DOM-$Gly_3$Ser-OVA-$Gly_3$Ser-6xHis-C fusion proteins have a significantly higher percentage of positive hepatocytes as compared to those treated with unmodified OVA.

**[0233]** 18B. By following the procedure described in Example 18A and substituting N-DOM-$Gly_3$Ser-OVA-$Gly_3$Ser-6xHis-C fusion protein and OVA with asialo-Factor VIII and Factor VIII, respectively, it is shown that animals injected with asialo-Factor VIII have a significantly higher percentage of positive hepatocytes as compared to those treated with unmodified Factor VIII.

**[0234]** 18C. By following the procedure described in Example 18A and substituting N-DOM-$Gly_3$Ser-OVA-$Gly_3$Ser-6xHis-C fusion protein with the compounds of Formula 1 obtained, for example, as described in Examples 3A, 4A, 5B, 6C, 7B and 19G, it is shown that animals injected with the compounds from Examples 3A, 4A, 5B, 6C, 7B and 19G have a significantly higher percentage of positive hepatocytes as compared to those treated with OVA.

**[0235]** 18D. By following the procedure described in Examples 18A and B, and substituting F1aA-OVA-$m_4$-$n_8$, F1b-OVA-$m_1$-$n_4$-$p_{34}$, and N-DOM-$Gly_3$Ser-OVA-$Gly_3$Ser-6xHis-C with the

compounds of Formulae 1 and 2 obtained, for example, as described in Examples 1E, 1G, 2C, 10D, 191, 19L, 20B, 20D and 20F, and substituting OVA with the antigens corresponding to X (or X' or X''), respectively, it is shown that it is shown that animals injected with the compounds from Examples 1E, 1G, 2C, 10D, 191, 19L, 20B, 20D and 20F have a significantly higher percentage of positive hepatocytes as compared to those treated with antigen X.

**Example 19**

**F1m-OVA-$m_2$-$n_{80}$-$p_{30}$-$q_4$-CMP-2NHAc**

**19A. Formula 1102 where $R^3$ is NHAc and $R^4$ is OH**

**[0236]** *N*-Acetyl-D-galactosamine (Formula 1101 where $R^3$ is NHAc and $R^4$ is OH) (5g, 22.6 mmol) was added to a stirred solution of chloroethanol (200 ml) at room temperature. The solution was cooled to 4°C and acetylchloride was added drop-wise to the solution. The solution was brought to room temperature and then heated to 70°C. After 4 hours, the unreacted choroethanol was removed under reduced pressure. 100 ml of ethanol was added to the crude product and the resulting solution was stirred in the presence of carbon for 2 hours. The solution was filtered, and the solvent was removed under reduced pressure. The corresponding product of Formula 1102, *N*-(2-(2-chloroethoxy)-4,5-dihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-3-yl)acetamide, was used without further purification.

**19B. Formula 1103 where $R^3$ is NHAc and $R^4$ is OH**

**[0237]** The *N*-(2-(2-chloroethoxy)-4,5-dihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-3-yl)acetamide prepared in Example 19A (2g, 7.4 mmol) was added to a stirred solution of DMF (100 ml) and sodium azide (4g, 61.5 mmol). The solution was headed at 90°C for 12 hours and then filtered. The residual solvent was removed under reduced pressure and the crude product was purified via flash chromatography (10% MeOH in dichloromethane) to give the corresponding product of Formula 1103, *N*-(2-(2-azidoethoxy)-4,5-dihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-3-yl)acetamide.

**19C. Formula 1104 where $R^3$ is NHAc and $R^4$ is OH**

**[0238]** The *N*-(2-(2-azidoethoxy)-4,5-dihydroxy-6-(hydroxymethyl)tetrahydro-2*H*-pyran-3-yl)acetamide prepared in Example 19B (2 g, 6.9 mmol) was added to a solution of palladium

on carbon and ethanol (50 ml). The solution was stirred under hydrogen gas (3 atm) for 4 hours. The resulting solution was filtered and the residual solvent was removed under reduced pressure to afford the corresponding product of Formula 1104, *N*-(2-(2-aminoethoxy)-4,5-dihydroxy-6-(hydroxymethyl)tetrahydro-2*H*-pyran-3-yl)acetamide, which was used without further purification.

**19D. Formula 1105 where $R^3$ is NHAc and $R^4$ is OH**

**[0239]** The *N*-(2-(2-aminoethoxy)-4,5-dihydroxy-6-(hydroxymethyl)tetrahydro-2*H*-pyran-3-yl)acetamide prepared in Example 19C (1.0 g, 3.78 mmol) was added to a solution of methacrylate anhydride (0.583 g, 3.78 mmol) in DMF (50 ml). Triethylamine was then added to the solution and the reaction was stirred for 2 hours at room temperature. After 2 hours, the excess solvent was removed under reduced pressure, and the corresponding product of Formula 1105, *N*-(2-((3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)tetrahydro-2*H*-pyran-2-yl)oxy)ethyl)methacrylamide, was isolated via flash chromatography.

**19E. Formula 1107 where p is 30, q is 4, $R^3$ is NHAc, $R^4$ is OH and $R^8$ is CMP**

**[0240]** An azide-modified uRAFT agent of Formula 1106 where q is 4 (28 mg) was added to a solution of *N*-(2-((3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)ethyl)methacrylamide prepared in Example 19D (579 mg, 1.74 mmol) and azobisisobutyronitrile (2.2 mg, 0.0116 mmol) in DMF. The reaction mixture was subjected to 4 free-pump-thaw cycles, and then stirred at 70°C. After 12 hours, the polymer product of Formula 1107, where p is 30 and q is 4 was precipitated from the reaction mixture via the addition of methanol. The solvent was decanted from the solid and the solid was collected and residual solvent was removed via reduced pressure.

**19F. Formula 1109 where X' is OVA, m is 2 and n is 80**

**[0241]** Ovalbumin (5 mg, 0.00012 mmol) was added to 100 µl of sodium phosphate buffer (pH 8.0) and stirred. To this solution was added 5 mg of the compound of Formula 1108 where n is 80. After 1 hour, the unreacted compound of Formula 1108 was removed from the solution via centrifugal size-exclusion chromatography. The resulting bufferd solution containing the corresponding product of Formula 1109 was used in the next reaction without further purification.

**19G. Formula 1m where X' is OVA, m is 2, n is 80, p is 30, q is 4, $R^3$ is NHAc and $R^8$ is CMP**

**[0242]** The solution prepared in Example 19F was added to 100 µl of sodium phosphate buffer (pH 8.0) which contained 10 mg of the product of Formula 1107 prepared in Example 19E. The reaction was allowed to stir for 2 hours and then the excess Formula 1107 was removed via centrifugal size exclusion chromatography to afford the corresponding isomeric product of Formula 1m in solution, which was used in biological studies without further purification. The $R^3$ substituent is shown in the name of the title compound as 2NHAc.

**19H. Other Compounds of Formula 1109**

**[0243]** By following the procedure described in Example 19F and substituting OVA with the following:

- Abciximab,
- Adalimumab,
- Agalsidase alfa,
- Agalsidase beta,
- Aldeslukin,
- Alglucosidase alfa,
- Factor VIII,
- Factor IX,
- L-asparaginase,
- Laronidase,
- Octreotide,
- Phenylalanine ammonia-lyase,
- Rasburicase,
- Insulin (SEQ ID NO:5),
- GAD-65 (SEQ ID NO:6),
- IGRP (SEQ ID NO:7)
- MBP (SEQ ID NO:8),
- MOG (SEQ ID NO:9),
- PLP (SEQ ID N0:10),
- MBP13-32 (SEQ ID NO:11),
- MBP83-99 (SEQ ID NO:12),
- MBP111-129 (SEQ ID NO:13),
- MBP146-170 (SEQ ID NO:14),
- MOG1-20 (SEQ ID NO:15),
- MOG35-55 (SEQ ID NO:16),
- PLP139-154 (SEQ ID NO:17),
- MART1 (SEQ ID NO:18),
- Tyrosinase (SEQ ID NO:19),
- PMEL (SEQ ID NO:20),
- Aquaporin-4 (SEQ ID NO:21),

- S-arrestin (SEQ ID NO:22),
- IRBP (SEQ ID NO:23),
- Conarachin (UNIPROT Q6PSU6),
- Alpha-gliadin "33-mer" native (SEQ ID NO:24),
- Alpha-gliadin "33-mer" deamidated (SEQ ID NO:25),
- Alpha-gliadin (SEQ ID NO:26),
- Omega-gliadin (SEQ ID NO:27),
- Fel d 1A (UNIPROT P30438),
- Cat albumin (UNIPROT P49064),
- Can f 1 (UNIPROT 018873),
- Dog albumin (UNIPROT P49822), and
- RhCE example (UNIPROT P18577),

there are obtained the following corresponding compounds of Formula 1109 where n is 80:

- X is Abciximab and m is 10,
- X is Adalimumab and m is 11,
- X is Agalsidase alfa and m is 14,
- X is Agalsidase beta and m is 14,
- X is Aldeslukin and m is 6,
- X is Alglucosidase alfa and m is 13,
- X is Factor VIII and m is 100,
- X is Factor IX and m is 18,
- X is L-asparaginase and m is 5,
- X is Laronidase and m is 7,
- X is Octreotide and m is 1,
- X is Phenylalanine ammonia-lyase and m is 12,
- X is Rasburicase and m is 12,
- X is Insulin (SEQ ID NO:5) and m is 2,
- X is GAD-65 (SEQ ID NO:6) and m is 8,
- X is IGRP (SEQ ID NO:7) and m is 7,
- X is MBP (SEQ ID NO:8) and m is 6,
- X is MOG (SEQ ID NO:9) and m is 5,
- X is PLP (SEQ ID NO:10) and m is 8,
- X is MBP13-32 (SEQ ID NO:11) and m is 1,
- X is MBP83-99 (SEQ ID NO:12) and m is 1,
- X is MBP111-129 (SEQ ID NO:13) and m is 1,
- X is MBP146-170 (SEQ ID NO:14) and m is 2,
- X is MOG1-20 (SEQ ID NO:15) and m is 1,
- X is MOG35-55 (SEQ ID NO:16) and m is 2,
- X is PLP139-154 (SEQ ID NO:17) and m is 3,
- X is MART1 (SEQ ID NO:18) and m is 4,
- X is Tyrosinase (SEQ ID NO:19) and m is 8,
- X is PMEL (SEQ ID NO:20) and m is 5,
- X is Aquaporin-4 (SEQ ID NO:21) and m is 4,

- X is S-arrestin (SEQ ID NO:22) and m is 12,
- X is IRBP (SEQ ID NO:23) and m is 21,
- X is Conarachin and m is 21,
- X is Alpha-gliadin "33-mer" native (SEQ ID NO:24) and m is 1,
- X is Alpha-gliadin "33-mer" deamidated (SEQ ID NO:25) and m is 1,
- X is Alpha-gliadin (SEQ ID NO:26) and m is 1,
- X is Omega-gliadin (SEQ ID NO:27) and m is 1,
- X is Fel d 1 and m is 4,
- X is Cat albumin and m is 16,
- X is Can f1 and m is 6,
- X is Dog albumin and m is 23, and
- X is RhCE example and m is 10.

**19I. Other Compounds of Formula 1m**

**[0244]** By following the procedure described in Example 19G and substituting the compounds of Formula 1109, for example as obtained in Example 19H, there are obtained the following corresponding compounds of Formula 1m:

- F1m-Abciximab-$m_{10}$-$n_{80}$-$p_{30}$-$q_4$-CMP-2NHAc,
- F1m-Adalimumab-$m_{11}$-$n_{80}$-$p_{30}$-$q_4$-CMP-2NHAc,
- F1m-Agalsidase alfa-$m_{14}$-$n_{80}$-$p_{30}$-$q_4$-CMP-2NHAc,
- F1m-Agalsidase beta-$m_{14}$-$n_{80}$-$p_{30}$-$q_4$-CMP-2NHAc,
- F1m-Aldeslukin-$m_6$-$n_{80}$-$p_{30}$-$q_4$-CMP-2NHAc,
- F1m-Alglucosidase alfa-$m_{13}$-$n_{80}$-$p_{30}$-$q_4$-CMP-2NHAc,
- F1m-Factor VIII-$m_{100}$-$n_{80}$-$p_{30}$-$q_4$-CMP-2NHAc,
- F1m-Factor IX-$m_{18}$-$n_{80}$-$p_{30}$-$q_4$-CMP-2NHAc,
- F1m-L-asparaginase-$m_5$-$n_{80}$-$p_{30}$-$q_4$-CMP-2NHAc,
- F1m-Laronidase-$m_7$-$n_{80}$-$p_{30}$-$q_4$-CMP-2NHAc,
- F1m-Octreotide-$m_1$-$n_{80}$-$p_{30}$-$q_4$-CMP-2NHAc,
- F1m-Phenylalanine ammonia-lyase-$m_{12}$-$n_{80}$-$p_{30}$-$q_4$-CMP-2NHAc,
- F1m-Rasburicase-$m_{12}$-$n_{80}$-$p_{30}$-$q_4$-CMP-2NHAc,
- F1m-Insulin-$m_2$-$n_{80}$-$p_{30}$-$q_4$-CMP-2NHAc,
- F1m-GAD-65-$m_8$-$n_{80}$-$p_{30}$-$q_4$-CMP-2NHAc,
- F1m-IGRP-$m_7$-$n_{80}$-$p_{30}$-$q_4$-CMP-2NHAc,
- F1m-MBP-$m_6$-$n_{80}$-$p_{30}$-$q_4$-CMP-2NHAc,
- F1m-MOG-$m_5$-$n_{80}$-$p_{30}$-$q_4$-CMP-2NHAc,
- F1m-PLP-$m_8$-$n_{80}$-$p_{30}$-$q_4$-CMP-2NHAc,
- F1m-MBP13-32-$m_1$-$n_{80}$-$p_{30}$-$q_4$-CMP-2NHAc,

- F1m-MBP83-99-$m_1$-$n_{80}$-$p_{30}$-$q_4$-CMP-2NHAc,
- F1 m-MBP1 11-129-$m_1$-$n_{80}$-$p_{30}$-$q_4$-CMP-2NHAc,
- F1m-MBP146-170-$m_2$-$n_{80}$-$p_{30}$-$q_4$-CMP-2NHAc,
- F1m-MOG1-20-$m_1$-$n_{80}$-$p_{30}$-$q_4$-CMP-2NHAc,
- F1m-MOG35-55-$m_2$-$n_{80}$-$p_{30}$-$q_4$-CMP-2NHAc,
- F1m-PLP139-154-$m_3$-$n_{80}$-$p_{30}$-$q_4$-CMP-2NHAc,
- F1m-MART1-$M_4$-$n_{80}$-$p_{30}$-$q_4$-CMP-2NHAc,
- F1m-Tyrosinase-$m_8$-$n_{80}$-$p_{30}$-$q_4$-CMP-2NHAc,
- F1m-PMEL-$m_5$-$n_{80}$-$p_{30}$-$q_4$-CMP-2NHAc,
- F1m-Aquaporin-4-$m_4$-$n_{80}$-$p_{30}$-$q_4$-CMP-2NHAc,
- F1m-S-arrestin-$m_{12}$-$n_{80}$-$p_{30}$-$q_4$-CMP-2NHAc,
- F1m-IRBP-$m_{21}$-$n_{80}$-$p_{30}$-$q_4$-CMP-2NHAc,
- F1m-Conarachin-$m_{21}$-$n_{80}$-$p_{30}$-$q_4$-CMP-2NHAc,
- F1m-Alpha-gliadin "33-mer" native-$m_1$-$n_{80}$-$p_{30}$-$q_4$-CMP-2NHAc,
- F1m-Alpha-gliadin "33-mer" deamidated-$m_1$-$n_{80}$-$p_{30}$-$q_4$-CMP-2NHAc,
- F1m-Alpha-gliadin-$m_1$-$n_{80}$-$p_{30}$-$q_4$-CMP-2NHAc,
- F1m-Omega-gliadin-$m_1$-$n_{80}$-$p_{30}$-$q_4$-CMP-2NHAc,
- F1m-Fel d 1-$m_4$-$n_{80}$-$p_{30}$-$q_4$-CMP-2NHAc,
- F1m-Cat albumin-$m_{16}$-$n_{80}$-$p_{30}$-$q_4$-CMP-2NHAc,
- F1m-Can f1$m_6$-$n_{80}$-$p_{30}$-$q_4$-CMP-2NHAc,
- F1m-Dog albumin-$m_{23}$-$n_{80}$-$p_{30}$-$q_4$-CMP-2NHAc, and
- F1m-RhCE-$m_{10}$-$n_{80}$-$p_{30}$-$q_4$-CMP-2NHAc.

**19J. Formula 1107 where where p is 30, q is 8, $R^3$ is OH, $R^4$ is OH and $R^8$ is CMP**

**[0245]** By following the procedure described in Example 19A and substituting the N-acetyl-D-galactosamine with galactose, and following through to the procedure desribed in Example 19E except using an azide-modified uRAFT agent of Formula 1106 where q is 8, there is obtained the compound of Formula 1107 where where p is 30, q is 8, $R^3$ is OH, $R^4$ is OH and $R^8$ is CMP.

**19K. Formula 1109 where n is 62 and where X' and m are as in Example 19H**

**[0246]** By following the procedure described in Example 19F, substituting the OVA with the compounds as described in Example 19H and employing the compound of Formula 1108 where n is 62, there are obtained the corresponding compounds of Formula 1109 where n is 62.

## 19L. Other Compounds of Formula 1m

**[0247]** By following the procedure described in Example 19G and substituting the compound of Formula 1107 with the compounds obtained in Example 19J, and substituting the compound of Formula 1109 with the compounds obtained in Example 19K, there are obtained the following corresponding compounds of Formula 1m:

- F1m-Abciximab-$m_{10}$-$n_{62}$-$p_{30}$-$q_8$-CMP-2OH,
- F1m-Adalimumab-$m_{11}$-$n_{62}$-$p_{30}$-$q_8$-CMP-2OH,
- F1m-Agalsidase alfa-$m_{14}$-$n_{62}$-$p_{30}$-$q_8$-CMP-2OH,
- F1m-Agalsidase beta-$m_{14}$-$n_{62}$-$p_{30}$-$q_8$-CMP-2OH,
- F1m-Aldeslukin-$m_6$-$n_{62}$-$p_{30}$-$q_8$-CMP-2OH,
- F1m-Alglucosidase alfa-$m_{13}$-$n_{62}$-$p_{30}$-$q_8$-CMP-2OH,
- F1m-Factor VIII-$m_{100}$-$n_{62}$-$p_{30}$-$q_8$-CMP-2OH,
- F1m-Factor IX-$m_{18}$-$n_{62}$-$p_{30}$-$q_8$-CMP-2OH,
- F1m-L-asparaginase-$m_5$-$n_{62}$-$p_{30}$-$q_8$-CMP-2OH,
- F1m-Laronidase-$m_7$-$n_{62}$-$p_{30}$-$q_8$-CMP-2OH,
- F1m-Octreotide-$m_1$-$n_{62}$-$p_{30}$-$q_8$-CMP-2OH,
- F1m-Phenylalanine ammonia-lyase-$m_{12}$-$n_{62}$-$p_{30}$-$q_8$-CMP-2OH,
- F1m-Rasburicase-$m_{12}$-$n_{62}$-$p_{30}$-$q_8$-CMP-2OH,
- F1m-Insulin-$m_2$-$n_{62}$-$p_{30}$-$q_8$-CMP-2OH,
- F1m-GAD-65-$m_8$-$n_{62}$-$p_{30}$-$q_8$-CMP-2OH,
- F1m-IGRP-$m_7$-$n_{62}$-$p_{30}$-$q_8$-CMP-2OH,
- F1m-MBP-$m_6$-$n_{62}$-$p_{30}$-$q_8$-CMP-2OH,
- F1m-MOG-$m_5$-$n_{62}$-$p_{30}$-$q_8$-CMP-2OH,
- F1m-PLP-$m_8$-$n_{62}$-$p_{30}$-$q_8$-CMP-2OH,
- F1m-MBP13-32-$m_1$-$n_{62}$-$p_{30}$-$q_8$-CMP-2OH,
- F1m-MBP83-99-$m_1$-$n_{62}$-$p_{30}$-$q_8$-CMP-2OH,
- F1m-MBP111-129-$m_1$-$n_{62}$-$p_{30}$-$q_8$-CMP-2OH,
- F1m-MBP146-170-$m_2$-$n_{62}$-$p_{30}$-$q_8$-CMP-2OH,
- F1m-MOG1-20-$m_1$-$n_{62}$-$p_{30}$-$q_8$-CMP-2OH,
- F1m-MOG35-55-$m_2$-$n_{62}$-$p_{30}$-$q_8$-CMP-2OH,
- F1m-PLP139-154-$m_3$-$n_{62}$-$p_{30}$-$q_8$-CMP-2OH,
- F1m-MART1-$m_4$-$n_{62}$-$p_{30}$-$q_8$-CMP-2OH,
- F1m-Tyrosinase-$m_8$-$n_{62}$-$p_{30}$-$q_8$-CMP-2OH,
- F1m-PMEL-$m_5$-$n_{62}$-$P30$-$q_8$-CMP-2OH,
- F1m-Aquaporin-4-$m_4$-$n_{62}$-$p_{30}$-$q_8$-CMP-2OH,
- F1m-S-arrestin-$m_{12}$-$n_{62}$-$p_{30}$-$q_8$-CMP-2OH,

- F1m-IRBP-$m_{21}$-$n_{62}$-$p_{30}$-$q_8$-CMP-2OH,
- F1m-Conarachin-$m_{21}$-$n_{62}$-$p_{30}$-$q_8$-CMP-2OH,
- F1m-Alpha-gliadin "33-mer" native-$m_1$-$n_{62}$-$p_{30}$-$q_8$-CMP-2OH,
- F1m-Alpha-gliadin "33-mer" deamidated-$m_1$-$n_{62}$-$p_{30}$-$q_8$-CMP-2OH,
- F1m-Alpha-gliadin-$m_1$-$n_{62}$-$p_{30}$-$q_8$-CMP-2OH,
- F1m-Omega-gliadin-$m_1$-$n_{62}$-$p_{30}$-$q_8$-CMP-2OH,
- F1m-Fel d1-$m_4$-$n_{62}$-$p_{30}$-$q_8$-CMP-2OH,
- F1m-Cat albumin-$m_{16}$-$n_{62}$-$p_{30}$-$q_8$-CMP-2OH,
- F1 m-Can f 1-$m_6$-$n_{62}$-$p_{30}$-$q_8$-CMP-2OH,
- F1m-Dog albumin-$m_{23}$-$n_{62}$-$p_{30}$-$q_8$-CMP-2OH, and
- F1m-RhCE-$m_{10}$-$n_{62}$-$p_{30}$-$q_8$-CMP-2OH.

## Example 20

## F1n-insulin-$m_2$-$n_1$-$p_{30}$-$q_4$-CMP-2NHAc

### 20A. Formula 1202 where X' is Insulin, m is 2 and n is 1

**[0248]** Recombinant human insulin (5 mg) was added to 100 µl of DMF containing 10 µl of triethylamine and stirred until the insulin became soluble. To this solution was added 10 mg (0.0161 mmol) of a linker precursor of Formula 1201 where n is 1 (obtained from???) and the reaction was allowed to stir. After 1 hour, 1.3 ml of tert-butyl methyl ether was added to isolate the corresponding product of Formula 1202, which was recovered as the precipitate. Residual DMF and tert-butyl methyl ether were removed under reduced pressure. Characterization via liquid chromatography, mass spectroscopy and polyacrylamide gell electrophoresis confirmed the identity of the product. The modified insulin product of Formula 1202 was used without further purification.

### 20B. Formula 1n where X' is Insulin, m is 2, n is 1, p is 30, q is 4 and $R^8$ is CMP

**[0249]** The product of Formula 1202 obtained in Example 20A was resuspended in 100 µl of DMF. The polymer product of Formula 1107 obtained in Example 19E (10 mg) was added and the reaction was allowed to stir for 1 hour. After 1 hour, the reaction products were precipitated via the addition of dichloromethane (1.3 ml). The product was filtered and the residual solvent was removed under reduced pressure. The crude product was then resuspended in 500 µl of

PBS, and the low molecular weight components were removed via centrifugal size exclusion chromatography to afford the corresponding isomeric product of Formula 1n. Characterization via liquid chromatography, mass spectroscopy and polyacrylamide gell electrophoresis confirmed the identity of the product. The modified insulin product of Formula 1202 was used without further purification.

**20C. Other Compounds of Formula 1202**

**[0250]** By following the procedure described in Example 19F and substituting OVA insulin the following:

- Abciximab,
- Adalimumab,
- Agalsidase alfa,
- Agalsidase beta,
- Aldeslukin,
- Alglucosidase alfa,
- Factor VIII,
- Factor IX,
- L-asparaginase,
- Laronidase,
- Octreotide,
- Phenylalanine ammonia-lyase,
- Rasburicase,
- GAD-65 (SEQ ID NO:6),
- IGRP (SEQ ID NO:7)
- MBP (SEQ ID NO:8),
- MOG (SEQ ID NO:9),
- PLP (SEQ ID NO:10),
- MBP13-32 (SEQ ID NO:11),
- MBP83-99 (SEQ ID NO:12),
- MBP111-129 (SEQ ID NO:13),
- MBP146-170 (SEQ ID NO:14),
- MOG1-20 (SEQ ID NO:15),
- MOG35-55 (SEQ ID NO:16),
- PLP139-154 (SEQ ID NO:17),
- MART1 (SEQ ID NO:18),
- Tyrosinase (SEQ ID NO:19),
- PMEL (SEQ ID NO:20),
- Aquaporin-4 (SEQ ID NO:21),
- S-arrestin (SEQ ID NO:22),
- IRBP (SEQ ID NO:23),
- Conarachin (UNIPROT Q6PSU6),

- Alpha-gliadin "33-mer" native (SEQ ID NO:24),
- Alpha-gliadin "33-mer" deamidated (SEQ ID NO:25),
- Alpha-gliadin (SEQ ID NO:26),
- Omega-gliadin (SEQ ID NO:27),
- Fel d 1A (UNIPROT P30438),
- Cat albumin (UNIPROT P49064),
- Can f 1 (UNIPROT 018873),
- Dog albumin (UNIPROT P49822), and
- RhCE example (UNIPROT P18577),

there are obtained the following corresponding compounds of Formula 1202 where n is 1:

- X is Abciximab and m is 10,
- X is Adalimumab and m is 11,
- X is Agalsidase alfa and m is 14,
- X is Agalsidase beta and m is 14,
- X is Aldeslukin and m is 6,
- X is Alglucosidase alfa and m is 13,
- X is Factor VIII and m is 100,
- X is Factor IX and m is 18,
- X is L-asparaginase and m is 5,
- X is Laronidase and m is 7,
- X is Octreotide and m is 1,
- X is Phenylalanine ammonia-lyase and m is 12,
- X is Rasburicase and m is 12,
- X is GAD-65 (SEQ ID NO:6) and m is 8,
- X is IGRP (SEQ ID NO:7) and m is 7,
- X is MBP (SEQ ID NO:8) and m is 6,
- X is MOG (SEQ ID NO:9) and m is 5,
- X is PLP (SEQ ID NO:10) and m is 8,
- X is MBP13-32 (SEQ ID NO:11) and m is 1,
- X is MBP83-99 (SEQ ID NO:12) and m is 1,
- X is MBP111-129 (SEQ ID NO:13) and m is 1,
- X is MBP146-170 (SEQ ID NO:14) and m is 2,
- X is MOG1-20 (SEQ ID NO:15) and m is 1,
- X is MOG35-55 (SEQ ID NO:16) and m is 2,
- X is PLP139-154 (SEQ ID NO:17) and m is 3,
- X is MART1 (SEQ ID NO:18) and m is 4,
- X is Tyrosinase (SEQ ID NO:19) and m is 8,
- X is PMEL (SEQ ID NO:20) and m is 5,
- X is Aquaporin-4 (SEQ ID NO:21) and m is 4,
- X is S-arrestin (SEQ ID NO:22) and m is 12,
- X is IRBP (SEQ ID NO:23) and m is 21,
- X is Conarachin and m is 21,
- X is Alpha-gliadin "33-mer" native (SEQ ID NO:24) and m is 1,

- X is Alpha-gliadin "33-mer" deamidated (SEQ ID NO:25) and m is 1,
- X is Alpha-gliadin (SEQ ID NO:26) and m is 1,
- X is Omega-gliadin (SEQ ID NO:27) and m is 1,
- X is Fel d 1 and m is 4,
- X is Cat albumin and m is 16,
- X is Can f 1 and m is 6,
- X is Dog albumin and m is 23, and
- X is RhCE example and m is 10.

**20D. Other Compounds of Formula 1n**

**[0251]** By following the procedure described in Example B and substituting the compounds of Formula 1202, for example as obtained in Example 20C, there are obtained the following corresponding compounds of Formula 1m:

- F1n-Abciximab-$m_{10}$-$n_1$-$p_{30}$-$q_4$-CMP-2NHAc,
- F1n-Adalimumab-$m_{11}$-$n_1$-$p_{30}$-$q_4$-CMP-2NHAc,
- F1n-Agalsidase alfa-$m_{14}$-$n_1$-$p_{30}$-$q_4$-CMP-2NHAc,
- F1n-Agalsidase beta-$m_{14}$-$n_1$-$p_{30}$-$q_4$-CMP-NHAc,
- F1n-Aldeslukin-$m_6$-$n_1$-$p_{30}$-$q_4$-CMP-2NHAc,
- F1n-Alglucosidase alfa-$m_{13}$-$n_1$-$p_{30}$-$q_4$-CMP-2NHAc,
- F1n-Factor VIII-$m_{100}$-$n_1$-$p_{30}$-$q_4$-CMP-2NHAc,
- F1n-Factor IX-$m_{18}$-$n_1$-$p_{30}$-$q_4$-CMP-2NHAc,
- F1n-L-asparaginase-$m_5$-$n_1$-$p_{30}$-$q_4$-CMP-2NHAc,
- F1n-Laronidase-$m_7$-$n_1$-$p_{30}$-$q_4$-CMP-2NHAc,
- F1n-Octreotide-$m_1$-$n_1$-$p_{30}$-$q_4$-CMP-2NHAc,
- F1n-Phenylalanine ammonia-lyase-$m_{12}$-$n_1$-$p_{30}$-$q_4$-CMP-2NHAc,
- F1n-Rasburicase-$m_{12}$-$n_1$-$p_{30}$-$q_4$-CMP-2NHAc,
- F1n-GAD-65-$m_8$-$n_1$-$p_{30}$-$q_4$-CMP-2NHAc,
- F1n-IGRP-$m_7$-$n_1$-$p_{30}$-$q_4$-CMP-2NHAc,
- F1n-MBP-$m_6$-$n_1$-$p_{30}$-$q_4$-CMP-2NHAc,
- F1n-MOG-$m_5$-$n_1$-$p_{30}$-$q_4$-CMP-2NHAc,
- F1n-PLP-$m_8$-$n_1$-$p_{30}$-$q_4$-CMP-2NHAc,
- F1n-MBP13-32-$m_1$-$n_1$-$p_{30}$-$q_4$-CMP-2NHAc,
- F1n-MBP83-99-$m_1$-$n_1$-$p_{30}$-$q_4$-CMP-2NHAc,
- F1n-MBP111-129-$m_1$-$n_1$-$p_{30}$-$q_4$-CMP-2NHAc,
- F1n-MBP146-170-$m_2$-$n_1$-$p_{30}$-$q_4$-CMP-2NHAc,
- F1n-MOG1-20-$m_1$-$n_1$-$p_{30}$-$q_4$-CMP-2NHAc,

- F1n-MOG35-55-$m_2$-$n_1$-$p_{30}$-$q_4$-CMP-2NHAc,
- F1n-PLP139-154-$m_3$-$n_1$-$p_{30}$-$q_4$-CMP-2NHAc,
- F1n-MART1-$m_4$-$n_1$-$p_{30}$-$q_4$-CMP-2NHAc,
- F1n-Tyrosinase-$m_8$-$n_1$-$p_{30}$-$q_4$-CMP-2NHAc,
- F1n-PMEL-$m_5$-$n_1$-$p_{30}$-$q_4$-CMP-2NHAc,
- F1n-Aquaporin-4-$m_4$-$n_1$-$p_{30}$-$q_4$-CMP-2NHAc,
- F1n-S-arrestin-$m_{12}$-$n_1$-$p_{30}$-$q_4$-CMP-2NHAc,
- F1n-IRBP-$m_{21}$-$n_1$-$p_{30}$-$q_4$-CMP-2NHAc,
- F1n-Conarachin-$m_{21}$-$n_1$-$p_{30}$-$q_4$-CMP-2NHAc,
- F1n-Alpha-gliadin "33-mer" native-$m_1$-$n_1$-$p_{30}$-$q_4$-CMP-2NHAc,
- F1n-Alpha-gliadin "33-mer" deamidated-$m_1$-$n_1$-$p_{30}$-$q_4$-CMP-2NHAc,
- F1n-Alpha-gliadin-$m_1$-$n_1$-$p_{30}$-$q_4$-CMP-2NHAc,
- F1n-Omega-gliadin-$m_1$-$n_1$-$p_{30}$-$q_4$-CMP-2NHAc,
- F1n-Fel d1-$m_4$-$n_1$-$p_{30}$-$q_4$-CMP-2NHAc,
- F1n-Cat albumin-$m_{16}$-$n_1$-$p_{30}$-$q_4$-CMP-2NHAc,
- F1n-Can f 1-$m_6$-$n_1$-$p_{30}$-$q_4$-CMP-2NHAc,
- F1n-Dog albumin-$m_{23}$-$n_1$-$p_{30}$-$q_4$-CMP-2NHAc, and
- F1n-RhCE-$m_{10}$-$n_1$-$p_{30}$-$q_4$-CMP-2NHAc.

**20E. Formula 1202 where n is 33 and where X' and m are as in Example 20C**

**[0252]** By following the procedure described in Example 19F, substituting the insulin with the compounds as described in Example 20C and employing the compound of Formula 1201 where n is 33, there are obtained the corresponding compounds of Formula 1202 where n is 33.

**20F. Other Compounds of Formula 1n**

**[0253]** By following the procedure described in Example 20B and substituting the compound of Formula 1107 with the compounds obtained in Example 19J, and substituting the compound of Formula 1202 with the compounds obtained in Example 20E, there are obtained the following corresponding compounds of Formula 1n:

- F1n-Abciximab-$m_{10}$-$n_{33}$-$p_{30}$-$q_8$-CMP-2OH,
- F1n-Adalimumab-$m_{11}$-$n_{33}$-$p_{30}$-$q_8$-CMP-2OH,
- F1n-Agalsidase alfa-$m_{14}$-$n_{33}$-$p_{30}$-$q_8$-CMP-2OH,
- F1n-Agalsidase beta-$m_{14}$-$n_{33}$-$p_{30}$-$q_8$-CMP-2OH,

- F1n-Aldeslukin-$m_6$-$n_{33}$-$p_{30}$-$q_8$-CMP-2OH,
- F1n-Alglucosidase alfa-$m_{13}$-$n_{33}$-$p_{30}$-$q_8$-CMP-2OH,
- F1n-Factor VIII-$m_{100}$-$n_{33}$-$p_{30}$-$q_8$-CMP-2OH,
- F1n-Factor IX-$m_{18}$-$n_{33}$-$p_{30}$-$q_8$-CMP-2OH,
- F1n-L-asparaginase-$m_6$-$n_{33}$-$p_{30}$-$q_8$-CMP-2OH,
- F1n-Laronidase-$m_7$-$n_{33}$-$p_{30}$-$q_8$-CMP-2OH,
- F1n-Octreotide-$m_1$-$n_{33}$-$p_{30}$-$q_8$-CMP-2OH,
- F1n-Phenylalanine ammonia-lyase-$m_{12}$-$n_{33}$-$p_{30}$-$q_8$-CMP-2OH,
- F1n-Rasburicase-$m_{12}$-$n_{33}$-$p_{30}$-$q_8$-CMP-2OH,
- F1n-GAD-65-$m_8$-$n_{33}$-$p_{30}$-$q_8$-CMP-2OH,
- F1n-IGRP-$m_7$-$n_{33}$-$p_{30}$-$q_8$-CMP-2OH,
- F1n-MBP-$m_6$-$n_{33}$-$p_{30}$-$q_8$-CMP-2OH,
- F1n-MOG-$m_5$-$n_{33}$-$p_{30}$-$q_8$-CMP-2OH,
- F1n-PLP-$m_8$-$n_{33}$-$p_{30}$-$q_8$-CMP-2OH,
- F1n-MBP13-32-$m_1$-$n_{33}$-$p_{30}$-$q_8$-CMP-2OH,
- F1n-MBP83-99-$m_1$-$n_{33}$-$p_{30}$-$q_8$-CMP-2OH,
- F1n-MBP111-129-$m_1$-$n_{33}$-$p_{30}$-$q_8$-CMP-2OH,
- F1n-MBP146-170-$m_2$-$n_{33}$-$p_{30}$-$q_8$-CMP-2OH,
- F1n-MOG1-20-$m_1$-$n_{33}$-$p_{30}$-$q_8$-CMP-2OH,
- F1n-MOG35-55-$m_2$-$n_{33}$-$p_{30}$-$q_8$-CMP-2OH,
- F1n-PLP139-154-$m_3$-$n_{33}$-$p_{30}$-$q_8$-CMP-2OH,
- F1n-MART1-$m_4$-$n_{33}$-$p_{30}$-$q_8$-CMP-2OH,
- F1n-Tyrosinase-$m_8$-$n_{33}$-$p_{30}$-$q_8$-CMP-2OH,
- F1n-PMEL-$m_5$-$n_{33}$-$p_{30}$-$q_8$-CMP-2OH,
- F1n-Aquaporin-4-$m_4$-$n_{33}$-$p_{30}$-$q_8$-CMP-2OH,
- F1n-S-arrestin-$m_{12}$-$n_{33}$-$p_{30}$-$q_8$-CMP-2OH,
- F1n-IRBP-$m_{21}$-$n_{33}$-$p_{30}$-$q_8$-CMP-2OH,
- F1n-Conarachin-$m_{21}$-$n_{33}$-$p_{30}$-$q_8$-CMP-2OH,
- F1n-Alpha-gliadin "33-mer" native-$m_1$-$n_{33}$-$p_{30}$-$q_8$-CMP-2OH,
- F1n-Alpha-gliadin "33-mer" deamidated-$m_1$-$n_{33}$-$p_{30}$-$q_8$-CMP-2OH,
- F1n-Alpha-gliadin-$m_1$-$n_{33}$-$p_{30}$-$q_8$-CMP-2OH,
- F1n-Omega-gliadin-$m_1$-$n_{33}$-$p_{30}$-$q_8$-CMP-2OH,
- F1n-Fel d 1-$m_4$-$n_{33}$-$p_{30}$-$q_8$-CMP-2OH,
- F1n-Cat albumin-$m_{16}$-$n_{33}$-$p_{30}$-$q_8$-CMP-2OH,
- F1n-Can f 1-$m_6$-$n_{33}$-$p_{30}$-$q_8$-CMP-2OH,
- F1n-Dog albumin-$m_{23}$-$n_{33}$-$p_{30}$-$q_8$-CMP-2OH, and
- F1n-RhCE-$m_{10}$-$n_{33}$-$p_{30}$-$q_8$-CMP-2OH.

**Example 21**

**Clearance of OVA-specific antibodies from circulation**

**[0254]** To induce production of OVA-specific antibodies for subsequent depletion, C57BL/6 mice were injected *i.v.* with up to five doses of 10 µg OVA until a titer of anti-OVA IgG in plasma, as determined by ELISA, reached 3 (Figure 9A). Plasma samples were prepared by centrifugation of blood collected into EDTA-coated tubes at 2000 x *g* for 10 minutes at room temperature and stored at -20°C until analysis. Titer is defined as the $\log_{10}$ of the maximal fold dilution of plasma with detectable anti-OVA IgG. Here, plasma samples were assayed at dilutions of 10-, 50-, 100-, 500-, 1,000-, 5,000-, 10,000-, and 50,000-fold, yielding potential titer measurements of 0, 1, 1.7, 2, 2.7, 3, 3.7, 4, and 4.7. Mice with titers below 3 after five doses of 10 µg OVA were given two additional doses of 10 µg OVA adjuvanted with 10 µg CpG-B to boost anti-OVA IgG production and hence the amount of circulating anti-OVA IgG available for depletion (Figure 9B).

**[0255]** To evaluate the efficacy of hepatocyte ASGPR-targeted OVA for anti-OVA antibody clearance, mice with circulating anti-OVA IgG were injected *i.v.* with saline or saline containing molar equivalents of DOM and OVA, DOM-OVA, or OVA-DOM. In particular, mice were treated with molar equivalents of 10, 50, 100, or 200 µg OVA, as indicated in Figure 9. At times *t* = -1 day, +3 hours, +1 day, and +7 days, relative to the time of treatment injection, blood samples were collected to assess, by ELISA analysis of plasma, the amount of anti-OVA IgG in circulation. Clearance of anti-OVA IgG from circulation is expected to decrease the amount of anti-OVA IgG in plasma and hence decrease plasma anti-OVA IgG titer as determined by ELISA. In mice immunized with OVA alone and treated with DOM-OVA or OVA-DOM, titers of anti-OVA IgG decreased by up to 3 or 2, respectively, representing decreases in the amount of circulating anti-OVA IgG by 1000- or 100-fold, which is up to 50-fold more effective than control treatment using saline or DOM and OVA (Figure 9A). In mice immunized with OVA adjuvanted with CpG-B, clearance of circulating anti-OVA IgG was not observed (Figure 9B).

**Example 22**

**NOD Mouse**

**[0256]** Non-obese diabetic (NOD) mice are susceptible to the spontaneous onset of autoimmune diabetes mellitus, which is the result of an autoimmune response to various pancreatic auto-antigens. Diabetes develops in NOD mice as a result of insulitis, characterized by the infiltration of various leukocytes into the pancreatic islets.

**[0257]** In order to evaluate the efficacy of a treatment for diabetes mellitus, starting at 6-weeks of age, NOD mice are divided into control or test grops and treated, respectively, with weekly intravenous injections of a test composition (10 µg) or an inactive control such as saline. The injections continue for 18 consecutive weeks.

**[0258]** The blood glucose concentration of the mice is measured weekly. Mice that maintain a blood glucose concentration of less than 300 mg/ml during the experiment are considered non-diabetic. In addition, at the end of the study the pancreases of the mice are harvested and T cell infiltration in the pancreas is determined via immunohistochemistry as an assessment of insulitis. Tolerance induction is assessed by the depletion of auto-antigen specific CD8 T cells as compared to mice that are treated with saline and develop diabetes. The existence of auto-antigen specific CD8 T cells is determined via ELISpot assay.

**[0259]** When tested as described above, compositions of Formulae 1 and 2 where X is insulin, such as F1m-insulin-m2-n1-p30-q4-2NAcGAL, show efficacy for treating diabetes mellitus.

**SEQUENCE LISTING**

**[0260]**

<110> ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE ANOKION SA

<120> Glycotargeting Therapeutics

<130> 2968.10US02

<150> 61/942,942
<151> 2014-02-21

<160> 31

<170> PatentIn version 3.5

<210> 1
<211> 6
<212> PRT
<213> Artificial Sequence

<220>
<223> His tag

<400> 1

| | | | | | |
|---|---|---|---|---|---|
| **His** | **His** | **His** | **His** | **His** | **His** |
| 1 | | | | 5 | |

<210> 2

<211> 4

<212> PRT

<213> Artificial Sequence

<220>

<223> Gly3Ser

<400> 2

```
Gly Gly Gly Ser
1
```

<210> 3

<211> 20

<212> PRT

<213> Homo sapiens

<400> 3

```
Met Glu Thr Asp Thr Leu Leu Leu Trp Val Leu Leu Leu Trp Val Pro
1               5                  10                  15

Gly Ser Thr Gly
            20
```

<210> 4

<211> 22

<212> PRT

<213> Homo sapiens

<400> 4

```
Met Lys Tyr Leu Leu Pro Thr Ala Ala Ala Gly Leu Leu Leu Leu Ala
1               5                  10                  15

Ala Gln Pro Ala Met Ala
            20
```

<210> 5

<211> 110

<212> PRT

<213> Homo sapiens

<400> 5

```
Met Ala Leu Trp Met Arg Leu Leu Pro Leu Leu Ala Leu Leu Ala Leu
1               5                  10                  15

Trp Gly Pro Asp Pro Ala Ala Ala Phe Val Asn Gln His Leu Cys Gly
            20                  25                  30

Ser His Leu Val Glu Ala Leu Tyr Leu Val Cys Gly Glu Arg Gly Phe
        35                  40                  45

Phe Tyr Thr Pro Lys Thr Arg Arg Glu Ala Glu Asp Leu Gln Val Gly
    50                  55                  60
```

```
Gln Val Glu Leu Gly Gly Gly Pro Gly Ala Gly Ser Leu Gln Pro Leu
65                  70                  75                  80

Ala Leu Glu Gly Ser Leu Gln Lys Arg Gly Ile Val Glu Gln Cys Cys
                85                  90                  95

Thr Ser Ile Cys Ser Leu Tyr Gln Leu Glu Asn Tyr Cys Asn
            100                 105                 110
```

<210> 6

<211> 585

<212> PRT

<213> Homo sapiens

<400> 6

```
Met Ala Ser Pro Gly Ser Gly Phe Trp Ser Phe Gly Ser Glu Asp Gly
1               5                   10                  15

Ser Gly Asp Ser Glu Asn Pro Gly Thr Ala Arg Ala Trp Cys Gln Val
            20                  25                  30

Ala Gln Lys Phe Thr Gly Gly Ile Gly Asn Lys Leu Cys Ala Leu Leu
        35                  40                  45

Tyr Gly Asp Ala Glu Lys Pro Ala Glu Ser Gly Gly Ser Gln Pro Pro
    50                  55                  60

Arg Ala Ala Ala Arg Lys Ala Ala Cys Ala Cys Asp Gln Lys Pro Cys
65                  70                  75                  80

Ser Cys Ser Lys Val Asp Val Asn Tyr Ala Phe Leu His Ala Thr Asp
                85                  90                  95

Leu Leu Pro Ala Cys Asp Gly Glu Arg Pro Thr Leu Ala Phe Leu Gln
            100                 105                 110

Asp Val Met Asn Ile Leu Leu Gln Tyr Val Val Lys Ser Phe Asp Arg
        115                 120                 125

Ser Thr Lys Val Ile Asp Phe His Tyr Pro Asn Glu Leu Leu Gln Glu
    130                 135                 140

Tyr Asn Trp Glu Leu Ala Asp Gln Pro Gln Asn Leu Glu Glu Ile Leu
145                 150                 155                 160

Met His Cys Gln Thr Thr Leu Lys Tyr Ala Ile Lys Thr Gly His Pro
                165                 170                 175

Arg Tyr Phe Asn Gln Leu Ser Thr Gly Leu Asp Met Val Gly Leu Ala
            180                 185                 190

Ala Asp Trp Leu Thr Ser Thr Ala Asn Thr Asn Met Phe Thr Tyr Glu
        195                 200                 205

Ile Ala Pro Val Phe Val Leu Leu Glu Tyr Val Thr Leu Lys Lys Met
```

210 215 220

Arg Glu Ile Ile Gly Trp Pro Gly Gly Ser Gly Asp Gly Ile Phe Ser
225 230 235 240

Pro Gly Gly Ala Ile Ser Asn Met Tyr Ala Met Met Ile Ala Arg Phe
245 250 255

Lys Met Phe Pro Glu Val Lys Glu Lys Gly Met Ala Ala Leu Pro Arg
260 265 270

Leu Ile Ala Phe Thr Ser Glu His Ser His Phe Ser Leu Lys Lys Gly
275 280 285

Ala Ala Ala Leu Gly Ile Gly Thr Asp Ser Val Ile Leu Ile Lys Cys

290 295 300

Asp Glu Arg Gly Lys Met Ile Pro Ser Asp Leu Glu Arg Arg Ile Leu
305 310 315 320

Glu Ala Lys Gln Lys Gly Phe Val Pro Phe Leu Val Ser Ala Thr Ala
325 330 335

Gly Thr Thr Val Tyr Gly Ala Phe Asp Pro Leu Leu Ala Val Ala Asp
340 345 350

Ile Cys Lys Lys Tyr Lys Ile Trp Met His Val Asp Ala Ala Trp Gly
355 360 365

Gly Gly Leu Leu Met Ser Arg Lys His Lys Trp Lys Leu Ser Gly Val
370 375 380

Glu Arg Ala Asn Ser Val Thr Trp Asn Pro His Lys Met Met Gly Val
385 390 395 400

Pro Leu Gln Cys Ser Ala Leu Leu Val Arg Glu Glu Gly Leu Met Gln
405 410 415

Asn Cys Asn Gln Met His Ala Ser Tyr Leu Phe Gln Gln Asp Lys His
420 425 430

Tyr Asp Leu Ser Tyr Asp Thr Gly Asp Lys Ala Leu Gln Cys Gly Arg
435 440 445

His Val Asp Val Phe Lys Leu Trp Leu Met Trp Arg Ala Lys Gly Thr
450 455 460

Thr Gly Phe Glu Ala His Val Asp Lys Cys Leu Glu Leu Ala Glu Tyr
465 470 475 480

Leu Tyr Asn Ile Ile Lys Asn Arg Glu Gly Tyr Glu Met Val Phe Asp
485 490 495

Gly Lys Pro Gln His Thr Asn Val Cys Phe Trp Tyr Ile Pro Pro Ser
500 505 510

Leu Arg Thr Leu Glu Asp Asn Glu Glu Arg Met Ser Arg Leu Ser Lys
515 520 525

Val Ala Pro Val Ile Lys Ala Arg Met Met Glu Tyr Gly Thr Thr Met
530 535 540

Val Ser Tyr Gln Pro Leu Gly Asp Lys Val Asn Phe Phe Arg Met Val
545 550 555 560

Ile Ser Asn Pro Ala Ala Thr His Gln Asp Ile Asp Phe Leu Ile Glu
565 570 575

Glu Ile Glu Arg Leu Gly Gln Asp Leu
580 585

<210> 7

<211> 355

<212> PRT

<213> Homo sapiens

<400> 7

Met Asp Phe Leu His Arg Asn Gly Val Leu Ile Ile Gln His Leu Gln
1 5 10 15

Lys Asp Tyr Arg Ala Tyr Tyr Thr Phe Leu Asn Phe Met Ser Asn Val
20 25 30

Gly Asp Pro Arg Asn Ile Phe Phe Ile Tyr Phe Pro Leu Cys Phe Gln
35 40 45

Phe Asn Gln Thr Val Gly Thr Lys Met Ile Trp Val Ala Val Ile Gly
50 55 60

Asp Trp Leu Asn Leu Ile Phe Lys Trp Ile Leu Phe Gly His Arg Pro
65 70 75 80

Tyr Trp Trp Val Gln Glu Thr Gln Ile Tyr Pro Asn His Ser Ser Pro
85 90 95

Cys Leu Glu Gln Phe Pro Thr Thr Cys Glu Thr Gly Pro Gly Ser Pro
100 105 110

Ser Gly His Ala Met Gly Ala Ser Cys Val Trp Tyr Val Met Val Thr
115 120 125

Ala Ala Leu Ser His Thr Val Cys Gly Met Asp Lys Phe Ser Ile Thr
130 135 140

Leu His Arg Leu Thr Trp Ser Phe Leu Trp Ser Val Phe Trp Leu Ile
145 150 155 160

Gln Ile Ser Val Cys Ile Ser Arg Val Phe Ile Ala Thr His Phe Pro
165 170 175

```
His Gln Val Ile Leu Gly Val Ile Gly Gly Met Leu Val Ala Glu Ala
            180                 185                 190

Phe Glu His Thr Pro Gly Ile Gln Thr Ala Ser Leu Gly Thr Tyr Leu
        195                 200                 205

Lys Thr Asn Leu Phe Leu Phe Leu Phe Ala Val Gly Phe Tyr Leu Leu
    210                 215                 220

Leu Arg Val Leu Asn Ile Asp Leu Leu Trp Ser Val Pro Ile Ala Lys
225                 230                 235                 240

Lys Trp Cys Ala Asn Pro Asp Trp Ile His Ile Asp Thr Thr Pro Phe
                245                 250                 255

Ala Gly Leu Val Arg Asn Leu Gly Val Leu Phe Gly Leu Gly Phe Ala
            260                 265                 270

Ile Asn Ser Glu Met Phe Leu Leu Ser Cys Arg Gly Gly Asn Asn Tyr
        275                 280                 285

Thr Leu Ser Phe Arg Leu Leu Cys Ala Leu Thr Ser Leu Thr Ile Leu
    290                 295                 300

Gln Leu Tyr His Phe Leu Gln Ile Pro Thr His Glu Glu His Leu Phe
305                 310                 315                 320

Tyr Val Leu Ser Phe Cys Lys Ser Ala Ser Ile Pro Leu Thr Val Val
                325                 330                 335

Ala Phe Ile Pro Tyr Ser Val His Met Leu Met Lys Gln Ser Gly Lys
            340                 345                 350

Lys Ser Gln
        355
```

<210> 8

<211> 304

<212> PRT

<213> Homo sapiens

<400> 8

```
Met Gly Asn His Ala Gly Lys Arg Glu Leu Asn Ala Glu Lys Ala Ser
1               5                   10                  15

Thr Asn Ser Glu Thr Asn Arg Gly Glu Ser Glu Lys Lys Arg Asn Leu
            20                  25                  30

Gly Glu Leu Ser Arg Thr Thr Ser Glu Asp Asn Glu Val Phe Gly Glu
        35                  40                  45

Ala Asp Ala Asn Gln Asn Asn Gly Thr Ser Ser Gln Asp Thr Ala Val
    50                  55                  60

Thr Asp Ser Lys Arg Thr Ala Asp Pro Lys Asn Ala Trp Gln Asp Ala
65                  70                  75                  80
```

```
His Pro Ala Asp Pro Gly Ser Arg Pro His Leu Ile Arg Leu Phe Ser
                85                  90                  95

Arg Asp Ala Pro Gly Arg Glu Asp Asn Thr Phe Lys Asp Arg Pro Ser
            100                 105                 110

Glu Ser Asp Glu Leu Gln Thr Ile Gln Glu Asp Ser Ala Ala Thr Ser
        115                 120                 125

Glu Ser Leu Asp Val Met Ala Ser Gln Lys Arg Pro Ser Gln Arg His
    130                 135                 140

Gly Ser Lys Tyr Leu Ala Thr Ala Ser Thr Met Asp His Ala Arg His
145                 150                 155                 160

Gly Phe Leu Pro Arg His Arg Asp Thr Gly Ile Leu Asp Ser Ile Gly
                165                 170                 175

Arg Phe Phe Gly Gly Asp Arg Gly Ala Pro Lys Arg Gly Ser Gly Lys
            180                 185                 190

Asp Ser His His Pro Ala Arg Thr Ala His Tyr Gly Ser Leu Pro Gln
        195                 200                 205

Lys Ser His Gly Arg Thr Gln Asp Glu Asn Pro Val Val His Phe Phe
    210                 215                 220

Lys Asn Ile Val Thr Pro Arg Thr Pro Pro Pro Ser Gln Gly Lys Gly
225                 230                 235                 240

Arg Gly Leu Ser Leu Ser Arg Phe Ser Trp Gly Ala Glu Gly Gln Arg
                245                 250                 255

Pro Gly Phe Gly Tyr Gly Gly Arg Ala Ser Asp Tyr Lys Ser Ala His
            260                 265                 270

Lys Gly Phe Lys Gly Val Asp Ala Gln Gly Thr Leu Ser Lys Ile Phe
        275                 280                 285

Lys Leu Gly Gly Arg Asp Ser Arg Ser Gly Ser Pro Met Ala Arg Arg
    290                 295                 300
```

<210> 9

<211> 247

<212> PRT

<213> Homo sapiens

<400> 9

```
Met Ala Ser Leu Ser Arg Pro Ser Leu Pro Ser Cys Leu Cys Ser Phe
1               5                  10                  15

Leu Leu Leu Leu Leu Leu Gln Val Ser Ser Ser Tyr Ala Gly Gln Phe
            20                  25                  30

Arg Val Ile Gly Pro Arg His Pro Ile Arg Ala Leu Val Gly Asp Glu
        35                  40                  45
```

```
         35                  40                  45

Val Glu Leu Pro Cys Arg Ile Ser Pro Gly Lys Asn Ala Thr Gly Met
    50                  55                  60

Glu Val Gly Trp Tyr Arg Pro Pro Phe Ser Arg Val Val His Leu Tyr
65                  70                  75                  80

Arg Asn Gly Lys Asp Gln Asp Gly Asp Gln Ala Pro Glu Tyr Arg Gly
                85                  90                  95

Arg Thr Glu Leu Leu Lys Asp Ala Ile Gly Glu Gly Lys Val Thr Leu
            100                 105                 110

Arg Ile Arg Asn Val Arg Phe Ser Asp Glu Gly Gly Phe Thr Cys Phe
        115                 120                 125

Phe Arg Asp His Ser Tyr Gln Glu Glu Ala Ala Met Glu Leu Lys Val
    130                 135                 140

Glu Asp Pro Phe Tyr Trp Val Ser Pro Gly Val Leu Val Leu Leu Ala
145                 150                 155                 160

Val Leu Pro Val Leu Leu Leu Gln Ile Thr Val Gly Leu Ile Phe Leu
                165                 170                 175

Cys Leu Gln Tyr Arg Leu Arg Gly Lys Leu Arg Ala Glu Ile Glu Asn
            180                 185                 190

Leu His Arg Thr Phe Asp Pro His Phe Leu Arg Val Pro Cys Trp Lys
        195                 200                 205

Ile Thr Leu Phe Val Ile Val Pro Val Leu Gly Pro Leu Val Ala Leu
    210                 215                 220

Ile Ile Cys Tyr Asn Trp Leu His Arg Arg Leu Ala Gly Gln Phe Leu
225                 230                 235                 240

Glu Glu Leu Arg Asn Pro Phe
                245
```

<210> 10

<211> 277

<212> PRT

<213> Homo sapiens

<400> 10

```
Met Gly Leu Leu Glu Cys Cys Ala Arg Cys Leu Val Gly Ala Pro Phe
1               5                  10                  15

Ala Ser Leu Val Ala Thr Gly Leu Cys Phe Phe Gly Val Ala Leu Phe
            20                  25                  30

Cys Gly Cys Gly His Glu Ala Leu Thr Gly Thr Glu Lys Leu Ile Glu
        35                  40                  45
```

Thr Tyr Phe Ser Lys Asn Tyr Gln Asp Tyr Glu Tyr Leu Ile Asn Val
50 55 60

Ile His Ala Phe Gln Tyr Val Ile Tyr Gly Thr Ala Ser Phe Phe Phe
65 70 75 80

Leu Tyr Gly Ala Leu Leu Leu Ala Glu Gly Phe Tyr Thr Thr Gly Ala
85 90 95

Val Arg Gln Ile Phe Gly Asp Tyr Lys Thr Thr Ile Cys Gly Lys Gly
100 105 110

Leu Ser Ala Thr Val Thr Gly Gly Gln Lys Gly Arg Gly Ser Arg Gly
115 120 125

Gln His Gln Ala His Ser Leu Glu Arg Val Cys His Cys Leu Gly Lys
130 135 140

Trp Leu Gly His Pro Asp Lys Phe Val Gly Ile Thr Tyr Ala Leu Thr
145 150 155 160

Val Val Trp Leu Leu Val Phe Ala Cys Ser Ala Val Pro Val Tyr Ile
165 170 175

Tyr Phe Asn Thr Trp Thr Thr Cys Gln Ser Ile Ala Phe Pro Ser Lys
180 185 190

Thr Ser Ala Ser Ile Gly Ser Leu Cys Ala Asp Ala Arg Met Tyr Gly
195 200 205

Val Leu Pro Trp Asn Ala Phe Pro Gly Lys Val Cys Gly Ser Asn Leu
210 215 220

Leu Ser Ile Cys Lys Thr Ala Glu Phe Gln Met Thr Phe His Leu Phe
225 230 235 240

Ile Ala Ala Phe Val Gly Ala Ala Ala Thr Leu Val Ser Leu Leu Thr
245 250 255

Phe Met Ile Ala Ala Thr Tyr Asn Phe Ala Val Leu Lys Leu Met Gly
260 265 270

Arg Gly Thr Lys Phe
275

<210> 11

<211> 20

<212> PRT

<213> Homo sapiens

<400> 11

Lys Tyr Leu Ala Thr Ala Ser Thr Met Asp His Ala Arg His Gly Phe
1 5 10 15

Leu Pro Arg His
20

<210> 12

<211> 16

<212> PRT

<213> Homo sapiens

<400> 12

Glu Asn Pro Trp His Phe Phe Lys Asn Ile Val Thr Pro Arg Thr Pro
1 5 10 15

<210> 13

<211> 19

<212> PRT

<213> Homo sapiens

<400> 13

Leu Ser Arg Phe Ser Trp Gly Ala Glu Gly Gln Arg Pro Gly Phe Gly
1 5 10 15

Tyr Gly Gly

<210> 14

<211> 25

<212> PRT

<213> Homo sapiens

<400> 14

Ala Gln Gly Thr Leu Ser Lys Ile Phe Lys Leu Gly Gly Arg Asp Ser
1 5 10 15

Arg Ser Gly Ser Pro Met Ala Arg Arg
20 25

<210> 15

<211> 20

<212> PRT

<213> Homo sapiens

<400> 15

Gly Gln Phe Arg Val Ile Gly Pro Arg His Pro Ile Arg Ala Leu Val
1 5 10 15

Gly Asp Glu Val
20

<210> 16

<211> 20

<212> PRT

<213> Homo sapiens

<400> 16

```
Met Glu Val Gly Trp Tyr Arg Pro Pro Phe Ser Arg Trp His Leu Tyr
1               5                  10                  15

Arg Asn Gly Lys
            20
```

<210> 17

<211> 16

<212> PRT

<213> Homo sapiens

<400> 17

```
His Cys Leu Gly Lys Trp Leu Gly His Pro Asp Lys Phe Val Gly Ile
1               5                  10                  15
```

<210> 18

<211> 118

<212> PRT

<213> Homo sapiens

<400> 18

```
Met Pro Arg Glu Asp Ala His Phe Ile Tyr Gly Tyr Pro Lys Lys Gly
1               5                  10                  15

His Gly His Ser Tyr Thr Thr Ala Glu Glu Ala Ala Gly Ile Gly Ile
            20                  25                  30

Leu Thr Val Ile Leu Gly Val Leu Leu Leu Ile Gly Cys Trp Tyr Cys
        35                  40                  45

Arg Arg Arg Asn Gly Tyr Arg Ala Leu Met Asp Lys Ser Leu His Val
    50                  55                  60

Gly Thr Gln Cys Ala Leu Thr Arg Arg Cys Pro Gln Glu Gly Phe Asp
65                  70                  75                  80

His Arg Asp Ser Lys Val Ser Leu Gln Glu Lys Asn Cys Glu Pro Val
                85                  90                  95

Val Pro Asn Ala Pro Pro Ala Tyr Glu Lys Leu Ser Ala Glu Gln Ser
            100                 105                 110

Pro Pro Pro Tyr Ser Pro
        115
```

<210> 19

<211> 529

<212> PRT

<213> Homo sapiens

<400> 19

```
Met Leu Leu Ala Val Leu Tyr Cys Leu Leu Trp Ser Phe Gln Thr Ser
1               5                  10                  15
```

```
Ala Gly His Phe Pro Arg Ala Cys Val Ser Ser Lys Asn Leu Met Glu
            20                  25                  30

Lys Glu Cys Cys Pro Pro Trp Ser Gly Asp Arg Ser Pro Cys Gly Gln
        35                  40                  45

Leu Ser Gly Arg Gly Ser Cys Gln Asn Ile Leu Leu Ser Asn Ala Pro
    50                  55                  60

Leu Gly Pro Gln Phe Pro Phe Thr Gly Val Asp Asp Arg Glu Ser Trp
65                  70                  75                  80

Pro Ser Val Phe Tyr Asn Arg Thr Cys Gln Cys Ser Gly Asn Phe Met
                85                  90                  95

Gly Phe Asn Cys Gly Asn Cys Lys Phe Gly Phe Trp Gly Pro Asn Cys
            100                 105                 110

Thr Glu Arg Arg Leu Leu Val Arg Arg Asn Ile Phe Asp Leu Ser Ala
        115                 120                 125

Pro Glu Lys Asp Lys Phe Phe Ala Tyr Leu Thr Leu Ala Lys His Thr
    130                 135                 140

Ile Ser Ser Asp Tyr Val Ile Pro Ile Gly Thr Tyr Gly Gln Met Lys
145                 150                 155                 160

Asn Gly Ser Thr Pro Met Phe Asn Asp Ile Asn Ile Tyr Asp Leu Phe
                165                 170                 175

Val Trp Met His Tyr Tyr Val Ser Met Asp Ala Leu Leu Gly Gly Ser
            180                 185                 190

Glu Ile Trp Arg Asp Ile Asp Phe Ala His Glu Ala Pro Ala Phe Leu
        195                 200                 205

Pro Trp His Arg Leu Phe Leu Leu Arg Trp Glu Gln Glu Ile Gln Lys
    210                 215                 220

Leu Thr Gly Asp Glu Asn Phe Thr Ile Pro Tyr Trp Asp Trp Arg Asp
225                 230                 235                 240

Ala Glu Lys Cys Asp Ile Cys Thr Asp Glu Tyr Met Gly Gly Gln His
                245                 250                 255

Pro Thr Asn Pro Asn Leu Leu Ser Pro Ala Ser Phe Phe Ser Ser Trp
            260                 265                 270

Gln Ile Val Cys Ser Arg Leu Glu Glu Tyr Asn Ser His Gln Ser Leu
        275                 280                 285

Cys Asn Gly Thr Pro Glu Gly Pro Leu Arg Arg Asn Pro Gly Asn His
    290                 295                 300
```

```
Asp Lys Ser Arg Thr Pro Arg Leu Pro Ser Ser Ala Asp Val Glu Phe
305                 310                 315                 320

Cys Leu Ser Leu Thr Gln Tyr Glu Ser Gly Ser Met Asp Lys Ala Ala
                325                 330                 335

Asn Phe Ser Phe Arg Asn Thr Leu Glu Gly Phe Ala Ser Pro Leu Thr
            340                 345                 350

Gly Ile Ala Asp Ala Ser Gln Ser Ser Met His Asn Ala Leu His Ile
        355                 360                 365

Tyr Met Asn Gly Thr Met Ser Gln Val Gln Gly Ser Ala Asn Asp Pro
    370                 375                 380

Ile Phe Leu Leu His His Ala Phe Val Asp Ser Ile Phe Glu Gln Trp
385                 390                 395                 400

Leu Arg Arg His Arg Pro Leu Gln Glu Val Tyr Pro Glu Ala Asn Ala
                405                 410                 415

Pro Ile Gly His Asn Arg Glu Ser Tyr Met Val Pro Phe Ile Pro Leu
            420                 425                 430

Tyr Arg Asn Gly Asp Phe Phe Ile Ser Ser Lys Asp Leu Gly Tyr Asp
        435                 440                 445

Tyr Ser Tyr Leu Gln Asp Ser Asp Pro Asp Ser Phe Gln Asp Tyr Ile
    450                 455                 460

Lys Ser Tyr Leu Glu Gln Ala Ser Arg Ile Trp Ser Trp Leu Leu Gly
465                 470                 475                 480

Ala Ala Met Val Gly Ala Val Leu Thr Ala Leu Leu Ala Gly Leu Val
                485                 490                 495

Ser Leu Leu Cys Arg His Lys Arg Lys Gln Leu Pro Glu Glu Lys Gln
            500                 505                 510

Pro Leu Leu Met Glu Lys Glu Asp Tyr His Ser Leu Tyr Gln Ser His
        515                 520                 525

Leu
```

<210> 20

<211> 661

<212> PRT

<213> Homo sapiens

<400> 20

```
Met Asp Leu Val Leu Lys Arg Cys Leu Leu His Leu Ala Val Ile Gly
1               5                   10                  15

Ala Leu Leu Ala Val Gly Ala Thr Lys Val Pro Arg Asn Gln Asp Trp
            20                  25                  30
```

Leu Gly Val Ser Arg Gln Leu Arg Thr Lys Ala Trp Asn Arg Gln Leu
35 40 45

Tyr Pro Glu Trp Thr Glu Ala Gln Arg Leu Asp Cys Trp Arg Gly Gly
50 55 60

Gln Val Ser Leu Lys Val Ser Asn Asp Gly Pro Thr Leu Ile Gly Ala
65 70 75 80

Asn Ala Ser Phe Ser Ile Ala Leu Asn Phe Pro Gly Ser Gln Lys Val
85 90 95

Leu Pro Asp Gly Gln Val Ile Trp Val Asn Asn Thr Ile Ile Asn Gly
100 105 110

Ser Gln Val Trp Gly Gly Gln Pro Val Tyr Pro Gln Glu Thr Asp Asp
115 120 125

Ala Cys Ile Phe Pro Asp Gly Gly Pro Cys Pro Ser Gly Ser Trp Ser
130 135 140

Gln Lys Arg Ser Phe Val Tyr Val Trp Lys Thr Trp Gly Gln Tyr Trp
145 150 155 160

Gln Val Leu Gly Gly Pro Val Ser Gly Leu Ser Ile Gly Thr Gly Arg
165 170 175

Ala Met Leu Gly Thr His Thr Met Glu Val Thr Val Tyr His Arg Arg
180 185 190

Gly Ser Arg Ser Tyr Val Pro Leu Ala His Ser Ser Ser Ala Phe Thr
195 200 205

Ile Thr Asp Gln Val Pro Phe Ser Val Ser Val Ser Gln Leu Arg Ala
210 215 220

Leu Asp Gly Gly Asn Lys His Phe Leu Arg Asn Gln Pro Leu Thr Phe
225 230 235 240

Ala Leu Gln Leu His Asp Pro Ser Gly Tyr Leu Ala Glu Ala Asp Leu
245 250 255

Ser Tyr Thr Trp Asp Phe Gly Asp Ser Ser Gly Thr Leu Ile Ser Arg
260 265 270

Ala Leu Val Val Thr His Thr Tyr Leu Glu Pro Gly Pro Val Thr Ala
275 280 285

Gln Val Val Leu Gln Ala Ala Ile Pro Leu Thr Ser Cys Gly Ser Ser
290 295 300

Pro Val Pro Gly Thr Thr Asp Gly His Arg Pro Thr Ala Glu Ala Pro
305 310 315 320

Asn Thr Thr Ala Gly Gln Val Pro Thr Thr Glu Val Val Gly Thr Thr
325 330 335

```
Pro Gly Gln Ala Pro Thr Ala Glu Pro Ser Gly Thr Thr Ser Val Gln
            340                 345                 350

Val Pro Thr Thr Glu Val Ile Ser Thr Ala Pro Val Gln Met Pro Thr
        355                 360                 365

Ala Glu Ser Thr Gly Met Thr Pro Glu Lys Val Pro Val Ser Glu Val
    370                 375                 380

Met Gly Thr Thr Leu Ala Glu Met Ser Thr Pro Glu Ala Thr Gly Met
385                 390                 395                 400

Thr Pro Ala Glu Val Ser Ile Val Val Leu Ser Gly Thr Thr Ala Ala
                405                 410                 415

Gln Val Thr Thr Thr Glu Trp Val Glu Thr Thr Ala Arg Glu Leu Pro
            420                 425                 430

Ile Pro Glu Pro Glu Gly Pro Asp Ala Ser Ser Ile Met Ser Thr Glu
        435                 440                 445

Ser Ile Thr Gly Ser Leu Gly Pro Leu Leu Asp Gly Thr Ala Thr Leu
    450                 455                 460

Arg Leu Val Lys Arg Gln Val Pro Leu Asp Cys Val Leu Tyr Arg Tyr
465                 470                 475                 480

Gly Ser Phe Ser Val Thr Leu Asp Ile Val Gln Gly Ile Glu Ser Ala
                485                 490                 495

Glu Ile Leu Gln Ala Val Pro Ser Gly Glu Gly Asp Ala Phe Glu Leu
            500                 505                 510

Thr Val Ser Cys Gln Gly Gly Leu Pro Lys Glu Ala Cys Met Glu Ile
        515                 520                 525

Ser Ser Pro Gly Cys Gln Pro Pro Ala Gln Arg Leu Cys Gln Pro Val
    530                 535                 540

Leu Pro Ser Pro Ala Cys Gln Leu Val Leu His Gln Ile Leu Lys Gly
545                 550                 555                 560

Gly Ser Gly Thr Tyr Cys Leu Asn Val Ser Leu Ala Asp Thr Asn Ser
                565                 570                 575

Leu Ala Val Val Ser Thr Gln Leu Ile Met Pro Gly Gln Glu Ala Gly
            580                 585                 590

Leu Gly Gln Val Pro Leu Ile Val Gly Ile Leu Leu Val Leu Met Ala
        595                 600                 605

Val Val Leu Ala Ser Leu Ile Tyr Arg Arg Arg Leu Met Lys Gln Asp
    610                 615                 620

Phe Ser Val Pro Gln Leu Pro His Ser Ser Ser His Trp Leu Arg Leu
625                 630                 635                 640
```

```
Pro Arg Ile Phe Cys Ser Cys Pro Ile Gly Glu Asn Ser Pro Leu Leu
                645                 650                 655

Ser Gly Gln Gln Val
            660
```

<210> 21

<211> 323

<212> PRT

<213> Homo sapiens

<400> 21

```
Met Ser Asp Arg Pro Thr Ala Arg Arg Trp Gly Lys Cys Gly Pro Leu
1               5                  10                  15

Cys Thr Arg Glu Asn Ile Met Val Ala Phe Lys Gly Val Trp Thr Gln
            20                  25                  30

Ala Phe Trp Lys Ala Val Thr Ala Glu Phe Leu Ala Met Leu Ile Phe
        35                  40                  45

Val Leu Leu Ser Leu Gly Ser Thr Ile Asn Trp Gly Gly Thr Glu Lys
    50                  55                  60

Pro Leu Pro Val Asp Met Val Leu Ile Ser Leu Cys Phe Gly Leu Ser
65                  70                  75                  80

Ile Ala Thr Met Val Gln Cys Phe Gly His Ile Ser Gly Gly His Ile
                85                  90                  95

Asn Pro Ala Val Thr Val Ala Met Val Cys Thr Arg Lys Ile Ser Ile
            100                 105                 110

Ala Lys Ser Val Phe Tyr Ile Ala Ala Gln Cys Leu Gly Ala Ile Ile
        115                 120                 125

Gly Ala Gly Ile Leu Tyr Leu Val Thr Pro Pro Ser Val Val Gly Gly
    130                 135                 140

Leu Gly Val Thr Met Val His Gly Asn Leu Thr Ala Gly His Gly Leu
145                 150                 155                 160

Leu Val Glu Leu Ile Ile Thr Phe Gln Leu Val Phe Thr Ile Phe Ala
                165                 170                 175

Ser Cys Asp Ser Lys Arg Thr Asp Val Thr Gly Ser Ile Ala Leu Ala
            180                 185                 190

Ile Gly Phe Ser Val Ala Ile Gly His Leu Phe Ala Ile Asn Tyr Thr
        195                 200                 205

Gly Ala Ser Met Asn Pro Ala Arg Ser Phe Gly Pro Ala Val Ile Met
    210                 215                 220

Gly Asn Trp Glu Asn His Trp Ile Tyr Trp Val Gly Pro Ile Ile Gly
```

225 230 235 240

Ala Val Leu Ala Gly Gly Leu Tyr Glu Tyr Val Phe Cys Pro Asp Val
245 250 255

Glu Phe Lys Arg Arg Phe Lys Glu Ala Phe Ser Lys Ala Ala Gln Gln
260 265 270

Thr Lys Gly Ser Tyr Met Glu Val Glu Asp Asn Arg Ser Gln Val Glu
275 280 285

Thr Asp Asp Leu Ile Leu Lys Pro Gly Val Val His Val Ile Asp Val
290 295 300

Asp Arg Gly Glu Glu Lys Lys Gly Lys Asp Gln Ser Gly Glu Val Leu
305 310 315 320

Ser Ser Val

<210> 22

<211> 405

<212> PRT

<213> Homo sapiens

<400> 22

Met Ala Ala Ser Gly Lys Thr Ser Lys Ser Glu Pro Asn His Val Ile
1 5 10 15

Phe Lys Lys Ile Ser Arg Asp Lys Ser Val Thr Ile Tyr Leu Gly Asn
20 25 30

Arg Asp Tyr Ile Asp His Val Ser Gln Val Gln Pro Val Asp Gly Val
35 40 45

Val Leu Val Asp Pro Asp Leu Val Lys Gly Lys Lys Val Tyr Val Thr
50 55 60

Leu Thr Cys Ala Phe Arg Tyr Gly Gln Glu Asp Ile Asp Val Ile Gly
65 70 75 80

Leu Thr Phe Arg Arg Asp Leu Tyr Phe Ser Arg Val Gln Val Tyr Pro
85 90 95

Pro Val Gly Ala Ala Ser Thr Pro Thr Lys Leu Gln Glu Ser Leu Leu
100 105 110

Lys Lys Leu Gly Ser Asn Thr Tyr Pro Phe Leu Leu Thr Phe Pro Asp
115 120 125

Tyr Leu Pro Cys Ser Val Met Leu Gln Pro Ala Pro Gln Asp Ser Gly
130 135 140

Lys Ser Cys Gly Val Asp Phe Glu Val Lys Ala Phe Ala Thr Asp Ser
145 150 155 160

Thr Asp Ala Glu Glu Asp Lys Ile Pro Lys Lys Ser Ser Val Arg Leu
165 170 175

Leu Ile Arg Lys Val Gln His Ala Pro Leu Glu Met Gly Pro Gln Pro
180 185 190

Arg Ala Glu Ala Ala Trp Gln Phe Phe Met Ser Asp Lys Pro Leu His
195 200 205

Leu Ala Val Ser Leu Asn Lys Glu Ile Tyr Phe His Gly Glu Pro Ile
210 215 220

Pro Val Thr Val Thr Val Thr Asn Asn Thr Glu Lys Thr Val Lys Lys
225 230 235 240

Ile Lys Ala Phe Val Glu Gln Val Ala Asn Val Val Leu Tyr Ser Ser
245 250 255

Asp Tyr Tyr Val Lys Pro Val Ala Met Glu Glu Ala Gln Glu Lys Val
260 265 270

Pro Pro Asn Ser Thr Leu Thr Lys Thr Leu Thr Leu Leu Pro Leu Leu
275 280 285

Ala Asn Asn Arg Glu Arg Arg Gly Ile Ala Leu Asp Gly Lys Ile Lys
290 295 300

His Glu Asp Thr Asn Leu Ala Ser Ser Thr Ile Ile Lys Glu Gly Ile
305 310 315 320

Asp Arg Thr Val Leu Gly Ile Leu Val Ser Tyr Gln Ile Lys Val Lys
325 330 335

Leu Thr Val Ser Gly Phe Leu Gly Glu Leu Thr Ser Ser Glu Val Ala
340 345 350

Thr Glu Val Pro Phe Arg Leu Met His Pro Gln Pro Glu Asp Pro Ala
355 360 365

Lys Glu Ser Tyr Gln Asp Ala Asn Leu Val Phe Glu Glu Phe Ala Arg
370 375 380

His Asn Leu Lys Asp Ala Gly Glu Ala Glu Glu Gly Lys Arg Asp Lys
385 390 395 400

Asn Asp Val Asp Glu
405

<210> 23

<211> 1247

<212> PRT

<213> Homo sapiens

<400> 23

Met Met Arg Glu Trp Val Leu Leu Met Ser Val Leu Leu Cys Gly Leu
1 5 10 15

Ala Gly Pro Thr His Leu Phe Gln Pro Ser Leu Val Leu Asp Met Ala
20 25 30

Lys Val Leu Leu Asp Asn Tyr Cys Phe Pro Glu Asn Leu Leu Gly Met
35 40 45

Gln Glu Ala Ile Gln Gln Ala Ile Lys Ser His Glu Ile Leu Ser Ile
50 55 60

Ser Asp Pro Gln Thr Leu Ala Ser Val Leu Thr Ala Gly Val Gln Ser
65 70 75 80

Ser Leu Asn Asp Pro Arg Leu Val Ile Ser Tyr Glu Pro Ser Thr Pro
85 90 95

Glu Pro Pro Pro Gln Val Pro Ala Leu Thr Ser Leu Ser Glu Glu Glu
100 105 110

Leu Leu Ala Trp Leu Gln Arg Gly Leu Arg His Glu Val Leu Glu Gly
115 120 125

Asn Val Gly Tyr Leu Arg Val Asp Ser Val Pro Gly Gln Glu Val Leu
130 135 140

Ser Met Met Gly Glu Phe Leu Val Ala His Val Trp Gly Asn Leu Met
145 150 155 160

Gly Thr Ser Ala Leu Val Leu Asp Leu Arg His Cys Thr Gly Gly Gln
165 170 175

Val Ser Gly Ile Pro Tyr Ile Ile Ser Tyr Leu His Pro Gly Asn Thr
180 185 190

Ile Leu His Val Asp Thr Ile Tyr Asn Arg Pro Ser Asn Thr Thr Thr
195 200 205

Glu Ile Trp Thr Leu Pro Gln Val Leu Gly Glu Arg Tyr Gly Ala Asp
210 215 220

Lys Asp Val Val Val Leu Thr Ser Ser Gln Thr Arg Gly Val Ala Glu
225 230 235 240

Asp Ile Ala His Ile Leu Lys Gln Met Arg Arg Ala Ile Val Val Gly
245 250 255

Glu Arg Thr Gly Gly Gly Ala Leu Asp Leu Arg Lys Leu Arg Ile Gly
260 265 270

Glu Ser Asp Phe Phe Phe Thr Val Pro Val Ser Arg Ser Leu Gly Pro
275 280 285

```
Leu Gly Gly Gly Ser Gln Thr Trp Glu Gly Ser Gly Val Leu Pro Cys
    290                 295                 300

Val Gly Thr Pro Ala Glu Gln Ala Leu Glu Lys Ala Leu Ala Ile Leu
305                 310                 315                 320

Thr Leu Arg Ser Ala Leu Pro Gly Val Val His Cys Leu Gln Glu Val
                325                 330                 335

Leu Lys Asp Tyr Tyr Thr Leu Val Asp Arg Val Pro Thr Leu Leu Gln
            340                 345                 350

His Leu Ala Ser Met Asp Phe Ser Thr Val Val Ser Glu Glu Asp Leu
        355                 360                 365

Val Thr Lys Leu Asn Ala Gly Leu Gln Ala Ala Ser Glu Asp Pro Arg
    370                 375                 380

Leu Leu Val Arg Ala Ile Gly Pro Thr Glu Thr Pro Ser Trp Pro Ala
385                 390                 395                 400

Pro Asp Ala Ala Ala Glu Asp Ser Pro Gly Val Ala Pro Glu Leu Pro
                405                 410                 415

Glu Asp Glu Ala Ile Arg Gln Ala Leu Val Asp Ser Val Phe Gln Val
            420                 425                 430

Ser Val Leu Pro Gly Asn Val Gly Tyr Leu Arg Phe Asp Ser Phe Ala
        435                 440                 445

Asp Ala Ser Val Leu Gly Val Leu Ala Pro Tyr Val Leu Arg Gln Val
    450                 455                 460

Trp Glu Pro Leu Gln Asp Thr Glu His Leu Ile Met Asp Leu Arg His
465                 470                 475                 480

Asn Pro Gly Gly Pro Ser Ser Ala Val Pro Leu Leu Leu Ser Tyr Phe
                485                 490                 495

Gln Gly Pro Glu Ala Gly Pro Val His Leu Phe Thr Thr Tyr Asp Arg
            500                 505                 510

Arg Thr Asn Ile Thr Gln Glu His Phe Ser His Met Glu Leu Pro Gly
        515                 520                 525

Pro Arg Tyr Ser Thr Gln Arg Gly Val Tyr Leu Leu Thr Ser His Arg
    530                 535                 540

Thr Ala Thr Ala Ala Glu Glu Phe Ala Phe Leu Met Gln Ser Leu Gly
545                 550                 555                 560

Trp Ala Thr Leu Val Gly Glu Ile Thr Ala Gly Asn Leu Leu His Thr
                565                 570                 575

Arg Thr Val Pro Leu Leu Asp Thr Pro Glu Gly Ser Leu Ala Leu Thr
            580                 585                 590
```

```
Val Pro Val Leu Thr Phe Ile Asp Asn His Gly Glu Ala Trp Leu Gly
        595                 600                 605

Gly Gly Val Val Pro Asp Ala Ile Val Leu Ala Glu Glu Ala Leu Asp
    610                 615                 620

Lys Ala Gln Glu Val Leu Glu Phe His Gln Ser Leu Gly Ala Leu Val
625                 630                 635                 640

Glu Gly Thr Gly His Leu Leu Glu Ala His Tyr Ala Arg Pro Glu Val
                645                 650                 655

Val Gly Gln Thr Ser Ala Leu Leu Arg Ala Lys Leu Ala Gln Gly Ala
            660                 665                 670

Tyr Arg Thr Ala Val Asp Leu Glu Ser Leu Ala Ser Gln Leu Thr Ala
        675                 680                 685

Asp Leu Gln Glu Val Ser Gly Asp His Arg Leu Leu Val Phe His Ser
    690                 695                 700

Pro Gly Glu Leu Val Val Glu Glu Ala Pro Pro Pro Pro Pro Ala Val
705                 710                 715                 720

Pro Ser Pro Glu Glu Leu Thr Tyr Leu Ile Glu Ala Leu Phe Lys Thr
                725                 730                 735

Glu Val Leu Pro Gly Gln Leu Gly Tyr Leu Arg Phe Asp Ala Met Ala
            740                 745                 750

Glu Leu Glu Thr Val Lys Ala Val Gly Pro Gln Leu Val Arg Leu Val
        755                 760                 765

Trp Gln Gln Leu Val Asp Thr Ala Ala Leu Val Ile Asp Leu Arg Tyr
    770                 775                 780

Asn Pro Gly Ser Tyr Ser Thr Ala Ile Pro Leu Leu Cys Ser Tyr Phe
785                 790                 795                 800

Phe Glu Ala Glu Pro Arg Gln His Leu Tyr Ser Val Phe Asp Arg Ala
                805                 810                 815

Thr Ser Lys Val Thr Glu Val Trp Thr Leu Pro Gln Val Ala Gly Gln
            820                 825                 830

Arg Tyr Gly Ser His Lys Asp Leu Tyr Ile Leu Met Ser His Thr Ser
        835                 840                 845

Gly Ser Ala Ala Glu Ala Phe Ala His Thr Met Gln Asp Leu Gln Arg
    850                 855                 860

Ala Thr Val Ile Gly Glu Pro Thr Ala Gly Gly Ala Leu Ser Val Gly
865                 870                 875                 880

Ile Tyr Gln Val Gly Ser Ser Pro Leu Tyr Ala Ser Met Pro Thr Gln
                885                 890                 895
```

Met Ala Met Ser Ala Thr Thr Gly Lys Ala Trp Asp Leu Ala Gly Val
900 905 910

Glu Pro Asp Ile Thr Val Pro Met Ser Glu Ala Leu Ser Ile Ala Gln
915 920 925

Asp Ile Val Ala Leu Arg Ala Lys Val Pro Thr Val Leu Gln Thr Ala
930 935 940

Gly Lys Leu Val Ala Asp Asn Tyr Ala Ser Ala Glu Leu Gly Ala Lys
945 950 955 960

Met Ala Thr Lys Leu Ser Gly Leu Gln Ser Arg Tyr Ser Arg Val Thr
965 970 975

Ser Glu Val Ala Leu Ala Glu Ile Leu Gly Ala Asp Leu Gln Met Leu
980 985 990

Ser Gly Asp Pro His Leu Lys Ala Ala His Ile Pro Glu Asn Ala Lys
995 1000 1005

Asp Arg Ile Pro Gly Ile Val Pro Met Gln Ile Pro Ser Pro Glu
1010 1015 1020

Val Phe Glu Glu Leu Ile Lys Phe Ser Phe His Thr Asn Val Leu
1025 1030 1035

Glu Asp Asn Ile Gly Tyr Leu Arg Phe Asp Met Phe Gly Asp Gly
1040 1045 1050

Glu Leu Leu Thr Gln Val Ser Arg Leu Leu Val Glu His Ile Trp
1055 1060 1065

Lys Lys Ile Met His Thr Asp Ala Met Ile Ile Asp Met Arg Phe
1070 1075 1080

Asn Ile Gly Gly Pro Thr Ser Ser Ile Pro Ile Leu Cys Ser Tyr
1085 1090 1095

Phe Phe Asp Glu Gly Pro Pro Val Leu Leu Asp Lys Ile Tyr Ser
1100 1105 1110

Arg Pro Asp Asp Ser Val Ser Glu Leu Trp Thr His Ala Gln Val
1115 1120 1125

Val Gly Glu Arg Tyr Gly Ser Lys Lys Ser Met Val Ile Leu Thr
1130 1135 1140

Ser Ser Val Thr Ala Gly Thr Ala Glu Glu Phe Thr Tyr Ile Met
1145 1150 1155

Lys Arg Leu Gly Arg Ala Leu Val Ile Gly Glu Val Thr Ser Gly
1160 1165 1170

Gly Cys Gln Pro Pro Gln Thr Tyr His Val Asp Asp Thr Asn Leu
1175 1180 1185

Tyr Leu Thr Ile Pro Thr Ala Arg Ser Val Gly Ala Ser Asp Gly
1190 1195 1200

Ser Ser Trp Glu Gly Val Gly Val Thr Pro His Val Val Val Pro
1205 1210 1215

Ala Glu Glu Ala Leu Ala Arg Ala Lys Glu Met Leu Gln His Asn
1220 1225 1230

Gln Leu Arg Val Lys Arg Ser Pro Gly Leu Gln Asp His Leu
1235 1240 1245

<210> 24

<211> 33

<212> PRT

<213> Triticum aestivum

<400> 24

Leu Gln Leu Gln Pro Phe Pro Gln Pro Gln Leu Pro Tyr Pro Gln Pro
1 5 10 15

Gln Leu Pro Tyr Pro Gln Pro Gln Leu Pro Tyr Pro Gln Pro Gln Pro
20 25 30

Phe

<210> 25

<211> 33

<212> PRT

<213> Artificial Sequence

<220>

<223> Alpha-gliadin 33-mer deamidated

<400> 25

Leu Gln Leu Gln Pro Phe Pro Gln Pro Glu Leu Pro Tyr Pro Gln Pro
1 5 10 15

Glu Leu Pro Tyr Pro Gln Pro Glu Leu Pro Tyr Pro Gln Pro Gln Pro
20 25 30

Phe

<210> 26

<211> 18

<212> PRT

<213> Triticum aestivum

<400> 26

Gln Gln Tyr Pro Ser Gly Gln Gly Ser Phe Gln Pro Ser Gln Gln Asn
1 5 10 15

Pro Gln

<210> 27

<211> 12

<212> PRT

<213> Triticum aestivum

<400> 27

Gln Pro Phe Pro Gln Pro Glu Gln Pro Phe Pro Trp
1 5 10

<210> 28

<211> 519

<212> PRT

<213> Homo sapiens

<400> 28

Gly Ser Ile Gly Ala Ala Ser Met Glu Phe Cys Phe Asp Val Phe Lys
1 5 10 15

Glu Leu Lys Val His His Ala Asn Glu Asn Ile Phe Tyr Cys Pro Ile
20 25 30

Ala Ile Met Ser Ala Leu Ala Met Val Tyr Leu Gly Ala Lys Asp Ser
35 40 45

Thr Arg Thr Gln Ile Asn Lys Val Val Arg Phe Asp Lys Leu Pro Gly
50 55 60

Phe Gly Asp Ser Ile Glu Ala Gln Cys Gly Thr Ser Val Asn Val His
65 70 75 80

Ser Ser Leu Arg Asp Ile Leu Asn Gln Ile Thr Lys Pro Asn Asp Val
85 90 95

Tyr Ser Phe Ser Leu Ala Ser Arg Leu Tyr Ala Glu Glu Arg Tyr Pro
100 105 110

Ile Leu Pro Glu Tyr Leu Gln Cys Val Lys Glu Leu Tyr Arg Gly Gly
115 120 125

Leu Glu Pro Ile Asn Phe Gln Thr Ala Ala Asp Gln Ala Arg Glu Leu
130 135 140

Ile Asn Ser Trp Val Glu Ser Gln Thr Asn Gly Ile Ile Arg Asn Val
145 150 155 160

Leu Gln Pro Ser Ser Val Asp Ser Gln Thr Ala Met Val Leu Val Asn
165 170 175

Ala Ile Val Phe Lys Gly Leu Trp Glu Lys Ala Phe Lys Asp Glu Asp
180 185 190

```
Thr Gln Ala Met Pro Phe Arg Val Thr Glu Gln Glu Ser Lys Pro Val
        195                 200                 205

Gln Met Met Tyr Gln Ile Gly Leu Phe Arg Val Ala Ser Met Ala Ser
    210                 215                 220

Glu Lys Met Lys Ile Leu Glu Leu Pro Phe Ala Ser Gly Thr Met Ser
225                 230                 235                 240

Met Leu Val Leu Leu Pro Asp Glu Val Ser Gly Leu Glu Gln Leu Glu
                245                 250                 255

Ser Ile Ile Asn Phe Glu Lys Leu Thr Glu Trp Thr Ser Ser Asn Val
            260                 265                 270

Met Glu Glu Arg Lys Ile Lys Val Tyr Leu Pro Arg Met Lys Met Glu
        275                 280                 285

Glu Lys Tyr Asn Leu Thr Ser Val Leu Met Ala Met Gly Ile Thr Asp
    290                 295                 300

Val Phe Ser Ser Ser Ala Asn Leu Ser Gly Ile Ser Ser Ala Glu Ser
305                 310                 315                 320

Leu Lys Ile Ser Gln Ala Val His Ala Ala His Ala Glu Ile Asn Glu
                325                 330                 335

Ala Gly Arg Glu Val Val Gly Ser Ala Glu Ala Gly Val Asp Ala Ala
            340                 345                 350

Ser Val Ser Glu Glu Phe Arg Ala Asp His Pro Phe Leu Phe Cys Ile
        355                 360                 365

Lys His Ile Ala Thr Asn Ala Val Leu Phe Phe Gly Arg Cys Val Ser
    370                 375                 380

Pro Gly Gly Gly Ser Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu
385                 390                 395                 400

Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe
                405                 410                 415

Thr Phe Glu Lys Tyr Ala Met Ala Trp Val Arg Gln Ala Pro Gly Lys
            420                 425                 430

Gly Leu Glu Trp Val Ser Arg Ile Ser Ala Arg Gly Val Thr Thr Tyr
        435                 440                 445

Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser
    450                 455                 460

Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr
465                 470                 475                 480

Ala Val Tyr Tyr Cys Ala Ser His Lys Arg His Glu His Thr Arg Phe
                485                 490                 495
```

```
Asp Ser Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly
            500                 505                 510

Ser His His His His His His
        515
```

<210> 29

<211> 519

<212> PRT

<213> Artificial Sequence

<220>

<223> Fusion protien

<400> 29

```
Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1               5                  10                  15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Glu Lys Tyr
            20                  25                  30

Ala Met Ala Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
        35                  40                  45

Ser Arg Ile Ser Ala Arg Gly Val Thr Thr Tyr Tyr Ala Asp Ser Val
    50                  55                  60

Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65                  70                  75                  80

Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
                85                  90                  95

Ala Ser His Lys Arg His Glu His Thr Arg Phe Asp Ser Trp Gly Gln
            100                 105                 110

Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly Ser Gly Ser Ile Gly
        115                 120                 125

Ala Ala Ser Met Glu Phe Cys Phe Asp Val Phe Lys Glu Leu Lys Val
    130                 135                 140

His His Ala Asn Glu Asn Ile Phe Tyr Cys Pro Ile Ala Ile Met Ser
145                 150                 155                 160

Ala Leu Ala Met Val Tyr Leu Gly Ala Lys Asp Ser Thr Arg Thr Gln
                165                 170                 175

Ile Asn Lys Val Val Arg Phe Asp Lys Leu Pro Gly Phe Gly Asp Ser
            180                 185                 190

Ile Glu Ala Gln Cys Gly Thr Ser Val Asn Val His Ser Ser Leu Arg
        195                 200                 205

Asp Ile Leu Asn Gln Ile Thr Lys Pro Asn Asp Val Tyr Ser Phe Ser
    210                 215                 220
```

Leu Ala Ser Arg Leu Tyr Ala Glu Glu Arg Tyr Pro Ile Leu Pro Glu
225 230 235 240

Tyr Leu Gln Cys Val Lys Glu Leu Tyr Arg Gly Gly Leu Glu Pro Ile
245 250 255

Asn Phe Gln Thr Ala Ala Asp Gln Ala Arg Glu Leu Ile Asn Ser Trp
260 265 270

Val Glu Ser Gln Thr Asn Gly Ile Ile Arg Asn Val Leu Gln Pro Ser
275 280 285

Ser Val Asp Ser Gln Thr Ala Met Val Leu Val Asn Ala Ile Val Phe
290 295 300

Lys Gly Leu Trp Glu Lys Ala Phe Lys Asp Glu Asp Thr Gln Ala Met
305 310 315 320

Pro Phe Arg Val Thr Glu Gln Glu Ser Lys Pro Val Gln Met Met Tyr
325 330 335

Gln Ile Gly Leu Phe Arg Val Ala Ser Met Ala Ser Glu Lys Met Lys
340 345 350

Ile Leu Glu Leu Pro Phe Ala Ser Gly Thr Met Ser Met Leu Val Leu
355 360 365

Leu Pro Asp Glu Val Ser Gly Leu Glu Gln Leu Glu Ser Ile Ile Asn
370 375 380

Phe Glu Lys Leu Thr Glu Trp Thr Ser Ser Asn Val Met Glu Glu Arg
385 390 395 400

Lys Ile Lys Val Tyr Leu Pro Arg Met Lys Met Glu Glu Lys Tyr Asn
405 410 415

Leu Thr Ser Val Leu Met Ala Met Gly Ile Thr Asp Val Phe Ser Ser
420 425 430

Ser Ala Asn Leu Ser Gly Ile Ser Ser Ala Glu Ser Leu Lys Ile Ser
435 440 445

Gln Ala Val His Ala Ala His Ala Glu Ile Asn Glu Ala Gly Arg Glu
450 455 460

Val Val Gly Ser Ala Glu Ala Gly Val Asp Ala Ala Ser Val Ser Glu
465 470 475 480

Glu Phe Arg Ala Asp His Pro Phe Leu Phe Cys Ile Lys His Ile Ala
485 490 495

Thr Asn Ala Val Leu Phe Phe Gly Arg Cys Val Ser Pro Gly Gly Gly
500 505 510

Ser His His His His His His

515

<210> 30
<211> 908
<212> PRT
<213> Artificial Sequence

<220>
<223> Fusion Protien

<400> 30

```
Gly Ser Ile Gly Ala Ala Ser Met Glu Phe Cys Phe Asp Val Phe Lys
1               5                  10                  15

Glu Leu Lys Val His His Ala Asn Glu Asn Ile Phe Tyr Cys Pro Ile
            20                  25                  30

Ala Ile Met Ser Ala Leu Ala Met Val Tyr Leu Gly Ala Lys Asp Ser
        35                  40                  45

Thr Arg Thr Gln Ile Asn Lys Val Val Arg Phe Asp Lys Leu Pro Gly
    50                  55                  60

Phe Gly Asp Ser Ile Glu Ala Gln Cys Gly Thr Ser Val Asn Val His
65                  70                  75                  80

Ser Ser Leu Arg Asp Ile Leu Asn Gln Ile Thr Lys Pro Asn Asp Val
                85                  90                  95

Tyr Ser Phe Ser Leu Ala Ser Arg Leu Tyr Ala Glu Glu Arg Tyr Pro
            100                 105                 110

Ile Leu Pro Glu Tyr Leu Gln Cys Val Lys Glu Leu Tyr Arg Gly Gly
        115                 120                 125

Leu Glu Pro Ile Asn Phe Gln Thr Ala Ala Asp Gln Ala Arg Glu Leu
    130                 135                 140

Ile Asn Ser Trp Val Glu Ser Gln Thr Asn Gly Ile Ile Arg Asn Val
145                 150                 155                 160

Leu Gln Pro Ser Ser Val Asp Ser Gln Thr Ala Met Val Leu Val Asn
                165                 170                 175

Ala Ile Val Phe Lys Gly Leu Trp Glu Lys Ala Phe Lys Asp Glu Asp
            180                 185                 190

Thr Gln Ala Met Pro Phe Arg Val Thr Glu Gln Glu Ser Lys Pro Val
        195                 200                 205

Gln Met Met Tyr Gln Ile Gly Leu Phe Arg Val Ala Ser Met Ala Ser
    210                 215                 220

Glu Lys Met Lys Ile Leu Glu Leu Pro Phe Ala Ser Gly Thr Met Ser
225                 230                 235                 240
```

Met Leu Val Leu Leu Pro Asp Glu Val Ser Gly Leu Glu Gln Leu Glu
245 250 255

Ser Ile Ile Asn Phe Glu Lys Leu Thr Glu Trp Thr Ser Ser Asn Val
260 265 270

Met Glu Glu Arg Lys Ile Lys Val Tyr Leu Pro Arg Met Lys Met Glu
275 280 285

Glu Lys Tyr Asn Leu Thr Ser Val Leu Met Ala Met Gly Ile Thr Asp
290 295 300

Val Phe Ser Ser Ser Ala Asn Leu Ser Gly Ile Ser Ser Ala Glu Ser
305 310 315 320

Leu Lys Ile Ser Gln Ala Val His Ala Ala His Ala Glu Ile Asn Glu
325 330 335

Ala Gly Arg Glu Val Val Gly Ser Ala Glu Ala Gly Val Asp Ala Ala
340 345 350

Ser Val Ser Glu Glu Phe Arg Ala Asp His Pro Phe Leu Phe Cys Ile
355 360 365

Lys His Ile Ala Thr Asn Ala Val Leu Phe Phe Gly Arg Cys Val Ser
370 375 380

Pro Gly Gly Gly Ser Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu
385 390 395 400

Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe
405 410 415

Thr Phe Glu Lys Tyr Ala Met Ala Trp Val Arg Gln Ala Pro Gly Lys
420 425 430

Gly Leu Glu Trp Val Ser Arg Ile Ser Ala Arg Gly Val Thr Thr Tyr
435 440 445

Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser
450 455 460

Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr
465 470 475 480

Ala Val Tyr Tyr Cys Ala Ser His Lys Arg His Glu His Thr Arg Phe
485 490 495

Asp Ser Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly
500 505 510

Ser Gly Ser Ile Gly Ala Ala Ser Met Glu Phe Cys Phe Asp Val Phe
515 520 525

Lys Glu Leu Lys Val His His Ala Asn Glu Asn Ile Phe Tyr Cys Pro
530 535 540

Ile Ala Ile Met Ser Ala Leu Ala Met Val Tyr Leu Gly Ala Lys Asp
545 550 555 560

Ser Thr Arg Thr Gln Ile Asn Lys Val Val Arg Phe Asp Lys Leu Pro
565 570 575

Gly Phe Gly Asp Ser Ile Glu Ala Gln Cys Gly Thr Ser Val Asn Val
580 585 590

His Ser Ser Leu Arg Asp Ile Leu Asn Gln Ile Thr Lys Pro Asn Asp
595 600 605

Val Tyr Ser Phe Ser Leu Ala Ser Arg Leu Tyr Ala Glu Glu Arg Tyr
610 615 620

Pro Ile Leu Pro Glu Tyr Leu Gln Cys Val Lys Glu Leu Tyr Arg Gly
625 630 635 640

Gly Leu Glu Pro Ile Asn Phe Gln Thr Ala Ala Asp Gln Ala Arg Glu
645 650 655

Leu Ile Asn Ser Trp Val Glu Ser Gln Thr Asn Gly Ile Ile Arg Asn
660 665 670

Val Leu Gln Pro Ser Ser Val Asp Ser Gln Thr Ala Met Val Leu Val
675 680 685

Asn Ala Ile Val Phe Lys Gly Leu Trp Glu Lys Ala Phe Lys Asp Glu
690 695 700

Asp Thr Gln Ala Met Pro Phe Arg Val Thr Glu Gln Glu Ser Lys Pro
705 710 715 720

Val Gln Met Met Tyr Gln Ile Gly Leu Phe Arg Val Ala Ser Met Ala
725 730 735

Ser Glu Lys Met Lys Ile Leu Glu Leu Pro Phe Ala Ser Gly Thr Met
740 745 750

Ser Met Leu Val Leu Leu Pro Asp Glu Val Ser Gly Leu Glu Gln Leu
755 760 765

Glu Ser Ile Ile Asn Phe Glu Lys Leu Thr Glu Trp Thr Ser Ser Asn
770 775 780

Val Met Glu Glu Arg Lys Ile Lys Val Tyr Leu Pro Arg Met Lys Met
785 790 795 800

Glu Glu Lys Tyr Asn Leu Thr Ser Val Leu Met Ala Met Gly Ile Thr
805 810 815

Asp Val Phe Ser Ser Ser Ala Asn Leu Ser Gly Ile Ser Ser Ala Glu
820 825 830

Ser Leu Lys Ile Ser Gln Ala Val His Ala Ala His Ala Glu Ile Asn
835 840 845

Glu Ala Gly Arg Glu Val Val Gly Ser Ala Glu Ala Gly Val Asp Ala
850 855 860

Ala Ser Val Ser Glu Glu Phe Arg Ala Asp His Pro Phe Leu Phe Cys
865 870 875 880

Ile Lys His Ile Ala Thr Asn Ala Val Leu Phe Phe Gly Arg Cys Val
885 890 895

Ser Pro Gly Gly Gly Ser His His His His His His
900 905

<210> 31

<211> 395

<212> PRT

<213> Homo sapiens

<400> 31

Gly Ser Ile Gly Ala Ala Ser Met Glu Phe Cys Phe Asp Val Phe Lys
1 5 10 15

Glu Leu Lys Val His His Ala Asn Glu Asn Ile Phe Tyr Cys Pro Ile
20 25 30

Ala Ile Met Ser Ala Leu Ala Met Val Tyr Leu Gly Ala Lys Asp Ser
35 40 45

Thr Arg Thr Gln Ile Asn Lys Val Val Arg Phe Asp Lys Leu Pro Gly
50 55 60

Phe Gly Asp Ser Ile Glu Ala Gln Cys Gly Thr Ser Val Asn Val His
65 70 75 80

Ser Ser Leu Arg Asp Ile Leu Asn Gln Ile Thr Lys Pro Asn Asp Val
85 90 95

Tyr Ser Phe Ser Leu Ala Ser Arg Leu Tyr Ala Glu Glu Arg Tyr Pro
100 105 110

Ile Leu Pro Glu Tyr Leu Gln Cys Val Lys Glu Leu Tyr Arg Gly Gly
115 120 125

Leu Glu Pro Ile Asn Phe Gln Thr Ala Ala Asp Gln Ala Arg Glu Leu
130 135 140

Ile Asn Ser Trp Val Glu Ser Gln Thr Asn Gly Ile Ile Arg Asn Val
145 150 155 160

Leu Gln Pro Ser Ser Val Asp Ser Gln Thr Ala Met Val Leu Val Asn
165 170 175

Ala Ile Val Phe Lys Gly Leu Trp Glu Lys Ala Phe Lys Asp Glu Asp

180 185 190

Thr Gln Ala Met Pro Phe Arg Val Thr Glu Gln Glu Ser Lys Pro Val
195 200 205

Gln Met Met Tyr Gln Ile Gly Leu Phe Arg Val Ala Ser Met Ala Ser
210 215 220

Glu Lys Met Lys Ile Leu Glu Leu Pro Phe Ala Ser Gly Thr Met Ser
225 230 235 240

Met Leu Val Leu Leu Pro Asp Glu Val Ser Gly Leu Glu Gln Leu Glu
245 250 255

Ser Ile Ile Asn Phe Glu Lys Leu Thr Glu Trp Thr Ser Ser Asn Val
260 265 270

Met Glu Glu Arg Lys Ile Lys Val Tyr Leu Pro Arg Met Lys Met Glu
275 280 285

Glu Lys Tyr Asn Leu Thr Ser Val Leu Met Ala Met Gly Ile Thr Asp
290 295 300

Val Phe Ser Ser Ser Ala Asn Leu Ser Gly Ile Ser Ser Ala Glu Ser
305 310 315 320

Leu Lys Ile Ser Gln Ala Val His Ala Ala His Ala Glu Ile Asn Glu
325 330 335

Ala Gly Arg Glu Val Val Gly Ser Ala Glu Ala Gly Val Asp Ala Ala
340 345 350

Ser Val Ser Glu Glu Phe Arg Ala Asp His Pro Phe Leu Phe Cys Ile
355 360 365

Lys His Ile Ala Thr Asn Ala Val Leu Phe Phe Gly Arg Cys Val Ser
370 375 380

Pro Gly Gly Gly Ser His His His His His His
385 390 395

# REFERENCES CITED IN THE DESCRIPTION

This list of references cited by the applicant is for the reader's convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.

**Patent documents cited in the description**

- US20120039989A [0002]
- US20120178139A [0002]
- WO2013121296A [0002]
- WO2014023709A1 [0003]
- WO2011086143A2 [0003]
- WO2012083185A2 [0003]
- US20130078216A [0071] [0071] [0151] [0156]
- WO61942942A [0260]


## Non-patent literature cited in the description


- **COULSTOCK et al.**PLOS ONE, 2013, [0003]
- J. Biol. Chem., 1969, vol. 243, 3552-3559 [0027]
- **BYRNE et al.**Drug Discovery Today, 2007, vol. 12, 7/8319-326 [0060]
- **SOLA et al.**BioDrugs, 2010, vol. 24, 19-21 [0060]
- **MAMIDYALA, SREEMAN K. et al.**J. Am. Chem. Soc., 2012, vol. 134, 1978-1981 [0069]
- **COULSTOCK E et al.**Liver-targeting of interferon-alpha with tissue-specific domain antibodiesPLoS One, 2013, vol. 8, 2e57263- [0071]
- **ZHU, L. et al.**Bioconjugate Chem., 2010, vol. 21, 2119-2127 [0080]
- **ANDERSONBLUESTONE**Annu. Rev. Immunol., 2005, vol. 23, 447-85 [0166]
- **REMINGTON**The Science and Practice of PharmacyPharmaceutical Press20120000 [0171]

**Patentkrav**

1. Sammensætning, der omfatter en forbindelse med formlen 1:



Formel 1

hvor:

m er et heltal fra 1 til 100;

X omfatter

et fødevareantigen udvalgt fra SEQ ID NO: 24, SEQ ID NO: 25, SEQ ID NO: 26, og SEQ ID NO: 27, mod hvilket patienter udvikler et allergisk eller hypersensitivitetsrespons,

eller

et antigen udvalgt fra SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, og SEQ ID NO: 17, mod hvilket en patient udvikler et autoimmunrespons;

Y omfatter en linkerdel; og

Z omfatter en levermålrettet del;

hvor den levermålrettede del omfatter galactose, galactosamin eller N-acetylgalactosamin.

2. Sammensætning ifølge krav 1, hvor Z er konjugeret til Y ved C1, C2 eller C6.

3. Sammensætning ifølge krav 1, hvor Y er udvalgt fra N-hydroxysuccinamidyl-linkere, malaemid-linkere, vinylsulfon-linkere, pyridyl-di-thiol-poly(ethylenglycol)-linkere, pyridyl-di-thiol-linkere, n-nitrophenyl-carbonat-linkere, NHS-ester-linkere og nitrophenoxypoly(ethylenglycol)ester-linkere.

4. Sammensætning ifølge krav 1, hvor Y omfatter:

en struktur, der er repræsenteret ved formlerne Ya til Yp:




Formel Ya



Formel Yb



Formel Yc



Formel Yd



Formel Ye



Formel Yf



Formel Yg



Formel Yh



Formel Yi



Formel Yj



Formel Yk



Formel YL



Formel Ym



Formel Yn



Formel Yo

og



Formel Yp

eller har en del, der er repræsenteret ved formlen Y'-CMP:




Formel Y'-CMP

hvor:

den venstre parentes "(" angiver bindingen mellem X og Y;

den højre parentes eller bundparentesen og ")" angiver bindingen mellem Y og Z;

n er et heltal fra 1 til 100;

p er et heltal fra 2 til 150;

q er et heltal fra 1 til 44;

$R^8$ er $-CH_2-$ eller $-CH_2-CH_2-C(CH_3)(CN)-$;

$R^9$ er en direkte binding eller $-CH_2-CH_2--NH-C(O)-$; og

Y' repræsenterer den resterende del af Y, hvor fortrinsvis:

(i) n er 40 til 80;

p er 10 til 100;

q er 3 til 20;

$R^8$ er $-CH_2-CH_2-C(CH_3)(CN)-$; og

når $R^9$ er $-CH_2-CH_2--NH-C(O)-$, Z er galactose eller N-acetylgalactosamin konjugeret ved dets C1; og/eller

(ii) Y omfatter formlen Ya, formlen Yb, formlen Yh, formlen Yi, formlen Yk, formlen Ym eller formlen Yn; eller

(iii) Y omfatter formlen Ya, formlen Yb, formlen Ym eller formlen Yn.

5. Sammensætning ifølge et hvilket som helst af kravene 1 til 4, hvor Y omfatter formlen Yc.

6. Sammensætning ifølge et hvilket som helst af kravene 1 til 4, hvor Y omfatter formlen Ym.

7. Sammensætning ifølge et hvilket som helst af kravene 1 til 6 eller en sammensætning, der omfatter en forbindelse med formlen 1:



Formel 1

hvor:

m er et heltal fra 1 til 100;

X omfatter et antigen, mod hvilket en patient udvikler et immunrespons;

Y omfatter en linkerdel; og

Z omfatter en levermålrettet del;

hvor den levermålrettede del omfatter galactose, galactosamin eller N-acetylgalactosamin,

til anvendelse ved forhøjelse af patientens tolerance over for antigendel X.

# DRAWINGS




FIG. 1


OTI proliferation
Proliferating OTI cells (% of OTI)
100
80
60
40
20
0
P=0.0002
naive
OVA
Gal-OVA
Antigen

**FIG. 2**


PD1+ % of OTI
A.
PD-1+ OTI cells (% of OTI)
15
10
5
0
P<0.0001
naive
OVA
Gal-OVA
G0 G1 G2 G3 G4 G5 G6 G7 G8 G9 G10 G11
Generation
B.
Annexin V+ OTI cells (% of OTI)
50
40
30
20
10
0
naive
OVA
Gal-OVA
G0 G1 G2 G3 G4 G5 G6
Generation

**FIG. 3**


Day 19
Ab-titers (long-1)
5
4
3
2
1
0
Gal-OVA (6µg)
Gal-OVA (30µg)
OVA (6µg)
OVA (30µg)
Veh.

**FIG. 4**


OVA IgG Titer (log-1)
6
4
2
0
-1 0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18
Day
20 µg Gal-OVA
20 µg Gal-OVA
20 µg Gal-OVA
20 µg Gal-OVA
20 µg Gal-OVA

**FIG. 5**




FIG. 6C




FIG. 6B




FIG. 6A




FIG. 6D

FIG. 6E

FIG. 6F




*A*



*B*

*FIGS. 7A-7B*


Normalized 800 nm signal
10
1
0.100
0.010
0.001
0
24
48
72
96
Hours after injection
OVA
DOM-OVA
OVA-DOM

FIG. 8

(a)


saline
DOM + OVA
DOM-OVA
OVA-DOM
titer of anti-OVA IgG
Days after first OVA injection
10 10 50 50 100 200 μg

(b)


DOM + OVA
DOM-OVA
OVA-DOM
titer of anti-OVA IgG
Days after first OVA injection
OVA
OVA + CpG

**FIG. 9**